ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION

Information

  • Patent Application
  • 20230414677
  • Publication Number
    20230414677
  • Date Filed
    February 27, 2023
    a year ago
  • Date Published
    December 28, 2023
    12 months ago
Abstract
A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.
Description
REFERENCE TO SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 2WL3392_ST26.xml. The text file is 24 KB, was created on Jun. 1, 2023, and is being submitted electronically via Patent Center.


FIELD OF THE DISCLOSURE

The disclosure relates generally to the field of transplantation. The disclosure further relates to methods for generating local immunosuppression in the environment of transplanted cells.


BACKGROUND OF THE DISCLOSURE

The advent of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells has had a paradigm-shifting effect on regenerative and translational medicine. These cells have can self-renew indefinitely in a pluripotent state while retaining the ability to differentiate into any cell type in the human body. Such properties have allowed researchers to better understand human development and the etiology of developmental disorders. They have also given modern medicine a powerful new tool against diseases that have been intractable or impossible to treat with conventional medicine, including spinal cord injury, diabetes, blindness, multiple sclerosis, and cancer, to name a few. The efficacy and range of applicable diseases for cell therapies will only increase with our growing understanding of how to control stem cell differentiation and the biology of the differentiated cell products.


With these applications come important and critical challenges. Along with cell safety, one of the most important concerns is immune rejection of cells from a different genetic background. Immune rejection remains a critical barrier because the immune system has evolved a complex set of mechanisms to recognize and eliminate “non-self” cells that express specific protein fragments—especially those from the major histocompatibility complex (MHC in mouse, HLA in humans)—that differ between donor and recipient (Yang et al., Nat Rev Genet. 18:309-26 (2017)). This response is almost certainty a by-product of the evolutionary pressure to protect against opportunistic infections and malignancies, which are often defined by the presence of “foreign” proteins and epitopes. Depending on the context, rejection of transplanted cells or tissues can occur over the timescale of minutes/hours (hyperacute), days/months (acute), and months/years (chronic) (LaRosa et al., J Immunol. 178:7503-9 (2007)). This rejection results from the complex and coordinated effects of cell types from both innate (Murphy et al., Immunol Rev. 241:39-48 (2011)) and adaptive immunity (Issa et al., Expert Rev Clin Immunol. 6:155-69 (2010)).


One of the most important pathways to rejection is the priming of the adaptive immune system and activation of CD8+ cytotoxic T-cells. This occurs after antigen presenting cells process donor-specific peptides and then activate recipient T-cells that are specific for the same peptides in secondary lymph organs (Lechler et al., J Exp Med. 155:31-41 (1982); Guermonprez et al., Annu Rev Immunol. 20:621-67 (2002); Stockwin et al., Immunol Cell Biol. 78:91-102 (2000)). These T-cells then migrate to and kill transplanted cells or tissues with the release of cytolytic factors like perforin and granzyme. NK-cells can also induce apoptosis in donor cells based on foreign or no MHC expression (Kitchens et al., Transplantation. 81:811-7 (2006); Benichou et al., Curr Opin Organ Transplant. 16:47-53 (2011)), and other cell types like macrophages can support rejection with the release of pro-inflammatory cytokines at the engraftment site (Mannon, Curr Opin Organ Transplant. 17:20-5 (2012)). Many other cell types and subtypes also have a role in allograft rejection. Since these are the same immune pathways used to eliminate common viral and bacterial pathogens, they are—along with rejection of an allograft—highly conserved across vertebrate species.


A current solution to prevent rejection of an allograft involves the following two options: find a donor with a matched histocompatibility haplotype (mostly likely from genetically-related family), and much more commonly, use broadly-directed immunosuppressant drugs (Wiseman, Clin J Am Soc Nephrol. 11:332-43 (2016); Malaise et al., Transplant Proc. 37:2840-2 (2005)). Common drugs include those from the families of calcineurin inhibitors (Flechner et al., Clin Transplant. 22:1-15 (2008); Casey et al., Curr Opin Nephrol Hypertens. 20:610-5 (2011)), anti-proliferative agents (Hardinger et al., World J Transplant. 3:68-77 (2013)), mTOR inhibitors (Macdonald, Expert Rev Clin Immunol. 3:423-36 (2007); Neuhaus et al., Liver Transpl. 7:473-84 (2001)), and steroids (Steiner et al., Semin Immunopathol. 33:157-67 (2011))— all of which suppress T-cell proliferation or function (particularly the former three). These drugs need to be taken every day for life, and even a single missed dose can increase the risk of rejection. Yet they do not always work, and when they do, rates of chronic rejection still continually climb over time (Demetris et al., Ann Transplant. 2:27-44 (1997); Libby et al., Immunity. 14:387-97 (2001)). Most importantly, they are systemically-acting and ultimately leave patients immunocompromised with increased rates of cancer and life-threatening infections (Gallagher et al., J Am Soc Nephrol. 21:852-8 (2010)). Pertaining to ES cells, these drugs have shown only marginal improvements in permitting survival across an MHC barrier (Swijnenburg et al., Proc Natl Acad Sci USA. 105:12991-6 (2008); Toriumi et al., Neurol Res. 31:220-7 (2009)). While newer and more targeted immunosuppressant reagents are becoming available and tested in skin and cardiac (Larsen et al., Nature. 381:434-8 (1996)), as well as ES cell allograft settings (Pearl et al., Cell Stem Cell. 8:309-17 (2011)), they are still systemically-acting and therefore likely to leave hosts immune compromised.


One proposed benefit to the discovery of iPS cells was that they could be created from, and for, each patient. These cells should, in theory, be protected from immune rejection by the corresponding patient (Pearl et al., Sci Transl Med. 4:164ps25 (2012)). However, the induction of an iPS cell state involves epigenetic alterations and in-vitro-culture pressures that can create abnormalities and malignancies, so each cell line would need to be vigorously tested and/or genetically modified to achieve safety as well as function (Hussein et al., Nature. 471:58-62 (2011); Laurent et al., Cell Stem Cell. 8:106-18 (2011); Lister et al., Nature. 471:68-73 (2011)). Ultimately, the cost and time needed to create and test an iPS cell line for each individual patient makes this approach practically and economically unrealistic. Even if the costs were dramatically reduced, it would not help those patients who need immediate treatment for conditions like burns, heart attacks, strokes, and spinal cord injury (among many others). Furthermore, given recent findings, it remains controversial whether iPS cell-derived cell types are truly protected from immune rejection even when transplanted into the same host from where they were derived (Zhao et al., Nature. 474:212-5 (2011)).


One proposed solution in this regard has been to use naturally suppressive or regulatory immune cells, like Tregs or others, that are expanded and/or transferred before, during, or after transplant of therapeutic cells or tissues (Cobbold et al., Cold Spring Harb Perspect Med. 3(6) (2013); Wood et al., Nature reviews Immunology. 12:417-30 (2012)). These strategies have been suggested based on the recognition of suppressive immune pathways, in particular the discovery of the master regulator FoxP3 that programs a subset of CD4+ cells regulatory T-cells (Hori et al., 299:1057-61 (2003); Fontenot et al., Nat Immunol. 4:330-6 (2003)) and proof of their critical importance in promoting tolerance to allografts (Kendal et al., J Exp Med. 208:2043-53 (2011)). This thinking is in contrast to some of the first tolerance-inducing strategies which focused almost exclusively on depletion of effector T-cells with monoclonal antibodies, coupled with bone marrow transplant and the creation of donor chimerism (Cobbold et al., Nature. 323:164-6 (1986); Qin et al., J Exp Med. 169:779-94 (1989)). The importance of suppressive T-cell phenotypes was later appreciated with strategies that did not kill the cells, but blocked critical T-cell receptors in a way that left them unresponsive to allografts (Cobbold et al., J Immunol. 172:6003-10 (2004)), yet simultaneously able to suppress naïve T-cells of other specificities (Cobbold et al., Immunol Rev. 129:165-201 (1992); Qin et al., Eur J Immunol. 20:2737-45 (1990)). These cells, now recognized as Tregs, may promote tolerance by a number of mechanisms, including (but not limited to) the expression of suppressive factors like TGF beta (Nakamura et al., The Journal of experimental medicine. 194:629-44 (2001); Nakamura et al., J Immunol. 172:834-42 (2004)), CTLA4 (Tang et al., J Immunol. 181:1806-13 (2008); Walker et al., Trends Immunol. 36:63-70 (2015)), IL10 (O'Garra et al., J Clin Invest. 114:1372-8 (2004); Chaudhry et al., Immunity. 34:566-78 (2011)), and IL35 (Collison et al., Nature. 450:566-9 (2007)), as well as the preferential consumption of IL-2 (Shevach et al., Immunity. 30:636-45 (2009); Setoguchi et al., J Exp Med. 201:723-35 (2005)), manipulation or killing of antigen presenting cells (Mahnke et al., Cell Immunol. 250:1-13 (2007); Shevach et al., Immunol Rev. 212:60-73 (2006)), and depletion of local ATP (Regateiro et al., Eur J Immunol. 41:2955-65 (2011); Regateiro et al., Clin Exp Immunol. 171:1-7 (2013)) or essential amino acids (Cobbold et al., Proc Natl Acad Sci USA. 106:12055-60 (2009)).


Two approaches for potential therapeutic uses of Tregs involve either in-vitro expansion using donor antigens coupled with transplantation, or selective in-vivo expansion that leverages differences between regulatory and effector T-cells. While these strategies are interesting, to date no long term of acceptance of an allograft has been demonstrated solely with the use of in-vitro or in-vivo expanded Tregs. There remain many complications and unknown facets to Treg biology, including the optimal methodology for in-vitro or in-vivo expansion, as well as the therapeutically-relevant dosage and timing. It has also been shown that antigen-specific Treg suppression can be “defeated” depending on the inflammatory context (Korn et al., Nat Med. 13:423-31 (2007)) and that Tregs can be killed by NK-cells (Roy et al., J Immunol. 180:1729-36 (2008)).


In addition to Tregs, other suppressive cell types have also been explored to induce allograft tolerance, such as antigen presenting cells like dendritic cells (DCs) (Walker et al., Trends Immunol. 36:63-70 (2015)). DCs are the link between innate and adaptive immunity, and they can induce both effector and suppressive immune responses depending on contexts like their maturation state and the local inflammatory cues. During allograft rejection, DCs present allograft antigens inside the binding grooves of MHC (mouse) or HLA (human) molecules on their surface, along with costimulatory molecules like CD80, CD86, and CD40 (among others), which allograft-specific T-cell clones recognize to become activated (Walker et al., Trends Immunol. 36:63-70 (2015)). Tolerogenic DCs can be induced from the immature state by exposure to suppressive cues, which keep expression levels of MHC and costimulatory molecules low and in turn promote naïve T-cells into anergic or even Tregulatory subtypes upon DC-Tcell interactions.


Therapeutically, one application of this biology is to expand DCs in vitro exposed simultaneously to specific allograft antigens of interest and immunosuppressive factors—many of which have been tested including TGF-beta, IL10, cAMP, prostaglandin E2, histamine, neuropeptides, vitamin D2, B2 agonists, HLA-G, glucosamine, as well drugs like corticosteroids, cyclosporine, tacrolimus, rapamycin, aspirin, mecophenolate mofetil, sanglifehrin, and deoxyspergualin (Hackstein et al., Nat Rev Immunol. 4:24-34 (2004)). Alternatively, DCs have been genetically engineered to directly express immunomodulatory factors like TGF-beta, IL-10, VEGF, FasL, CTLA4-Ig, IDO, NFKb decoy receptors, soluble TNFR, CCR7, as well as siRNA-induced silencing of IL-12 (Morelli et al., Immunol Rev. 196:125-46 (2003)). These cultured or engineered DCs are then transferred into recipients concomitantly with an allograft to test whether they can prolong the survival of an allograft, with the assumption that they suppress allograft-specific T-cells, or increase the number of allograft-focused Tregulatory cells.


In one prototypical approach of this kind, bone-marrow derived DCs were transduced with SOCS1 (preventing upregulation of costimulatory molecules and MHCII), which prolonged mouse cardiac allografts (Fu et al., Cell Mol Immunol. 6:87-95 (2009)). In another demonstration, FasL-expressing DCs were also able to prolong mouse cardiac allografts (Min et al., J Immunol. 164:161-7 (2000)). In general there have been many singular and combinatorial approaches using tolerogenic DCs along these lines (Bjorck et al., J Heart Lung Transplant. 24:1118-20 (2005): Sun et al., PLoS One. 7:e52096 (2012); Li et al., J Immunol. 178:5480-7 (2007); Xu et al., Transplant Proc. 38:1561-3 (2006); Lan et al., J Immunol. 177:5868-77 (2006); Lutz et al., Eur J Immunol. 30:1813-22 (2000); Fischer et al., Transpl Immunol. 25:20-6 (2011)), and the outcomes are highly variable depending on the type of modification to the DCs, culture conditions, timing, and type of allograft being tested (Zhou et al., J Immunol Res. 2016:5730674 (2016); Xia et al., J Evid Based Med. 7:135-46 (2014)). Almost all of these studies have been done in mouse, although recent human testing has begun including testing for safety in healthy volunteers (Dhodapkar et al., J Exp Med. 193:233-8 (2001); Dhodapkar et al., Blood. 100:174-7 (2002)) as well as a phase I clinical trial in 10 patients with diabetes (Giannoukakis et al., Diabetes Care. 34:2026-32 (2011)).


There remain many unknowns to both adoptive Treg and tolerogenic DC therapies, and one of the most important is the duration of their efficacy. While in-vivo studies show that prolonged allograft survival is possible using these two approaches (with or without additional immunosuppressive drugs), it is not long-term, and in almost every case the allograft eventually dies. This is fitting with the fact that both Tregs and DCs have a finite time-span. Also, it is possible for tolerogenic phenotypes, especially among DCs, to “convert” and instead promote inflammatory pathways (Delamarre et al., Semin Immunol. 23:2-11 (2011); Schreibelt et al., Cancer Immunol Immunother. 59:1573-82 (2010); Satpathy et al., Nat Immunol. 14:937-48 (2013)). This is likely due to the highly adaptive nature of DCs, and their ability to sense and respond to a large breadth of inflammatory cues. It has also been shown that these cells can die very quickly after in-vivo adoptive transfer. There are also many subsets of suppressive Tregs and tolerogenic DCs that have been described, and it is still unclear which is the ideal subtype, or if it will entirely depend on the context of the allograft transplant.


Additionally, there is a huge practical and economical barrier to these kinds of approaches in that they require clinicians to manipulate and work with a complicated immune cell type in addition to the therapeutic one. Given their finite lifespan, it is still unclear if these cells would need to be continuously and/or repeatedly delivered to confer long-term tolerance to an allograft. This would compound the already expensive and timely methodology for culturing, expanding, or transducing the cells with critical immunomodulatory factors, and ultimately impede the uses for treatments that are extremely time-sensitive.


Another approach for inducing tolerance is the use of Hematopoietic Cell transplantation (HCT), in which recipients of an HLA-mismatched organ receive an HCT using hematopoietic cells from the same donor (Gozzo et al., Surg Forum. 21:281-4 (1970); Ildstad et al., Nature. 307:168-70 (1984); Sayegh et al., Ann Intern Med. 114:954-5 (1991); Huang et al., J Clin Invest. 105:173-81 (2000); Kawai et al., N Engl J Med. 358:353-61 (2008); Sachs et al., Semin Immunol. 23:165-73 (2011)). This results in a chimerism that can allow newly developing T and B-cells in the recipient to be tolerant of both the recipient and the donor antigens (Tomita et al., J Immunol. 153:1087-98 (1994); Tomita et al., Transplantation. 61:469-77 (1996); Tomita et al., Transplantation. 61:477-85 (1996); Khan et al., Transplantation. 62:380-7 (1996); Manilay et al., Transplantation. 66:96-102 (1998)). This is due to the role that hematopoietic cells play in positive and negative selection in the thymus, where they eliminate cells with an affinity for hematopoietic cell-containing antigens that might also be present in the allograft, ultimately leading to their rejection. (Griesemer et al., Transplantation. 90:465-74 (2010)). However, the inherent and dangerous risk of this approach is the potential for Graft vs. Host Disease (GVHD), in which transplanted hematopoietic cells recognize and systemically attack the recipient tissues as foreign (Sun et al., PLoS One. 7:e52096 (2012)). Since its inception, several variants of HCT to dampen rejection have been developed, including the use of nonmyeloablative strategies. These strategies use altered chemotherapy regimens, often involving lower dosages, so that the recipient receiving the HCT does not receive total ablation of their hematopoietic compartment. The most recent of these strategies, for instance, used a tolerance-promoting facilitating cell (FC)-based HCT to promote tolerance in HLA-mismatched kidney recipients while largely avoiding GHVD (Leventhal et al., Sci Transl Med. 4:124ra28 (2012)).


Besides the risk of GHVD and risk of a secondary HCT procedure, the general limitation to these chimerism-inducing approaches is the need to have the HLA-matched donor available for the collection of marrow. While this is easily accomplished in rodent studies, it is quite demanding in humans. Donor organs should ideally be taken from the donor as soon as possible, which leaves an incredibly short window from which to collect marrow, if at all possible. It is also an expensive and logistically demanding procedure that requires a very patient and operation-specific approach. And, as with regulatory cell approaches, it is not clear how it would be practically applied to those situations where the patient could benefit from or needs therapy immediately for treatment of acute injuries or disease.


Another approach that has been tested for reducing allorejection in vivo is the removal of histocompatibility molecules (Torikai et al. Blood. 122:1341-9 (2013)), which are the major antigenic source of “non-self” recognition in allorejection. This fits with the empirical data that HLA-matched donors and recipients have greatly improved rates of organ survival after transplantation (Opelz et al., Rev lmmunogenet. 1:334-42 (1999)). While there have been some positive results with this approach, removal of MHC class I renders cells extremely susceptible to NK cells (Pegram et al., Immunol Cell Biol. 89:216-24 (2011); Raulet et al., Nat Rev Immunol. 6:520-31 (2006); Huntington, Immunol Cell Biol. 92:208-9 (2014)). It also leaves MHC-independent killing pathways among CD8+ T-cells intact (Haspot et al., Am J Transplant. 14:49-58 (2014)) and does not address antigenic differences (minor antigens) outside the MHC/HLA gene family (Roopenian et al., Immunol Rev. 190:86-94 (2002)).


An employment of this approach involved the deletion of all classical HLA class I molecules from pluripotent stem cells, coupled with the introduction of the gene encoding HLA-E, a minimally polymorphic HLA that inhibits NK-cells (Gornalusse et al., Nat Biotechnol. (2017)). While this approach showed short-term resistance to NK and CD8 T-cell attack in partially immune compromised humanized mice, it was not demonstrated that these cells could survive long term in a fully immune-competent host. In another approach ES cells were engineered to express PD-L1 and CTLA4-Ig, which improved survival in allogenic hosts (Rong et al., Cell Stem Cell. 14:121-30 (2014)), but with the severe limitation that CTLA4-Ig can lead to systemic immune suppression. It has not yet been demonstrated that a set of modifications to ES or iPS cells allows them to escape allorejection without the potential for systemic immunosuppression and without the need for immunosuppressive drugs.


It is an object of the present disclosure to mitigate and/or obviate one or more of the above deficiencies.


SUMMARY OF THE DISCLOSURE

In an aspect, a cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is provided. The genetically modified cell comprises: a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and has one or more of the following functions: a) to mitigate antigen presenting cell activation and function; b) to mitigate graft attacking leukocyte activity or cytolytic function; c) to mitigate macrophage cytolytic function and phagocytosis of allograft cells; d) to induce apoptosis in graft attacking leukocytes; e) to mitigate local inflammatory proteins; and f) to protect against leukocyte-mediated apoptosis.


In an embodiment of the cell, the set of transgenes comprises one or more (e.g., one, two, three, four, five, six, seven, or all eight) of the following genes: PD-L1, HLA-G (or the mouse version of HLA-G, H2-M3), Cd47, Cd200, FASLG (or the mouse version of FASLG, FasL), Ccl21 (or the mouse version of Ccl21, Ccl21b), Mfge8, and Serpin B9 (or the mouse version of Serpin B9, Spi6).


In an embodiment of the cell, the set of transgenes comprises two or more of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In an embodiment of the cell, the set of transgenes genes comprises PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) or a gene encoding a biologic that acts as an agonist of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In an embodiment of the cell, the cell further comprises one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or all eleven) of the following transgenes: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and IFNγR1 d39 or a gene encoding a biologic that acts as an agonist of TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, or IFNγR1 d39.


In an embodiment of the cell, the TGF-β or the biologic is local acting in the graft environment. In an embodiment of the cell, the TGF-β or the biologic is local acting in the graft environment with minimal systemic effect.


In various embodiments of the cell, the cell is a stem cell, a cell amenable for genome editing, and/or a source of a therapeutic cell type (e.g., a cell that can be differentiated into a therapeutic cell type, or a cell of a desired target tissue). In various embodiments, the cell is an embryonic stem cell, a pluripotent stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a mesenchymal stem cell, an endothelial stem cell, an epithelial stem cell, an adipose stem or progenitor cell, a germline stem cell, a lung stem or progenitor cells, a mammary stem cell, an olfactory adult stem cell, a hair follicle stem cell, an intestinal stem or progenitor cell, a multipotent stem cell, an amniotic stem cell, a cord blood stem cell, a neural stem or progenitor cell, an adult stem cell, a somatic stem cell, a tissue-specific stem cell, a totipotent stem cell, a fibroblast, a monocytic precursor, a B cell, an exocrine cell, a pancreatic progenitor, an endocrine progenitor, a hepatoblast, a myoblast, a preadipocyte, a hepatocyte, a chondrocyte, a smooth muscle cell, a K562 human erythroid leukemia cell line, a bone cell, a synovial cell, a tendon cell, a ligament cell, a meniscus cell, an adipose cell, a dendritic cell, a natural killer cell, a skeletal muscle cell, a cardiac muscle cell, an erythroid-megakaryocytic cell, an eosinophil, a macrophage, a T cell, an islet beta-cell, a neuron, a cardiomyocyte, a blood cell, an exocrine progenitor, a ductal cell, an acinar cell, an alpha cell, a beta cell, a delta cell, a PP cell, a cholangiocyte, a white or brown adipocyte, a hormone-secreting cell, an epidermal keratinocyte, an epithelial cell, a kidney cell, a germ cell, a skeletal joint synovium cell, a periosteum cell, a perichondrium cell, a cartilage cell, an endothelial cell, a pericardium cell, a meningeal cell, a keratinocyte precursor cell, a keratinocyte stem cell, a pericyte, a glial cell, an ependymal cell, a cell isolated from an amniotic or placental membrane, a serosal cell, a somatic cell, or a cell derived from skin, heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder, bone marrow, spleen, intestine, or stomach.


In an embodiment of the cell, the cell is further genetically modified to comprise at least one (e.g., one, two, three, or more) mechanism for controlling cell proliferation (e.g., to reduce the tumorigenic potential of the modified cell or to reduce proliferation of a modified cell that has become tumorigenic). The genetically modified cell comprises: a genetic modification of one or more (e.g., one, two, three, or more) cell division locus/loci (CDL), the CDL being one or more loci whose transcription product(s) is expressed by dividing cells (e.g., all dividing cells containing one or more of the immunosuppressive transgenes), the genetic modification being one or more of: a) an ablation link (ALINK) system, the ALINK system comprising a DNA sequence encoding a negative selectable marker that is transcriptionally linked to a DNA sequence encoding the CDL; and b) an exogenous activator of regulation of a CDL (EARC) system, the EARC system comprising an inducible activator-based gene expression system that is operably linked to the CDL.


In an embodiment of the cell, the genetic modification of the CDL comprises performing targeted replacement of the CDL with one or more of: a) a DNA vector comprising the ALINK system; b) a DNA vector comprising the EARC system; and c) a DNA vector comprising the ALINK system and the EARC system; wherein the ALINK and/or EARC systems are each operably linked to the CDL.


In various embodiments of the cell, the ALINK genetic modification of the CDL is homozygous, heterozygous, hemizygous or compound heterozygous and/or the EARC genetic modification ensures that functional CDL modification can only be generated through EARC-modified alleles.


In various embodiments of the cell, the CDL is one or more (e.g., one, two, three, or more) of the loci recited in Table 5. In various embodiments, the CDL encodes a gene product that functions in one or more of: cell cycle, DNA replication, RNA transcription, protein translation, and metabolism. In various embodiments, the CDL is one or more of Cdk1/CDK1, Top2A/TOP2A, Cenpa/CENPA, Birc5/BIRC5, and Eef2/EEF2, preferably the CDL is Cdk1 or CDK1. In some embodiments, the CDL is Top2A. In some embodiments, the CDL is Eef2. In various embodiments, the CDL is two or more of Cdk1/CDK1, Top2A/TOP2A, Cenpa/CENPA, Birc5/BIRC5, and Eef2/EEF2, preferably the CDL is Cdk1 and Top2A or Cdk1 and Eef2.


In various embodiments of the cell, the ALINK system comprises a herpes simplex virus-thym idine kinase/ganciclovir system, a cytosine deaminase/5-fluorocytosine system, a carboxyl esterase/irinotecan system or an iCasp9/AP1903 system, preferably the ALINK system is a herpes simplex virus-thymidine kinase/ganciclovir system.


In various embodiments of the cell, the EARC system is a doxycycline inducible “dox-bridge” system, a cumate switch inducible system, an ecdysone inducible system, a radio wave inducible system, or a ligand-reversible dimerization system, preferably the EARC system is a dox-bridge system.


In an aspect, a method for providing a local immunosuppression at a transplant site in an allogeneic host is provided. The method comprises providing a cell; and expressing in the cell a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and has one or more of the following functions: a) to mitigate antigen presenting cell activation and function; b) to mitigate graft attacking leukocyte activity or cytolytic function; c) to mitigate macrophage cytolytic function and phagocytosis of allograft cells; d) to induce apoptosis in graft attacking leukocytes; e) to mitigate local inflammatory proteins; and f) to protect against leukocyte-mediated apoptosis.


In an embodiment of the method, the set of transgenes comprises one or more (e.g., one, two, three, four, five, six, seven, or all eight) of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) or a gene encoding a biologic that acts as an agonist of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, or Serpin B9 (Spi6).


In an embodiment of the method, the set of transgenes comprises two or more of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In an embodiment of the method, the set of transgenes genes comprises PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) or a gene encoding a biologic that acts as an agonist of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In an embodiment of the method, the method further comprises expressing one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or all eleven) of the following transgenes: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and IFNγR1 d39 or a gene encoding a biologic that acts as an agonist of TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, or IFNγR1 d39. In an embodiment, the TGF-β or the biologic is local acting in the graft environment. In an embodiment of the cell, the TGF-β or the biologic is local acting in the graft environment with minimal systemic effect.


In various embodiments of the method, the cell is a stem cell, a cell amenable to genome editing, and/or a source of a therapeutic cell type (e.g., a cell that can be differentiated into a therapeutic cell type, or a cell of a desired target tissue). In various embodiments, the cell is an embryonic stem cell, a pluripotent stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a mesenchymal stem cell, an endothelial stem cell, an epithelial stem cell, an adipose stem or progenitor cell, a germline stem cell, a lung stem or progenitor cells, a mammary stem cell, an olfactory adult stem cell, a hair follicle stem cell, an intestinal stem or progenitor cell, a multipotent stem cell, an amniotic stem cell, a cord blood stem cell, a neural stem or progenitor cell, an adult stem cell, a somatic stem cell, a tissue-specific stem cell, a totipotent stem cell, a fibroblast, a monocytic precursor, a B cell, an exocrine cell, a pancreatic progenitor, an endocrine progenitor, a hepatoblast, a myoblast, a preadipocyte, a hepatocyte, a chondrocyte, a smooth muscle cell, a K562 human erythroid leukemia cell line, a bone cell, a synovial cell, a tendon cell, a ligament cell, a meniscus cell, an adipose cell, a dendritic cell, a natural killer cell, a skeletal muscle cell, a cardiac muscle cell, an erythroid-megakaryocytic cell, an eosinophil, a macrophage, a T cell, an islet beta-cell, a neuron, a cardiomyocyte, a blood cell, an exocrine progenitor, a ductal cell, an acinar cell, an alpha cell, a beta cell, a delta cell, a PP cell, a cholangiocyte, a white or brown adipocyte, a hormone-secreting cell, an epidermal keratinocyte, an epithelial cell, a kidney cell, a germ cell, a skeletal joint synovium cell, a periosteum cell, a perichondrium cell, a cartilage cell, an endothelial cell, a pericardium cell, a meningeal cell, a keratinocyte precursor cell, a keratinocyte stem cell, a pericyte, a glial cell, an ependymal cell, a cell isolated from an amniotic or placental membrane, a serosal cell, a somatic cell, or a cell derived from skin, heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder, bone marrow, spleen, intestine, or stomach.


In various embodiments of the method, the cell is provided (e.g., injected) to or near the transplant site. In various embodiments of the method, the cell is provided (e.g., injected or implanted) into the transplant (e.g., injected or implanted into the tissue or organ transplant before, during, or after transplantation). In some embodiments, the cell in which the transgenes are expressed is a cell of the transplant (e.g., a cell of the tissue or organ that is being transplanted is modified to express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)).


In an aspect, a method of controlling proliferation of a cell at a transplant site in an allogeneic host is provided (e.g., to reduce the tumorigenic potential of the cell at the transplant site or to reduce proliferation of the cell that has become tumorigenic at the transplant site). The method comprises: a) genetically modifying in the cell one or more (e.g., one, two, three, or more) cell division locus/loci (CDL), the CDL being one or more loci whose transcription product(s) is expressed by dividing cells (e.g., all dividing cells containing one or more of the immunosuppressive transgenes), the genetic modification of the CDL comprising one or more of: i) an ablation link (ALINK) system, the ALINK system comprising a DNA sequence encoding a negative selectable marker that is transcriptionally linked to a DNA sequence encoding the CDL; and i) an inducible exogenous activator of regulation of a CDL (EARC) system, the EARC system comprising an inducible activator-based gene expression system that is operably linked to the CDL; b) genetically modifying the cell to comprise at least one mechanism for providing a local immunosuppression at a transplant site; c) transplanting the cell or a population of the cells at a transplantation site in an allogeneic host; and d) permitting proliferation of the genetically modified cell comprising the ALINK system by maintaining the genetically modified cell comprising the ALINK system in the absence of an inducer of the negative selectable marker or ablating and/or inhibiting proliferation of the genetically modified cell comprising the ALINK system by exposing the cell comprising the ALINK system to the inducer of the negative selectable marker; and/or permitting proliferation of the genetically modified cell comprising the EARC system by exposing the genetically modified cell comprising the EARC system to an inducer of the inducible activator-based gene expression system or preventing or inhibiting proliferation of the genetically modified cell comprising the EARC system by maintaining the cell comprising the EARC system in the absence of the inducer of the inducible activator-based gene expression system.


In an embodiment of the method, the genetic modification of the CDL comprises performing targeted replacement of the CDL with one or more of: a) a DNA vector comprising the ALINK system; b) a DNA vector comprising the EARC system; and c) a DNA vector comprising the ALINK system and the EARC system; wherein the ALINK and/or EARC systems are each operably linked to the CDL.


In various embodiments of the method the ALINK genetic modification of the CDL is homozygous, heterozygous, hemizygous or compound heterozygous and/or the EARC genetic modification ensures that functional CDL modification can only be generated through EARC-modified alleles.


In various embodiments of the method, the CDL is one or more (e.g., one, two, three, or more) of the loci recited in Table 5. In various embodiments, the CDL encodes a gene product whose function is involved with one or more of: cell cycle, DNA replication, RNA transcription, protein translation, and metabolism. In various embodiments, the CDL is one or more of Cdk1/CDK1, Top2A/TOP2A, Cenpa/CENPA, Birc5/BIRC5, and Eef2/EEF2, preferably the CDL is Cdk1 or CDK1. In some embodiments, the CDL is Top2A. In some embodiments, the CDL is Eef2. In various embodiments, the CDL is two or more of Cdk1/CDK1, Top2A/TOP2A, Cenpa/CENPA, Birc5/BIRC5, and Eef2/EEF2, preferably the CDL is Cdk1 and Top2A or Cdk1 and Eef2.


In various embodiments of the method, the ALINK system comprises a herpes simplex virus-thymidine kinase/ganciclovir system, a cytosine deaminase/5-fluorocytosine system, a carboxyl esterase/irinotecan system or an iCasp9/AP1903 system, preferably the ALINK system is a herpes simplex virus-thymidine kinase/ganciclovir system.


In various embodiments of the method, the EARC system is a doxycycline inducible “dox-bridge” system, a cumate switch inducible system, an ecdysone inducible system, a radio wave inducible system, or a ligand-reversible dimerization system, preferably the EARC system is a dox-bridge system.


In an embodiment of the method, the genetically modified cell comprises: a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting and has one or more of the following functions: a) to mitigate antigen presenting cell activation and function; b) to mitigate graft attacking leukocyte activity or cytolytic function; c) to mitigate macrophage cytolytic function and phagocytosis of allograft cells; d) to induce apoptosis in graft attacking leukocytes; e) to mitigate local inflammatory proteins; and f) to protect against leukocyte-mediated apoptosis.


In an embodiment of the method, the set of transgenes comprises one or more (e.g., one, two, three, four, five, six, seven, or all eight) of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) or a gene encoding a biologic that acts as an agonist of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, or Serpin B9 (Spi6).


In an embodiment of the method, the set of transgenes comprises two or more of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In an embodiment of the method, the set of transgenes genes comprises PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) or a gene encoding a biologic that acts a as an agonist of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In an embodiment of the method, the cell further comprises one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, or all eleven) of the following transgenes: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and IFNγR1 d39 or a gene encoding a biologic that acts as an agonist of TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, or IFNγR1 d39.


In an embodiment of the method, the TGF-β or the biologic is local acting in the graft environment. In an embodiment, the TGF-β or the biologic is local acting in the graft environment with minimal systemic effect


In various embodiments of the method, the cell is a stem cell, a cell amenable to genome editing, and/or a source of therapeutic cell type (e.g., a cell that can be differentiated into a therapeutic cell type, or a cell of a desired target tissue). In various embodiments, the cell is an embryonic stem cell, a pluripotent stem cell, an induced pluripotent stem cell, a hematopoietic stem cell, a mesenchymal stem cell, an endothelial stem cell, an epithelial stem cell, an adipose stem or progenitor cell, a germline stem cell, a lung stem or progenitor cells, a mammary stem cell, an olfactory adult stem cell, a hair follicle stem cell, an intestinal stem or progenitor cell, a multipotent stem cell, an amniotic stem cell, a cord blood stem cell, a neural stem or progenitor cell, an adult stem cell, a somatic stem cell, a tissue-specific stem cell, a totipotent stem cell, a fibroblast, a monocytic precursor, a B cell, an exocrine cell, a pancreatic progenitor, an endocrine progenitor, a hepatoblast, a myoblast, a preadipocyte, a hepatocyte, a chondrocyte, a smooth muscle cell, a K562 human erythroid leukemia cell line, a bone cell, a synovial cell, a tendon cell, a ligament cell, a meniscus cell, an adipose cell, a dendritic cell, a natural killer cell, a skeletal muscle cell, a cardiac muscle cell, an erythroid-megakaryocytic cell, an eosinophil, a macrophage, a T cell, an islet beta-cell, a neuron, a cardiomyocyte, a blood cell, an exocrine progenitor, a ductal cell, an acinar cell, an alpha cell, a beta cell, a delta cell, a PP cell, a cholangiocyte, a white or brown adipocyte, a hormone-secreting cell, an epidermal keratinocyte, an epithelial cell, a kidney cell, a germ cell, a skeletal joint synovium cell, a periosteum cell, a perichondrium cell, a cartilage cell, an endothelial cell, a pericardium cell, a meningeal cell, a keratinocyte precursor cell, a keratinocyte stem cell, a pericyte, a glial cell, an ependymal cell, a cell isolated from an amniotic or placental membrane, a serosal cell, a somatic cell, or a cell derived from skin, heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder, bone marrow, spleen, intestine, or stomach.


In various embodiments of the method, the cell is provided (e.g., injected) to or near the transplant site. In various embodiments of the method, the cell is provided (e.g., injected or implanted) into the transplant (e.g., injected or implanted into the tissue or organ transplant before, during, or after transplantation). In some embodiments, the cell in which the transgenes are expressed is a cell of the transplant (e.g., a cell of the tissue or organ that is being transplanted is modified to express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)).


In various embodiments of the method, the allogeneic host is a mammal. In various embodiments of the method, the allogeneic host is a mouse or a human.


In various embodiments of the method, the host has a degenerative disease or condition that can be treated with cell therapy. In various embodiments, the disease or condition is blindness, arthritis (e.g., osteoarthritis or rheumatoid arthritis), ischemia, diabetes (e.g., Type 1 or Type 2 diabetes), multiple sclerosis, spinal cord injury, stroke, cancer, a lung disease, a blood disease, a neurological disease, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS, an enzyme or hormone deficiency, a metabolic disorder (e.g., a lysosomal storage disorder, Galactosemia, Maple syrup urine disease, Phenylketonuria, a glycogen storage disease, a mitochondrial disorder, Friedrich's ataxia, a peroxisomal disorder, a metal metabolism disorder, or an organic academia), an autoimmune disease (e.g., Psoriasis, Systemic Lupus Erythematosus, Grave's disease, Inflammatory Bowel Disease, Addison's Diseases, Sjogren's Syndrome, Hashimoto's Thyroiditis, Vasculitis, Autoimmune Hepatitis, Alopecia Areata, Autoimmune pancreatitis, Crohn's Disease, Ulcerative colitis, Dermatomyositis), age-related macular degeneration, retinal dystrophy, an infectious disease, hemophilia, a degenerative disease (e.g., Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, Cystic Fibrosis, Cytochrome C Oxidase deficiency, Ehlers-Danlos syndrome, essential tremor, Fribrodisplasia Ossificans Progressiva, infantile neuroaxonal dystrophy, keratoconus, keratoglobus, muscular dystrophy, neuronal ceroid lipofuscinosis, a prior disease, progressive supranuclear palsy, sandhoff disease, spinal muscular atrophy, retinitis pigmentosa), or an age-related disease (e.g., atherosclerosis, cardiovascular disease (e.g., angina, myocardial infarction), cataracts, osteoporosis, or hypertension).


In some embodiments of any of the foregoing aspects, one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) is expressed at a level that is equal to or greater than the expression level of the corresponding endogenous gene in an activated leukocyte (e.g., a T cell, e.g., the expression level of the cloaking transgene is equal to the level of expression of the endogenous gene in activated leukocytes, or is 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more higher than the level of expression of the endogenous gene in activated leukocytes). In some embodiments, all eight of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) are expressed at a level that is equal to or greater than the expression level of the corresponding endogenous gene in an activated leukocyte.


In some embodiments of any of the foregoing aspects, one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) is expressed at a level that is greater than the expression level of the corresponding endogenous gene in a wild-type stem cell (e.g., a wild-type ES cell from the same species, e.g., the expression level of the cloaking transgene is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 500, 1,000-fold or more higher in cloaked cells compared to expression of the endogenous gene in unmodified wild-type ES cells from the same species). In some embodiments, all 8 of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) are expressed at a level that is greater (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or 100-fold higher or more) than the expression level of the endogenous gene in a wild-type stem cell (e.g., an embryonic stem cell from the same species as the cloaked cell). In some embodiments, one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) is expressed at a level that is in the top 5% of gene expression for all genes in the ES cell genome. In some embodiments, one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) is expressed at a level that is in the top 1% of gene expression for all genes in the ES cell genome. In some embodiments, all of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) are expressed at a level that is in the top 5% of gene expression for all genes in the ES cell genome.


In some embodiments of any of the foregoing aspects, the PD-L1 transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 11 or SEQ ID NO: 12.


In some embodiments of any of the foregoing aspects, the HLA-G (H2-M3) transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 16 or SEQ ID NO: 15.


In some embodiments of any of the foregoing aspects, the Cd47 transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.


In some embodiments of any of the foregoing aspects, the CD200 transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.


In some embodiments of any of the foregoing aspects, the FASLG (FasL) transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 9.


In some embodiments of any of the foregoing aspects, the Ccl21 (Ccl21b) transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 1.


In some embodiments of any of the foregoing aspects, the Mfge8 transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 14.


In some embodiments of any of the foregoing aspects, the Serpin B9 (Spi6) transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 7.


In some embodiments of any of the foregoing aspects, the IFNγR1 d39 transgene encodes a protein having at least 85% identity (e.g., 85%, 90%, 95%, 96%, 97%, 98%, 99% sequence identity or more) to the amino acid sequence of SEQ ID NO: 17.


In some embodiments of any of the foregoing aspects, the one or more transgenes is operably linked to a constitutive promoter. In some embodiments, the constitutive promoter is selected from the group consisting of the CAG promoter, the cytomegalovirus (CMV) promoter, the EF1α promoter, the PGK promoter, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, promoter of moloney virus, Epstein barr virus (EBV) promoter, and the Rous sarcoma virus (RSV) promoter.


In some embodiments of any of the foregoing aspects, the cell further comprises (e.g., the cell is further modified to include) a transgene encoding a therapeutic agent. In some embodiments, the therapeutic agent is a protein or antibody. In some embodiments, the antibody is an inhibitory antibody or agonist antibody. In some embodiments, the therapeutic agent is an agent listed in Table 2. In some embodiments, the therapeutic agent is the wild-type version of a gene that is mutated in the subject (e.g., the wild-type version of the mutated gene that is associated with the disease or condition in the subject, e.g., a genetic mutation that is associated with cancer, an enzyme or hormone deficiency, a metabolic disorder, or a degenerative disease). In some embodiments, the therapeutic agent is expressed using an inducible expression system selected from the group consisting of a tetracycline response element, a light inducible system, a radiogenetic system, a cumate switch inducible system, an ecdysone inducible system, a destabilization domain system, or a ligand-reversible dimerization system. In some embodiments, the therapeutic agent is expressed using a constitutive promoter selected from the group consisting of the CAG promoter, the cytomegalovirus (CMV) promoter, the EF1α promoter, the PGK promoter, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, promoter of moloney virus, Epstein barr virus (EBV) promoter, and the Rous sarcoma virus (RSV) promoter.


In another aspect, there is provided a population of genetically modified cells according to any of the cells described above.


In an aspect, a method for providing a local immunosuppression at a transplant site in an allogeneic host is provided. The method comprises transplanting a genetically modified cell as described above or a population of genetically modified cells as described above at a transplantation site in an allogeneic host.


In another aspect, the invention features a composition containing a cell of the invention. In some embodiments, the composition further includes a pharmaceutically acceptable excipient.


In another aspect, featured is a kit including a cell of the invention or a pharmaceutical composition of the invention.


In another aspect, featured is a method of treating a disease or condition in a subject in need thereof by administering to the subject the cell of the invention or a composition of the invention. In some embodiments, the disease or condition is blindness, arthritis (e.g., osteoarthritis or rheumatoid arthritis), ischemia, diabetes (e.g., Type 1 or Type 2 diabetes), multiple sclerosis, spinal cord injury, stroke, cancer, a lung disease, a blood disease, a neurological disease, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS, an enzyme or hormone deficiency, a metabolic disorder (e.g., a lysosomal storage disorder, Galactosemia, Maple syrup urine disease, Phenylketonuria, a glycogen storage disease, a mitochondrial disorder, Friedrich's ataxia, a peroxisomal disorder, a metal metabolism disorder, or an organic academia), an autoimmune disease (e.g., Psoriasis, Systemic Lupus Erythematosus, Grave's disease, Inflammatory Bowel Disease, Addison's Diseases, Sjogren's Syndrome, Hashimoto's Thyroiditis, Vasculitis, Autoimmune Hepatitis, Alopecia Areata, Autoimmune pancreatitis, Crohn's Disease, Ulcerative colitis, Dermatomyositis), age-related macular degeneration, retinal dystrophy, an infectious disease, hemophilia, a degenerative disease (e.g., Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, Cystic Fibrosis, Cytochrome C Oxidase deficiency, Ehlers-Danlos syndrome, essential tremor, Fribrodisplasia Ossificans Progressiva, infantile neuroaxonal dystrophy, keratoconus, keratoglobus, muscular dystrophy, neuronal ceroid lipofuscinosis, a prior disease, progressive supranuclear palsy, sandhoff disease, spinal muscular atrophy, retinitis pigmentosa), or an age-related disease (e.g., atherosclerosis, cardiovascular disease (e.g., angina, myocardial infarction), cataracts, osteoporosis, or hypertension), or a disease or condition listed in Table 2 and/or the cell further includes a transgene encoding a corresponding therapeutic agent listed in Table 2 or the wild-type version of a gene that is mutated in the subject (e.g., the wild-type version of the mutated gene that is associated with the disease or condition in the subject, e.g., a genetic mutation associated with cancer, an enzyme or hormone deficiency, a metabolic disorder, or a degenerative disease). In some embodiments, the disease or condition is age-related macular degeneration (e.g., wet AMD) or retinal dystrophy and the therapeutic agent is a VEGF inhibitor (e.g., a soluble form of a VEGF receptors (e.g., soluble VEGFR-1 or NRP-1), platelet factor-4, prolactin, SPARC, a VEGF inhibitory antibody (e.g., bevacizumab or ranibizumab), or a soluble decoy receptor described in Holash et al., Proc Natl Acad Sci U.S.A. 99:11383-11398, 2002, e.g., VEGF-Trapparental, VEGF-TrapΔB1, VEGF-TrapΔB2, VEGF-TrapR1R2, e.g., aflibercept). In some embodiments, the disease or condition is osteoarthritis or rheumatoid arthritis and the therapeutic agent is an anti-inflammatory biologic (e.g. a TNFα inhibitor (e.g., adalimumab, etanercept, infliximab, golimumab, or certolizumab), an interleukin-6 (IL6) receptor inhibitor (e.g., tocilizumab), an IL1 receptor inhibitor (e.g., anakinra), or another agent used to treat rheumatoid arthritis (e.g., abatacept, rituximab)). In some embodiments, the disease or condition is diabetes (e.g., Type 1 diabetes or Type 2 diabetes) and the therapeutic agent is insulin. In some embodiments, the disease or condition is hemophilia and the therapeutic agent is Factor VIII. In some embodiments, the disease or condition is a metabolic deficiency and the therapeutic agent is a transgene having the nucleic acid sequence of the wild-type version of the gene that is mutated in the subject or a transgene encoding an enzyme that is deficient in the subject.


In some embodiments of any of the foregoing aspects, the cells are differentiated into a lineage restricted cell type prior to administration to the subject. In some embodiments, the disease or condition is myocardial infarction and the cells are differentiated into cardiac muscle cells. In some embodiments, the disease or condition is blindness and the cells are differentiated into photoreceptor cells. In some embodiments, the disease or condition is spinal cord injury, Parkinson's disease, Huntington's disease, or Alzheimer's disease and the cells are dissociated into neurons. In some embodiments, the disease or condition is multiple sclerosis and the cells are differentiated into glial cells.


In some embodiments of any of the foregoing aspects, the cells are administered (e.g., injected or implanted) locally to the tissue or body site in need of cells or the therapeutic agent.


In some embodiments of any of the foregoing aspects, the cells are administered intravenously, subcutaneously, intramuscularly, percutaneously, intradermally, parenterally, intraarterially, intravascularly, or by perfusion.


In some embodiments of any of the foregoing aspects, the cells are administered by subcutaneous injection to produce a cloaked subcutaneous tissue.


In some embodiments of any of the foregoing aspects, the cells are administered as a tissue. In some embodiments, the tissue is administered with a gel, biocompatible matrix, or cellular scaffold.


In some embodiments of any of the foregoing aspects, the cells are administered in an amount of 25,000 to 5,000,000,000 cells (e.g., 2.5×104, 5×104, 7.5×104, 1×105, 2×105, 3×105, 4×105, 6×105, 6×105, 7×105, 8×105, 9×105, 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, or 5×109 cells).


In some embodiments of any of the foregoing aspects, the cells are administered in an amount of 800,000,000 to 100,000,000,000 cells (e.g., 8×108, 9×108, 1×109, 2×109, or 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010, 2×1010, 3×1010, 4×1010, 5×1010, 6×1010, 7×1010, 8×1010, 9×1010, or 1×1011, cells).


In some embodiments of any of the foregoing methods, the method further includes administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is administered prior to administration of the cells. In some embodiments, the additional therapeutic agent is administered after administration of the cells. In some embodiments, the additional therapeutic agent is administered concurrently with administration of the cells. In some embodiments, the additional therapeutic agent is an immunosuppressive agent, a disease-modifying anti-rheumatic drug (DMARD), a biologic response modifier (a type of DMARD), a corticosteroid, or a nonsteroidal anti-inflammatory medication (NSAID), prednisone, prednisolone, methylprednisolone, methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, cyclophosphamide, azathioprine, tofacitinib, adalimumab, abatacept, anakinra, kineret, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab, 6-mercaptopurine, 6-thioguanine, abatacept, adalimumab, alemtuzumab, an aminosalicylate, an antibiotic, an anti-histamine, Anti-TNFα, azathioprine, belimumab, beta interferon, a calcineurin inhibitor, certolizumab, a corticosteroid, cromolyn, cyclosporin A, cyclosporine, dimethyl fumarate, etanercept, fingolimod, fumaric acid esters, glatiramer acetate, golimumab, hydroxyurea, IFNγ, IL-11, leflunomide, leukotriene receptor antagonist, long-acting beta2 agonist, mitoxantrone, mycophenolate mofetil, natalizumab, ocrelizumab, pimecrolimus, a probiotic, a retinoid, salicylic acid, short-acting beta2 agonist, sulfasalazine, tacrolimus, teriflunomide, theophylline, tocilizumab, ustekinumab, or vedolizumab, bevacuzimab, ranibizumab, or aflibercept), photodynamic therapy, photocoagulation, carbidopa-levodopa, a dopamine agonist, an MAO-B inhibitor, a catechol-O-methyltransferase inhibitor, an anticholinergic, amantadine, deep brain stimulation, an anticoagulant, an anti-platelet agent, an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, an angiotensin receptor neprilysin inhibitor, a beta blocker, a combined alpha and beta blocker, a calcium channel blocker, a cholesterol lowering medication, a nicotinic acid, a cholesterol absorption inhibitor, a digitalis preparation, a diuretic, a vasodilator, a dual anti-platelet therapy, a cardiac procedure, an antiviral compound, a nucleoside-analog reverse transcriptase inhibitor (NRTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor, an antibacterial compound, an antifungal compound, an antiparasitic compound, insulin, a sulfonylurea, a biguanide, a meglitinide, a thiazolidinedione, a DPP-4 inhibitor, an SGLT2 inhibitor, an alpha-glucosidase inhibitor, a bile acid sequestrant, aspirin, a dietary regimen, a clotting factor, desmopressin, a clot-preserving medication, a fibrin sealant, physical therapy, a coenzyme, a bone marrow transplant, an organ transplant, hemodialysis, hemofiltration, exchange transfusion, peritoneal dialysis, medium-chain triacylglycerols, miglustat, enzyme supplementation therapy, a checkpoint inhibitor, a chemotherapeutic drug, a biologic drug, radiation therapy, cryotherapy, hyperthermia, surgical excision or tumor tissue, or an anti-cancer vaccine.


In some embodiments of any of the foregoing methods, the method further comprises controlling proliferation of the cell. In some embodiments, the cell comprises an ALINK system, and the method of controlling proliferation comprises: i) permitting proliferation of the cell comprising the ALINK system by maintaining the cell comprising the ALINK system in the absence of an inducer of the negative selectable marker; or ii) ablating or inhibiting proliferation of the cell comprising the ALINK system by exposing the cell comprising the ALINK system to the inducer of the negative selectable marker. In some embodiments, the cell comprises an EARC system, and the method of controlling cell proliferation comprises: i) permitting proliferation of the cell comprising the EARC system by exposing the cell comprising the EARC system to an inducer of the inducible activator-based gene expression system; or ii) preventing or inhibiting proliferation of the cell comprising the EARC system by maintaining the cell comprising the EARC system in the absence of the inducer of the inducible activator-based gene expression system.


In some embodiments of any of the foregoing methods, the cell is removed after completion of the therapy. Removal of the cell(s) can be by surgery (e.g., to remove transplanted tissue or organs, or to remove cloaked subcutaneous tissue) or by the use of the ALINK and/or EARC systems. In some embodiments, one or more (e.g., one, two, three, four, or more) ALINK and/or EARC systems are used to eliminate all of the cloaked cells.


In another aspect, the invention provides a cell of the invention or a composition of the invention for use in treating a disease or condition in a subject in need thereof. In some embodiments, disease or condition is blindness, arthritis (e.g., osteoarthritis or rheumatoid arthritis), ischemia, diabetes (e.g., Type 1 or Type 2 diabetes), multiple sclerosis, spinal cord injury, stroke, cancer, a lung disease, a blood disease, a neurological disease, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS, an enzyme or hormone deficiency, a metabolic disorder (e.g., a lysosomal storage disorder, Galactosemia, Maple syrup urine disease, Phenylketonuria, a glycogen storage disease, a mitochondrial disorder, Friedrich's ataxia, a peroxisomal disorder, a metal metabolism disorder, or an organic academia), an autoimmune disease (e.g., Psoriasis, Systemic Lupus Erythematosus, Grave's disease, Inflammatory Bowel Disease, Addison's Diseases, Sjogren's Syndrome, Hashimoto's Thyroiditis, Vasculitis, Autoimmune Hepatitis, Alopecia Areata, Autoimmune pancreatitis, Crohn's Disease, Ulcerative colitis, Dermatomyositis), age-related macular degeneration, retinal dystrophy, an infectious disease, hemophilia, a degenerative disease (e.g., Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, Cystic Fibrosis, Cytochrome C Oxidase deficiency, Ehlers-Danlos syndrome, essential tremor, Fribrodisplasia Ossificans Progressiva, infantile neuroaxonal dystrophy, keratoconus, keratoglobus, muscular dystrophy, neuronal ceroid lipofuscinosis, a prior disease, progressive supranuclear palsy, sandhoff disease, spinal muscular atrophy, retinitis pigmentosa), or an age-related disease (e.g., atherosclerosis, cardiovascular disease (e.g., angina, myocardial infarction), cataracts, osteoporosis, or hypertension), or a disease or condition listed in Table 2.


In another aspect, the invention provides a cell of the invention or a composition of the invention for use in providing a local immunosuppression at a transplant site in an allogeneic host.


In some embodiments of any of the foregoing aspects, the cell is comprises two of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) (e.g., PD-L1 and HLA-G (H2-M3); PD-L1 and Cd47; PD-L1 and Cd200; PD-L1 and FASLG (FasL); PD-L1 and Ccl21 (Ccl21b); PD-L1 and Mfge8; PD-L1 and Serpin B9 (Spi6); HLA-G (H2-M3) and Cd47; HLA-G (H2-M3) and Cd200; HLA-G (H2-M3) and FASLG (FasL); HLA-G (H2-M3) and Ccl21 (Ccl21b); HLA-G (H2-M3) and Mfge8; HLA-G (H2-M3) and Serpin B9 (Spi6); Cd47 and Cd200; Cd47 and FASLG (FasL); Cd47 and Ccl21 (Ccl21b); Cd47 and Mfge8; Cd47 and Serpin B9 (Spi6); Cd200 and FASLG (FasL); Cd200 and Ccl21 (Ccl21b); Cd200 and Mfge8; Cd200 and Serpin B9 (Spi6); FASLG (FasL) and Ccl21 (Ccl21b); FASLG (FasL) and Mfge8; FASLG (FasL) and Serpin B9 (Spi6); Ccl21 (Ccl21b) and Mfge8; Ccl21 (Ccl21b) and Serpin B9 (Spi6); or Mfge8 and Serpin B9 (Spi6)).


In some embodiments of any of the foregoing aspects, the cell comprises three of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) (e.g., PD-L1, HLA-G (H2-M3), and Cd47; PD-L1, HLA-G (H2-M3), and Cd200; PD-L1, HLA-G (H2-M3), and FASLG (FasL); PD-L1, HLA-G (H2-M3), and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), and Mfge8; PD-L1, HLA-G (H2-M3), and Serpin B9 (Spi6); PD-L1, Cd47, and Cd200; PD-L1, Cd47, and FASLG (FasL); PD-L1, Cd47, and Ccl21 (Ccl21b); PD-L1, Cd47, and Mfge8; PD-L1, Cd47, and Serpin B9; PD-L1, Cd200, and FASLG (FasL); PD-L1, Cd200, and Ccl21 (Ccl21b); PD-L1, Cd200, and Mfge8; PD-L1, Cd200, and Serpin B9 (Spi6); PD-L1, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, FASLG (FasL), and Mfge8; PD-L1, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, Ccl21 (Ccl21b), and Mfge8; PD-L1, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, and Cd200; HLA-G (H2-M3), Cd47, and FASLG (FasL); HLA-G (H2-M3), Cd47, and Ccl21 (Ccl21b); HLA-G (H2-M3), Cd47, and Mfge8; HLA-G (H2-M3), Cd47, and Serpin B9; HLA-G (H2-M3), Cd200, and FASLG (FasL); HLA-G (H2-M3), Cd200, and Ccl21 (Ccl21b); HLA-G (H2-M3), Cd200, and Mfge8; HLA-G (H2-M3), Cd200, and Serpin B9; HLA-G (H2-M3), FASLG (FasL), and Ccl21 (Ccl21b); HLA-G (H2-M3), FASLG (FasL), and Mfge8; HLA-G (H2-M3), FASLG (FasL), and Serpin B9 (Spi6); HLA-G (H2-M3), Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Mfge8, and Serpin B9 (Spi6); Cd47, Cd200, and FASLG (FasL); Cd47, Cd200, and Ccl21 (Ccl21b); Cd47, Cd200, and Mfge8; Cd47, Cd200, and Serpin B9 (Spi6); Cd47, FASLG (FasL), and Ccl21 (Ccl21b); Cd47, FASLG (FasL), and Mfge8; Cd47, FASLG (FasL), and Serpin B9 (Spi6); Cd47, Ccl21 (Ccl21b), and Mfge8; Cd47, Ccl21 (Ccl21b), and Serpin B9 (Spi6); Cd47, Mfge8, and Serpin B9 (Spi6); Cd200, FASLG (FasL), and Ccl21 (Ccl21b); Cd200, FASLG (FasL), and Mfge8; Cd200, FASLG (FasL), and Serpin B9 (Spi6); Cd200, Ccl21 (Ccl21b), and Mfge8; Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); Cd200, Mfge8, and Serpin B9 (Spi6); FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)).


In some embodiments of any of the foregoing aspects, the cell comprises four of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) (e.g., PD-L1, HLA-G (H2-M3), Cd47, and Cd200; PD-L1, HLA-G (H2-M3), Cd47, and FASLG (FasL); PD-L1, HLA-G (H2-M3), Cd47, and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), Cd47, and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, and FASLG (FasL); PD-L1, HLA-G (H2-M3), Cd200, and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), Cd200, and Mfge8; PD-L1, HLA-G (H2-M3), Cd200, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), FASLG (FasL), and Mfge8; PD-L1, HLA-G (H2-M3), FASLG (FasL), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-1, HLA-G (H2-M3), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, and FASLG (FasL); PD-1, Cd47, Cd200, and Ccl21 (Ccl21b); PD-L1, Cd47, Cd200, and Mfge8; PD-L1, Cd47, Cd200, and Serpin B9 (Spi6); PD-L1, Cd47, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, Cd47, FASLG (FasL), and Mfge8; PD-L1, Cd47, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, Cd47, Ccl21 (Ccl21b), and Mfge8; PD-L1, Cd47, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Cd47, Mfge8, and Serpin B9 (Spi6); PD-L1, Cd200, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, Cd200, FASLG (FasL), and Mfge8; PD-L1, Cd200, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, Cd200, Ccl21 (Ccl21b), and Mfge8; PD-L1, Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Cd200, Mfge8, and Serpin B9 (Spi6); PD-L1, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, and FASLG (FasL); HLA-G (H2-M3), Cd47, Cd200, and Ccl21 (Ccl21b); HLA-G (H2-M3), Cd47, Cd200, and Mfge8; HLA-G (H2-M3), Cd47, Cd200, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, FASLG (FasL), and Ccl21 (Ccl21b); HLA-G (H2-M3), Cd47, FASLG (FasL), and Mfge8; HLA-G (H2-M3), Cd47, FASLG (FasL), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Cd47, Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, FASLG (FasL), and Ccl21 (Ccl21b); HLA-G (H2-M3), Cd200, FASLG (FasL), and Mfge8; HLA-G (H2-M3), Cd200, FASLG (FasL), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), FASLG (FasL), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); Cd47, Cd200, FASLG (FasL), and Ccl21 (Ccl21b); Cd47, Cd200, FASLG (FasL), and Mfge8; Cd47, Cd200, FASLG (FasL), and Serpin B9 (Spi6); Cd47, Cd200, Ccl21 (Ccl21b), and Mfge8; Cd47, Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); Cd47, Cd200, Mfge8, and Serpin B9 (Spi6); Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); Cd47, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); or FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)).


In some embodiments of any of the foregoing aspects, the cell comprises five of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) (e.g., PD-L1, HLA-G (H2-M3), Cd47, Cd200, and FASLG (FasL); PD-L1, HLA-G (H2-M3), Cd47, Cd200, and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), Cd47, Cd200, and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, Cd200, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), Cd47, FASLG (FasL), and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), and Mfge8, PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, Cd47, Cd200, FASLG (FasL), and Mfge8, PD-L1, Cd47, Cd200, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, Ccl21 (Ccl21b), and Mfge8; PD-L1, Cd47, Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-1, Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Cd47, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), and Ccl21 (Ccl21b); HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), and Mfge8; HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); Cd47, Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); Cd47, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); Cd47, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); or Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)). In some embodiments of any of the foregoing aspects, the cell comprises six of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) (e.g., PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), and Ccl21 (Ccl21b); PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, Cd200, Mfge8, and Serpin B9 (Spi6); PD-1, HLA-G (H2-M3), Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd47, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); HLA-G (H2-M3), Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); or Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)).


In some embodiments of any of the foregoing aspects, the cell comprises seven of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) (e.g., PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Mfge8; PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd47, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, HLA-G (H2-M3), Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); PD-L1, Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6); or HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)).


In some embodiments of any of the foregoing aspects, the cell comprises all eight of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In some embodiments of any of the foregoing aspects, the cell comprises one or more (e.g., one, two, three, four, five, six, or all seven) of the set of transgenes HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In some embodiments of any of the foregoing aspects, the cell comprises one or more (e.g., one, two, three, four, five, six, or all seven) of the set of transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In some embodiments of any of the foregoing aspects, the cell comprises one or more (e.g., one, two, three, four, five, or all six) of the set of transgenes HLA-G (H2-M3), Cd47, Cd200, Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


In some embodiments of any of the foregoing aspects, the cell is not modified to express PD-L1.


In some embodiments of any of the foregoing aspects, the cell is not modified to express FasL.


In some embodiments of any of the foregoing aspects, the cell is not modified to express TGF-β. In some embodiments of any of the foregoing aspects, the cell is not modified to express CTLA4 or CLTA4-Ig. In some embodiments of any of the foregoing aspects, the cell is not modified to express IDO. In some embodiments of any of the foregoing aspects, the cell is not modified to express IL-35. In some embodiments of any of the foregoing aspects, the cell is not modified to express IL-10. In some embodiments of any of the foregoing aspects, the cell is not modified to express VEGF. In some embodiments of any of the foregoing aspects, the cell is not modified to express an NFκb decoy receptor. In some embodiments of any of the foregoing aspects, the cell is not modified to express soluble TNFR. In some embodiments of any of the foregoing aspects, the cell is not modified to express CCR7. In some embodiments of any of the foregoing aspects, the cell is not modified to express SOCS1. In some embodiments of any of the foregoing aspects, the cell is not modified to express HLA-E. In some embodiments of any of the foregoing aspects, the cell is not modified to express siRNA directed to IL-12.


Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.


As used herein, the term “about” refers to a value that is no more than 10% above or below the value being described. For example, the term “about 5 nM” indicates a range of from 4.5 nM to 5.5 nM.


As used herein, the term “activated leukocyte” refers to the state of a leukocyte (e.g., a granulocyte, such as a neutrophil, eosinophil, or basophil; a monocyte, or a lymphocyte, such as a B or T cell) caused by response to a perceived insult. When leukocytes become activated, they can proliferate, secrete cytokines, differentiate, present antigens, become more polarized, become more phagocytic, and/or become more cytotoxic. Factors that stimulate immune cell activation include pro-inflammatory cytokines, pathogens, and non-self antigen presentation.


Activated leukocytes can be isolated from lymphoid organs. Leukocytes, such as T cells, can also be activated in vitro using anti-CD3/CD28 beads or other methods employed by those of skill in the art (see, e.g., Frauwith and Thompson, J. Clin Invest 109:295-299 (2002); and Trickett and Kwan, J Immunol Methods 275:251-255 (2003)).


As used herein, “allogeneic” means cells, tissue, DNA, or factors taken or derived from a different subject of the same species.


As used herein, the term “stem cell” refers to a cell that can differentiate into one or more specialized cells and has the capacity for self-renewal. Stem cells include pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), and multipotent stem cells, such as cord blood stem cells, mesenchymal stromal cells and adult stem cells, which are found in various tissues. The term “stem cell” also includes cells amenable for genome editing, cells that can serve as a source of a therapeutic cell type (e.g., cells that can be directed to differentiate into a lineage restricted or terminally differentiated cell that is used for cell therapy, or cells of a desired target tissue), and cells with “artificial” cell acquired stem cell properties (e.g., pluripotency or multipotency or self-renewal).


As used herein, the terms “embryonic stem cell” and “ES cell” refer to an embryo-derived totipotent or pluripotent stem cell, derived from the inner cell mass of a blastocyst that can be maintained in an in vitro culture under suitable conditions. ES cells are capable of differentiating into cells of any of the three vertebrate germ layers, e.g., the endoderm, the ectoderm, or the mesoderm. ES cells are also characterized by their ability propagate indefinitely under suitable in vitro culture conditions. See, for example, Thomson et al., Science 282:1145 (1998).


As used herein, the terms “induced pluripotent stem cell,” “iPS cell,” and “iPSC” refer to a pluripotent stem cell that can be derived directly from a differentiated somatic cell. Human PS cells can be generated by introducing specific sets of reprogramming factors into a non-pluripotent cell that can include, for example, Oct3/4, Sox family transcription factors (e.g., Sox1, Sox2, Sox3, SoxI5), Myc family transcription factors (e.g., c-Myc, 1-Myc, n-Myc), Kruppel-like family (KLF) transcription factors (e.g., KLF1, KLF2, KLF4, KLF5), and/or related transcription factors, such as NANOG, LIN28, and/or Glis1. Human PS cells can also be generated, for example, by the use of miRNAs, small molecules that mimic the actions of transcription factors, or lineage specifiers. Human PS cells are characterized by their ability to differentiate into any cell of the three vertebrate germ layers, e.g., the endoderm, the ectoderm, or the mesoderm. Human PS cells are also characterized by their ability propagate indefinitely under suitable in vitro culture conditions. See, for example, Takahashi and Yamanaka, Cell 126:663 (2006).


As used herein, the term “mitigate antigen presenting cell activation and function” refers to a transgene that encodes a gene product whose function is to inhibit antigen presenting cell activation or the ability of an antigen presenting cell to promote the activation of graft attacking leukocytes (Fiorentino et al., J Immunol. 146:3444-51 (1991); Salio et al., Eur J Immunol. 29:3245-53 (1999)). In an embodiment, mitigation of antigen presenting cell activation and function refers to a decrease in APC activation and function of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, relative to a control (e.g., as determined using an assay for antigen presenting cell activation, such as reduced proliferation, reduced secretion of pro-inflammatory cytokines (e.g., interleukin-1 (IL-1, e.g., IL-1β), IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-18, tumor necrosis factor (TNF, e.g., TNFα), interferon gamma (IFNγ), and granulocyte macrophage colony stimulating factor (GMCSF), which can be measured using an ELISA or Western Blot analysis of culture media or a patient sample, such as a blood sample), or reduced levels of cell surface markers (e.g., CD11c, CD11b, HLA molecules (e.g., MHC-II), CD40, B7, IL-2, CD80 or CD86, which can be assessed using flow cytometry, immunohistochemistry, in situ hybridization, and other assays that allow for measurement of cell surface markers)). Antigen presenting cells include dendritic cells, B cells, and macrophages. Mast cells and neutrophils can also be induced to present antigens. Methods for determining mitigation of antigen presenting cell activation and function are known in the art. Examples of gene products that mitigate antigen presenting cell activation and function include, but are not limited to: Ccl21 (Ccl21b) and PD-L1. Such transgenes may be referred herein to “cloaking” or “cloaked” genes.


As used herein, the term “mitigate graft attacking leukocyte activity or cytolytic function” refers to a transgene that encodes a gene product whose function is to inhibit or prevent graft attacking leukocyte activity or cytolytic function near allograft cells (MacDonald et al., J Immunol. 126:1671-5 (1981); Bongrand et al., Eur J Immunol. 13:424-9 (1983); MacDonald et al., Eur J Immunol. 9:466-70 (1979)). In an embodiment, mitigation of graft attacking leukocyte activity or cytolytic function refers to a decrease in leukocyte activity or cytolytic function of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, relative to a control (e.g., as determined using an assay for leukocyte activation, such as reduced proliferation, reduced secretion of pro-inflammatory cytokines (e.g., interleukin-1 (IL-1, e.g., IL-1β), IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-18, tumor necrosis factor (TNF, e.g., TNFα), interferon gamma (IFNγ), and granulocyte macrophage colony stimulating factor (GMCSF), which can be measured using an ELISA or Western Blot analysis of culture media or a patient sample, such as a blood sample), or reduced polarization (e.g., a reduction in the level of IL-12, TNF, IL-1β, IL-6, IL-23, MARCO, MHC-II, CD86, iNOS, CXCL9, and CXCL10 in a macrophage or monocyte, or a reduction in the level of a Th1-specific marker (e.g., T-bet, IL-12R, STAT4), a chemokine receptor (e.g., CCR5, CXCR6, or CXCR3); or a Th2-specific marker: (e.g., CCR3, CXCR4, STAT6, GATA3, or IL-4Rα) in a T cell, which can be assessed using flow cytometry, immunohistochemistry, situ hybridization, qPCR, or western blot analysis for cell surface markers or intracellular proteins, and ELISA or western blot analysis for secreted proteins); or as determined using an assay for cytolytic function (e.g., by incubating leukocytes with a target cell line that has been pre-coated with antibodies to a surface antigen expressed by the target cell line and measuring the number of surviving target cells with a fluorescent viability stain, or by measuring the secretion of cytolytic granules (e.g., perforin, granzymes, or other cytolytic proteins released from immune cells) from the leukocytes). Methods for determining mitigation of graft attacking leukocyte activity or cytolytic function are known in the art. Examples of gene products that mitigate graft attacking leukocyte activity or cytolytic function include, but are not limited to: PD-L1, HLA-G (H2-M3), Cd39, Cd73, and Lag3. Such transgenes may be referred herein to “cloaking” or “cloaked” genes.


As used herein, the term “mitigate macrophage cytolytic function and phagocytosis of allograft cells” refers to a transgene that encodes a gene product whose function is to inhibit or prevent macrophage cytolytic function and/or phagocytosis of allograft cells (Fish et al., Toxicology. 19:127-38. (1981); Sung et al., J Biol Chem. 260:546-54 (1985); Amash et al., J Immunol. 196:3331-40 (2016)). In an embodiment, mitigation of macrophage cytolytic function and phagocytosis of allograft cells refers to a decrease in macrophage cytolytic function and/or phagocytosis of allograft cells of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, relative to a control (e.g., as determined using an assay for macrophage cytolytic function (e.g., by incubating macrophages with a target cell line that has been pre-coated with antibodies to a surface antigen expressed by the target cell line and measuring the number of surviving target cells with a fluorescent viability stain, or by measuring the secretion of cytolytic granules (e.g., perforin, granzymes, or other cytolytic proteins released from immune cells) released from the macrophages; or as determined using an assay for macrophage phagocytosis (e.g., culturing macrophages with fluorescent beads or a target cell line that has been pre-coated with antibodies to a surface antigen expressed by the target cell line and measuring fluorescence inside the immune cell or quantifying the number of beads or cells engulfed)). Methods for determining mitigation of macrophage cytolytic function and phagocytosis of allograft cells are known in the art. Examples of gene products that mitigate macrophage cytolytic function include, but are not limited to: Cd47, Cd200, Mfge8, and Il1r2. Such transgenes may be referred herein to “cloaking” or “cloaked” genes.


As used herein, the term “induce apoptosis in graft attacking leukocytes” refers to a transgene that encodes a gene product whose function is to kill graft attacking leukocytes near allograft cells (Huang et al., Proc Natl Acad Sci USA. 96:14871-6 (1999); Suzuki et al., Proc Natl Acad Sci USA. 97:1707-12 (2000); Simon et al., Proc Natl Acad Sci USA. 98:5158-63 (2001)). In an embodiment, induction of apoptosis in graft attacking leukocytes refers to an increase in apoptosis in graft attacking leukocytes of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, relative to a control (e.g., as determined using an assay for apoptosis, such as TUNEL staining, caspase staining, or Annexin-V staining, or use of fluorescent viability stains). Methods for determining induction of apoptosis in graft attacking leukocytes are known in the art. Examples of gene products that can induce apoptosis in graft attacking leukocytes include, but are not limited to: FASLG (FasL) and Tnfsf10. Such transgenes may be referred herein to “cloaking” or “cloaked” genes.


As used herein, the term “mitigate local inflammatory proteins” refers to a transgene that encodes a gene product whose function is to inhibit the activity of local proteins, where the function of said proteins is to promote graft attacking leukocyte accumulation, and/or their cytolytic function (Felix et al., Nat Rev Immunol. 17:112-29 (2017)). In an embodiment, mitigation of local inflammatory proteins refers to a reduction in local inflammatory proteins of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, relative to a control (e.g., as determined using an assay for inflammatory proteins that promote leukocyte activation or migration to a site of inflammation (e.g., a chemokine, such as CCL2, CCL3, CCL5, CXCL1, CXCL2, and CXCL8, or a pro-inflammatory cytokine, such as IL-1β, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-18, TNFα, IFNγ, or GMCSF, which can be measured using an ELISA, Western blot analysis, or other techniques known in the art for measuring secreted proteins)). Methods for determining mitigation of local inflammatory proteins are known in the art. Examples of gene products that mitigate local inflammatory proteins include, but are not limited to: PD-L1, Il1r2, and Ackr2. Such transgenes may be referred herein to “cloaking” or “cloaked” genes.


As used herein, the term “protect against leukocyte-mediated apoptosis” refers to a transgene that encodes a gene product whose function is to inhibit any cell component that may induce apoptosis or cytolysis of an allograft cell (Abdullah et al., J Immunol. 178:3390-9 (2007)). In an embodiment, protection against leukocyte-mediated apoptosis refers to a decrease in leukocyte-mediated apoptosis of at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100%, relative to a control (e.g., as determined using an assay for leukocyte-mediated apoptosis (e.g., by incubating leukocytes with a target cell line that has been pre-coated with antibodies to a surface antigen expressed by the target cell line and measuring the number of surviving target cells with a fluorescent viability stain, or by measuring the secretion of cytolytic granules (e.g., perforin, granzymes, or other cytolytic proteins released from immune cells) released from the leukocyte). Methods for determining protection against leukocyte-mediated apoptosis are known in the art. Examples of gene products that protect against leukocyte-mediated apoptosis include, but are not limited to: Serpin B9 (Spi6) and Dad1. Such transgenes may be referred herein to “cloaking” or “cloaked” genes.


As used herein, the term “biologic” refers to a designed polypeptide and corresponding encoding DNA, which can be expressed as a transgene. The polypeptide may agonize or inhibit the function of an endogenous gene or inhibit or activate a biological process. Methods for determining whether a polypeptide has agonist or antagonist activity or function are generally known in the art. In an embodiment, the agonist function is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90, 95% or 100% of the function, relative to the function of a control. In an embodiment, the antagonist function is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90, 95% or 100% of the function, relative to the function of a control.


As used herein, the term “operably linked” refers to a first molecule joined to a second molecule, wherein the molecules are so arranged that the first molecule affects the function or expression of the second molecule. The two molecules may or may not be part of a single contiguous molecule and may or may not be adjacent. For example, a promoter is operably linked to a transcribable polynucleotide molecule if the promoter modulates transcription of the transcribable polynucleotide molecule of interest in a cell. Additionally, two portions of a transcription regulatory element are operably linked to one another if they are joined such that the transcription-activating functionality of one portion is not adversely affected by the presence of the other portion. Two transcription regulatory elements may be operably linked to one another by way of a linker nucleic acid (e.g., an intervening non-coding nucleic acid) or may be operably linked to one another with no intervening nucleotides present.


As used herein, the term “promoter” refers to a recognition site on DNA that is bound by an RNA polymerase. The polymerase drives transcription of the transgene.


“Percent (%) sequence identity” with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to the nucleic acids or amino acids in the reference polynucleotide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid or amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, percent sequence identity values may be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence, A, to, with, or against a given nucleic acid or amino acid sequence, B, (which can alternatively be phrased as a given nucleic acid or amino acid sequence, A that has a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence, B) is calculated as follows:


100 multiplied by (the fraction X/Y)


where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program's alignment of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.


As used herein, the term “pharmaceutical composition” refers to a mixture containing a therapeutic agent, optionally in combination with one or more pharmaceutically acceptable excipients, diluents, and/or carriers, to be administered to a subject, such as a mammal, e.g., a human, in order to prevent, treat or control a particular disease or condition affecting or that may affect the subject.


As used herein, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions and/or dosage forms, which are suitable for contact with the tissues of a subject, such as a mammal (e.g., a human) without excessive toxicity, irritation, allergic response and/or other problem complications commensurate with a reasonable benefit/risk ratio.


As used herein, the term “wild-type” refers to a genotype with the highest frequency for a particular gene in a given organism.


The terms “cell division locus”, “cell division loci”, and “CDL” as used herein, refer to a genomic locus (or loci) whose transcription product(s) is expressed by dividing cells. When a CDL comprises a single locus, absence of CDL expression in a cell (or its derivatives) means that tumour initiation and/or formation is prohibited either because the cell(s) will be ablated in the absence of CDL expression or because proliferation of the cell(s) will be blocked or compromised in the absence of CDL expression. When a CDL comprises multiple loci, absence of expression by all or subsets of the loci in a cell (or its derivatives) means that tumour initiation and/or formation is prohibited either because the cell(s) will be ablated in the absence of CDL expression or because proliferation of the cell(s) will be blocked or compromised in the absence of CDL expression. A CDL may or may not be expressed in non-dividing and/or non-proliferating cells. A CDL may be endogenous to a host cell or it may be a transgene. If a CDL is a transgene, it may be from the same or different species as a host cell or it may be of synthetic origin. In an embodiment, a CDL is a single locus that is transcribed during cell division. For example, in an embodiment, a single locus CDL is CDK1. In an embodiment, a CDL comprises two or more loci that are transcribed during cell division. For example, in an embodiment, a multi-locus CDL comprises two MYC genes (c-Myc and N-myc) (Scognamiglio et al., 2016). In an embodiment, a multi-locus CDL comprises AURORA B and C kinases, which may have overlapping functions (Fernandez-Miranda et al., 2011). Cell division and cell proliferation are terms that may be used interchangeably herein.


The terms “normal rate of cell division”, “normal cell division rate”, “normal rate of cell proliferation”, and “normal cell proliferation rate” as used herein, refer to a rate of cell division and/or proliferation that is typical of a non-cancerous healthy cell. A normal rate of cell division and/or proliferation may be specific to cell type. For example, it is widely accepted that the number of cells in the epidermis, intestine, lung, blood, bone marrow, thymus, testis, uterus and mammary gland is maintained by a high rate of cell division and a high rate of cell death. In contrast, the number of cells in the pancreas, kidney, cornea, prostate, bone, heart and brain is maintained by a low rate of cell division and a low rate of cell death (Pellettieri and Senchez Alvarado, 2007).


The terms “inducible negative effector of proliferation” and “iNEP” as used herein, refer to a genetic modification that facilitates use of CDL expression to control cell division and/or proliferation by: i) inducibly stopping or blocking CDL expression, thereby prohibiting cell division and proliferation; ii) inducibly ablating at least a portion of CDL-expressing cells (i.e., killing at least a portion of proliferating cells); or iii) inducibly slowing the rate of cell division relative to a cell's normal cell division rate, such that the rate of cell division would not be fast enough to contribute to tumor formation.


The terms “ablation link” and “ALINK” as used herein, refer to an example of an iNEP, which comprises a transcriptional link between a CDL and a sequence encoding a negative selectable marker. The ALINK modification allows a user to inducibly kill proliferating host cells comprising the ALINK or inhibit the host cell's proliferation by killing at least a portion of proliferating cells by exposing the ALINK-modified cells to an inducer of the negative selectable marker. For example, a cell modified to comprise an ALINK at a CDL may be treated with an inducer (e.g., a prodrug) of the negative selectable marker in order to ablate proliferating cells or to inhibit cell proliferation by killing at least a portion of proliferating cells.


The terms “exogenous activator of regulation of CDL” and “EARC” as used herein, refer to an example of an iNEP, which comprises a mechanism or system that facilitates exogenous alteration of non-coding or coding DNA transcription or corresponding translation via an activator. An EARC modification allows a user to inducibly stop or inhibit division of cells comprising the EARC by removing from the EARC-modified cells an inducer that permits transcription and/or translation of the EARC-modified CDL. For example, an inducible activator-based gene expression system may be operably linked to a CDL and used to exogenously control expression of a CDL or CDL translation, such that the presence of a drug inducible activator and corresponding inducer drug are required for CDL transcription and/or translation. In the absence of the inducer drug, cell division and/or proliferation would be stopped or inhibited (e.g., slowed to a normal cell division rate). For example, the CDL Cdk1/CDK1 may be modified to comprise a dox-bridge, such that expression of Cdk1/CDK1 and cell division and proliferation are only possible in the presence of an inducer (e.g., doxycycline).


The term “proliferation antagonist system” as used herein, refers to a natural or engineered compound(s) whose presence inhibits (completely or partially) proliferation of a cell.


The term “dox-bridge” as used herein, refers to a mechanism for separating activity of a promoter from a target transcribed region by expressing rtTA (Gossen et al., 1995) by the endogenous or exogenous promoter and rendering the transcription of target region under the control of TRE. As used herein, “rtTA” refers to the reverse tetracycline transactivator elements of the tetracycline inducible system (Gossen et al., 1995) and “TRE” refers to a promoter consisting of TetO operator sequences upstream of a minimal promoter. Upon binding of rtTA to the TRE promoter in the presence of doxycycline, transcription of loci downstream of the TRE promoter increases. The rtTA sequence may be inserted in the same transcriptional unit as the CDL or in a different location of the genome, so long as the transcriptional expression's permissive or non-permissive status of the target region is controlled by doxycycline. A dox-bridge is an example of an EARC.


As used herein, the term “fail-safe cell” refers to a cell that contains one or more homozygous, heterozygous, hemizygous or compound heterozygous ALINKs or EARCs in one or more CDLs (e.g., at least two, three, four, or five CDLs). Fail-safe cells may contain either ALINKs or EARCs or both ALINK and EARC modifications (e.g., ALINK and EARC modifications in different CDLs or in a single CDL).


As used herein, the term “fail-safe” refers to a property of a cell that is unlikely to exhibit uncontrolled (e.g., tumorigenic) proliferation. A cell can be considered “fail safe” when cell proliferation is under the control of a negative regulator or inducer, and the possibility of the cell losing the activity of the system that controls proliferation due to genetic mutation is low. The fail-safe volume will depend on the number of ALINKs and the number of ALINK-targeted CDLs (e.g., a cell with homozygous modifications of two different CDLs has a higher fail safe volume (e.g., it is less likely to lose all systems that control proliferation through genetic mutation) than a cell with a heterozygous modification of a single CDL). The fail-safe property is further described in Table 3.





DESCRIPTION OF THE DRAWINGS

Many of the drawings submitted herein are better understood in color, which is not available in patent application publications at the time of filing. Applicants consider the color versions of the drawings as part of the original submission and reserve the right to present color images of the drawings in later proceedings.


These and other features of the disclosure will become more apparent in the following detailed description in which reference is made to the appended drawings wherein:



FIGS. 1A-1D depict representative images showing the expression of cloaking proteins (Cd200 (FIG. 1A), FasL (FIG. 1B), H2-M3 (FIG. 1C) and Cd47 (FIG. 1D)) in C57BL/6 mouse embryonic stem cell line C2 using immunohistochemistry.



FIGS. 2A-2E are flow cytometry plots showing T-cell activation using splenocytes (FIG. 2A), wt B16 melanoma cells (FIG. 2B), cloaked B16 melanoma cells (FIG. 2C), wt ES cells (FIG. 2D), and cloaked ES cells (FIG. 2E) in a mixed lymphocyte reaction.



FIGS. 3A-3B are schematics and images showing that cloaked (FIG. 3B) B16F10 cancer cells in an allogenic model are protected from rejection compared to their WT counterparts (FIG. 3A). Representative images of uncloaked cells in C57BL/6 (n=5) and uncloaked cells in FVB/N (n=4) (FIG. 3A); cloaked cells in C57BL/6 (n=5) and cloaked cells in FVB/N (n=6) (FIG. 3B).



FIG. 4 is a schematic showing that cloaked embryonic stem cells form tumors in isogenic B6 mouse recipients (upper panel) and in FVB allogenic recipients (lower panel).



FIGS. 5A-5C are a series of photographs depicting allogenic mice bearing teratomas formed from subcutaneous injection of cloaked C57BL/6 ES cells. Red arrows indicate teratomas.



FIG. 5A shows teratomas in C3H mice, FIG. 5B shows teratomas in FVB/N mice, and FIG. 5C shows teratomas in CD1 mice.



FIG. 6 is a schematic and series of images showing that animals with cloaked tissue are not immune compromised.



FIG. 7 is a series of images of FVB/N mice showing additional results showing that animals with cloaked tissues are not immune compromised.



FIGS. 8A-8H show transgene expression in clonal FailSafe containing embryonic stem cells derived from C57BL/6 mice. FIG. 8A shows FasL expression, FIG. 8B shows Ccl21b expression, FIG. 8C shows Cd200 expression, FIG. 8D shows Cd47 expression, FIG. 8E shows Mfge8 expression, FIG. 8F shows Spi6 expression, FIG. 8G H2-M3 expression, and FIG. 8H shows PD-L1 expression.



FIG. 9 is a series of graphs depicting cloaking transgene expression in ES cell clones. Each cloaking transgene is depicted in a different color. Concentric circles represent expression level on a log 10 scale. The thick black circle represents 1× expression normalized to positive controls (activated leukocytes isolated from murine lymph organs), with the next outer ring representing 10× and 100× expression compared to positive controls, respectively. The innermost ring is 0.1× expression compared to positive controls. Clones NT2 and 15 (indicated with red squares) had the highest expression of the cloaking genes. These clones survived in allogenic hosts.



FIG. 10 is a graph depicting the expression of the cloaking transgenes among the whole genome gene expression level distribution for the whole genome of ES cells. All 8 cloaking transgenes in the NT2 cell line and NT2-derived teratoma had an expression level that was among the top 5% of all genes in the ES cell genome, with 5 of the cloaking transgenes having an expression level in the top 1% of all genes in the ES cell genome. The expression levels of the transgenes in the NT2 line and NT2-derived teratoma succeeded to achieve allograft tolerance.



FIGS. 11A-11 are photographs showing C57BL/6 derived teratomas in FVB/N mice. The transgenic line, NT2, resulted in 9 teratomas out of 10 injection sites. Images were taken 3 months post injection. FIG. 11B is an enlarged image of the teratoma indicated by the arrow in FIG. 11A.



FIGS. 12A-12B are graphs showing the teratoma tumor size in isogenic (FIG. 12A) and allogenic (FIG. 12B) mice treated with ganciclovir.



FIGS. 13A-13B are a series of photomicrographs showing that cloaked embryonic stem cells, injected into both isogenic (FIG. 13A) and allogenic (FIG. 13B) hosts, can differentiate into all three cell lineages.



FIGS. 14A-14D are photomicrographs showing the formation of all three germ layers in a teratoma formed from subcutaneous injection of cloaked ES cells into a mouse. FIG. 14A, FIG. 14B, and FIG. 14C show the three germ layers (ec=ectoderm, shown in FIG. 14A; en=endoderm, shown in FIG. 14C; me=mesoderm, shown in FIG. 14B). FIG. 14D shows a blood vessel, indicated by the red arrow, confirming that the tissues are well vascularized.



FIG. 15 is a schematic showing the construction of vectors that express target genes essential for allo-tolerance.



FIGS. 16A-16H are fluorescent photomicrographs showing the expression of proteins encoded by the cloaking transgenes in ES cells. FIG. 16A shows the expression of PD-L1, FIG. 16B shows the expression of CD200, FIG. 16C shows the expression of CD47, FIG. 16D shows the expression of FasL, FIG. 16E shows the expression of H2-M3, FIG. 16F shows the expression of Ccl21, FIG. 16G shows the expression of Mfge8, and FIG. 16H shows the expression of Spi6.



FIGS. 17A-17B are photomicrographs showing that cloaked ES cells have typical ES cell morphology (FIG. 17A) and express the ES cell marker alkaline phosphatase (FIG. 17B).



FIGS. 18A-18B are fluorescent photomicrographs showing the expression of markers of pluripotent ES cells (Oct4 (FIG. 18A) and SSEA1 (FIG. 18B)) in cloaked ES cells. The insets in FIGS. 18A-18B show single channel images of the fluorescent micrographs for the ES cell markers (Oct4 and SSEA) and DAPI, which labels the nucleus, to demonstrate that staining for the ES cell markers colocalizes with the cloaked cells.



FIG. 19 is a schematic depicting the immune processes that are inhibited by the cloaking transgenes (top) and the expression cassette (bottom) used to express the cloaking transgenes in ES cells.



FIG. 20 is a series of graphs depicting the effect of interferon gamma (IFNγ) on MHC levels in ES cells. IFNγ increased MHC levels in wild-type ES cells and ES cells overexpressing the wild-type IFNγ receptor IFNγR1, but did not increase MHC levels in ES cells overexpressing a dominant negative form of the IFNγ receptor (IFNγR1 d39), indicating that IFNγR1 d39 completely inhibited the IFNγ-mediated upregulation of MHCs in ES cells.





DETAILED DESCRIPTION OF THE DISCLOSURE

Description of Cells and Methods


Featured are tools, such as genetically modified cells, and methods for providing a local immune suppression at a transplant site using the cells, e.g., when the cells are transplanted in an allogeneic host. The genetically modified cell comprises: one or a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting and whose function is to mitigate function of the host immune system (e.g., graft attacking leukocyte and NK cell activation) or act as a defense mechanism against attacking leukocytes.


Various cytoplasmic, membrane-bound, or local acting immune factors have been found to regulate the local immune compartment and local immune populations. Immune factors like PD-L1 (Brown et al., J Immunol. 170:1257-66 (2003: Curiel et al., Nat Med. 9:562-7 (2003); Dong et al., Nat Med. 8:793-800 (2002)), CD47 ((Willingham et al., Proc Natl Acad Sci USA. 109:6662-7 (2012); Liu et al., PLoS One. 10:e0137345 (2015); Demeure et al., J Immunol. 164:2193-9 (2000)), CD200 (Jenmalm et al., J Immunol. 176:191-9 (2006); Cherwinski et al., J Immunol. 174:1348-56 (2005); Kretz-Rommel et al., J Immunol. 178:5595-605 (2007)), FasL (O'Connell et al., J Exp Med. 184:1075-82 (1996); Ju et al., Nature. 373:444-8 (1995); Mazar et al., J Biol Chem. 284:22022-8 (2009)), and Spi6 (Medema Proceedings of the National Academy of Sciences of the United States of America. 98:11515-20 (2001); Zhang et al., Immunity. 24:451-61 (2006); Soriano et al., Lung Cancer. 77:38-45 (2012)) are among the very many that have been described, including their role in immune modulation. We discovered that expression of one or more of these immune regulatory factors in an allogenic cell can be used to provide local immune suppression and/or reduce allorejection in a host to which the cells are administered.


We modified allogenic cells through the use of specific immunomodulatory factors introduced into a cell or population of cells. The modified cells evade immune rejection through the simultaneous modulation of many different local immune pathways. Such genetically engineered cells can be transplanted “off the shelf” into many recipients regardless of genetic background and without rejection by the recipient's immune system. This immunomodulatory approach overcomes the requirement for systemic immunosuppression of the transplant recipient, which can be dangerous to the recipient. Thus, although an immunosuppressive agent(s) can be administered to a patient that receives the modified cells described herein, the therapy need not include the administration of an immunosuppressive agent(s). This immunomodulatory approach also overcomes the costly and impractical methodology of deriving patient-specific iPS cells, manipulating regulatory cells, or inducing chimerism through hematopoietic cell transplantation (HCT).


Cells can be genetically modified to express a set of transgenes encoding gene products that are cytoplasmic, membrane bound, or local acting, and whose function is to mitigate immune function (e.g., graft attacking leukocyte and NK cell activation) or to act as a defense mechanism against the immune response (e.g., attacking leukocytes). The set of transgenes may be selected from the genes having a role in the immune modulatory pathways described above. Such genes include, but are not limited to those provided in Table 1.









TABLE 1







Genes that can be expressed by allogenic cells for local immunosuppression








Gene
Function





PD-L1
Induces cell death in PD-L1 expressing T cells and macrophages


HLA-G
Inhibits NK cells from attacking cells lacking MHC molecules


(mouse gene: H2-M3)



Cd47
Negative regulator of macrophages and killer T cells


Cd200
Inhibits macrophage activation


FASLG
Induces apoptosis in Fas expressing CD8+ T cells


(mouse gene: FasL)



Clc21
Chemo-attractant for antigen presenting cells (APCs)


(mouse gene: Ccl21b)



Mfge8
Inhibition of macrophage phagocytosis


Serpin B9
Inhibition of granzyme/perforin attack


(mouse gene: Spi6)



Dad1
Negative regulator of programmed cell death


Tnfrsf10
Induces apoptosis in leukocytes expressing the TRAIL receptor


Cd39
Converts ATP to AMP, inhibits T-cells


Cd73
Converts AMP to adenosine, inhibits T-cells, suppresses dendritic



cells


Lag3
Inhibits T-cell activation, proliferation, function


ll1r2
Blocks IL-1B activity, blocks inflammation and innate cell activation


Ackr2
Decoy receptor for chemokines, prevents leukocyte accumulation


Tnfrsf22
Decoy receptor, blocks TRAIL-induced apoptosis from T-cells


Tnfrsf23
Decoy receptor, blocks TRAIL-induced apoptosis from T-cells


IFNγR1 d39
Dominant negative interferon gamma receptor 1, prevents IFNγ-



mediated upregulation of MHCs in ES cells









C—C motif chemokine ligand 21 (Ccl21) is expressed by local lymph nodes where it acts to attract activated antigen presenting cells (APCs). This key function offers an opportunity to “reverse” the migration of APCs by overexpressing this gene on grafted cells. Indeed, some melanomas express Ccl21 and recruit CCR7+ cells that, in turn, can reorganize portions of their tumor stroma as “self”. This leads to a stromal reconstruction that directs the recruitment and maintenance of Cd4+ Tregs (Zindl et al., Science. 328:697-8 (2010)). In fact, the expression of Ccl21 on tumors can protect co-implanted Ccl21 deficient tumor cells from rejection in a syngeneic allograft setting (Shields et al., Science. 328:749-52(2010)). Ccl21b is the mouse ortholog of human Ccl21.


The amino acid sequences of mouse and human Ccl21 are:











Mouse Ccl21



(SEQ ID NO: 1)



MAQMMTLSLLSLVLALCIPWTQGSDGGGQDCCLKYSQKKI







PYSIVRGYRKQEPSLGCPIPAILFLPRKHSKPELCANPEE







GWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSK







GCKRTEQTQPSRG







Human Ccl21



(SEQ ID NO: 2)



MAQSLALSLLILVLAFGIPRTQGSDGGAQDCCLKYSQRKI







PAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKE







LWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSK







GCKRTERSQTPKGP






Expression of Cd47 in umbilical cord blood can promote the development of hyporesponsive T-cells (Avice et al., J Immunol. 167:2459-68 (2001)). Erythrocytes also up-regulate Cd47 to avoid dendritic cell activation due to their lack of “self” presentation (van den Berg et al., Immunity. 43:622-4 (2015)). More recently, it was shown that expression of human Cd47 increases engraftment in a mouse model of pig-to-human hematopoietic cell transplantation (Tena et al., Am J Transplant. 14:2713-22 (2014)).


The amino acid sequences of mouse and human Cd47 are:











Mouse Cd47



(SEQ ID NO: 3)



MWPLAAALLLGSCCCGSAQLLFSNVNSIEFTSCNETVVIP







CIVRNVEAQSTEEMFVKWKLNKSYIFIYDGNKNSTTTDQN







FTSAKISVSDLINGIASLKMDKRDAMVGNYTCEVTELSRE







GKTVIELKNRTVSWFSPNEKILIVIFPILAILLFWGKFGI







LTLKYKSSHTNKRIILLLVAGLVLTVIVVVGAILLIPGEK







PVKNASGLGLIVISTGILILLQYNVFMTAFGMTSFTIAIL







ITQVLGYVLALVGLCLCIMACEPVHGPLLISGLGIIALAE







LLGLVYMKFVASNQRTIQPPRNR







Human Cd47



(SEQ ID NO: 4)



MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIP







CFVTNMEAQNTTEVYVKWKFKGRDIYTFDGALNKSTVPTD







FSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELT







REGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQF







GIKTLKYRSGGMDEKTIALLVAGLVITVIVIVGAILFVPG







EYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIA







ILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILAL







AQLLGLVYMKFVASNQKTIQPPRKAVEEPLNAFKESKGMM







NDE






Cd200 is also as an important immunoregulatory molecule; increased expression can reduce the severity of allograft rejection, autoimmunity, and allergic disease (Gorczynski et al., J Immunol. 172:7744-9 (2004)). It has been shown that, in vitro, APC expression of Cd200 suppresses production of interferon gamma (IFN-γ) and cytolytic granules by activated Cd8+ T-cells (Misstear et al., J Virol. 86:6246-57 (2012)). Most interestingly, overexpression of Cd200 increases the survival of skin and cardiac allografts in mice by promoting of Foxp3+ Treg cells (Gorczynski et al., Transplantation. 98:1271-8 (2014)).


The amino acid sequences of mouse and human Cd200 are:











Mouse Cd200



(SEQ ID NO: 5)



MGSLVFRRPFCHLSTYSLIWGMAAVALSTAQVEVVTQDER







KALHTTASLRCSLKTSQEPLIVTWQKKKAVSPENMVTYSK







THGVVIQPAYKDRINVTELGLWNSSITFWNTTLEDEGCYM







CLFNTFGSQKVSGTACLTLYVQPIVHLHYNYFEDHLNITC







SATARPAPAISWKGTGTGIENSTESHFHSNGTTSVTSILR







VKDPKTQVGKEVICQVLYLGNVIDYKQSLDKGFWFSVPLL







LSIVSLVILLVLISILLYWKRHRNQERGESSQGMQRMK







Human Cd200



(SEQ ID NO: 6)



MERLVIRMPFSHLSTYSLVWVMAAVVLCTAQVQVVTQDER







EQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSE







NHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYM







CLFNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITC







SATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILH







IKDPKNQVGKEVICQVLHLGTVTDFKQTVNKGYWFSVPLL







LSIVSLVILLVLISILLYWKRHRNQDRGELSQGVQKMT






Spi6 is an endogenous inhibitor of the cytotoxic effector molecule granzyme B released by activated Cd8+ T-cells (Sun et al., J Biol Chem. 272:15434-41 (1997)). Some data shows that Mesenchymal Stem Cells (MSCs) escape immune rejection by upregulating this molecule (El Haddad et al., Blood. 117:1176-83 (2011)). It has also recently been demonstrated that the ability of dendritic cells to present antigen to cytotoxic T cells without themselves being killed through contact mediated cytotoxicity is mediated by Spi6 (Lovo et al., J Immunol. 188:1057-63 (2012)). Spi6 is also known as Serpin B9.


The amino acid sequences of mouse Spi6 and the human counterpart, Serpin B9, are:











Mouse Spi6



(SEQ ID NO: 7)



MNTLSEGNGTFAIHLLKMLCQSNPSKNVCYSPASISSALA







MVLLGAKGQTAVQISQALGLNKEEGIHQGFQLLLRKLNKP







DRKYSLRVANRLFADKTCEVLQTFKESSLHFYDSEMEQLS







FAEEAEVSRQHINTWVSKQTEGKIPELLSGGSVDSETRLV







LINALYFKGKWHQPFNKEYTMDMPFKINKDEKRPVQMMCR







EDTYNLAYVKEVQAQVLVMPYEGMELSLVVLLPDEGVDLS







KVENNLTFEKLTAWMEADFMKSTDVEVFLPKFKLQEDYDM







ESLFQRLGVVDVFQEDKADLSGMSPERNLCVSKFVHQSVV







EINEEGTEAAAASAIIEFCCASSVPTFCADHPFLFFIRHN







KANSILFCGRFSSP







Human Serpin B9



(SEQ ID NO: 8)



METLSNASGTFAIRLLKILCQDNPSHNVFCSPVSISSALA







MVLLGAKGNTATQMAQALSLNTEEDIHRAFQSLLTEVNKA







GTQYLLRTANRLFGEKTCQFLSTFKESCLQFYHAELKELS







FIRAAEESRKHINTWVSKKTEGKIEELLPGSSIDAETRLV







LVNAIYFKGKWNEPFDETYTREMPFKINQEEQRPVQMMYQ







EATFKLAHVGEVRAQLLELPYARKELSLLVLLPDDGVELS







TVEKSLTFEKLTAWTKPDCMKSTEVEVLLPKFKLQEDYDM







ESVLRHLGIVDAFQQGKADLSAMSAERDLCLSKFVHKSFV







EVNEEGTEAAAASSCFVVAECCMESGPRFCADHPFLFFIR







HNRANSILFCGRFSSP






Activated, cytotoxic, Cd8+ can kill target cells by expression of FasL, which binds to the FAS receptor and activates a caspase-mediated apoptosis in targeted cells. However, many tumors have developed a “counterattack” by upregulating FasL on their surface (Chen et al., J Immunol. 171:1183-91 (2003)). Selective expression of FasL in the vasculature of human and mouse solid tumors has been associated with scarce Cd8+ T-cell infiltration and a predominance of FoxP3+ Treg cells (Motz et al. Nat Med. 20:607-15 (2014)). Most recently, it was shown that B-lymphocytes also use the expression of FasL to kill T helper cells at the effector stage of immune responses (Lundy et al., Front Immunol. 6:122 (2015)). FasL is the mouse ortholog of human FASLG.


The amino acid sequences of mouse FasL and the human counterpart, FASLG, are:











Mouse FasL



(SEQ ID NO: 9)



MQQPMNYPCPQIFWVDSSATSSWTPPGSVFPCPSSGPRGP







DQRRPPPPPPPVSPLPPPSQPLPLPPLTPLKKKDHNTNLW







LPVVFFMVLVALVGMGLGMYQLFHLQKELAELREFTNQSL







KVSSFEKQIANPSTPSEKKELRSVAHLTGNPHSRSIPLEW







EDTYGTALISGVKYKKGSLVINEAGLYFVYSKVYFRGQSC







NNQPLNHKVYMRNSKYPGDLVLMEEKRLNYCTTGQIWAHS







SYLGAVFNLTSADHLYVNISQLSLINFEESKTFFGLYKL







Human FASLG



(SEQ ID NO: 10)



MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRP







GQRRPPPPPPPPPLPPPPPPPPLPPLPLPPLKKRGNHSTG







LCLLVMFFMVLVALVGLGLGMFQLFHLQKELAELRESTSQ







MHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPL







EWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQ







SCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWA







RSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYK







L






PD-L1 is a critical immune modulatory molecule that binds to Programmed Cell Death 1 (PD-1). PD-1 is expressed on T-cells, and binding to PD-L1 results in T-cell anergy (MacDonald et al., J Immunol. 126:1671-5 (1981)).


The amino acid sequences of mouse and human PD-L1 are:











Mouse PD-L1



(SEQ ID NO: 11)



MRIFAGIIFTACCHLLRAFTITAPKDLYVVEYGSNVTMEC







RFPVERELDLLALVVYWEKEDEQVIQFVAGEEDLKPQHSN







FRGRASLPKDQLLKGNAALQITDVKLQDAGVYCCIISYGG







ADYKRITLKVNAPYRKINQRISVDPATSEHELICQAEGYP







EAEVIWTNSDHQPVSGKRSVTTSRTEGMLLNVTSSLRVNA







TANDVFYCTFWRSQPGQNHTAELIIPELPATHPPQNRTHW







VLLGSILLFLIVVSTVLLFLRKQVRMLDVEKCGVEDTSSK







NRNDTQFEET







Human PDL1 (CD274)



(SEQ ID NO: 12)



MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIEC







KFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSS







YRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGG







ADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGY







PKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRIN







TTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTH







LVILGAILLCLGVALTFIFRLRKGRMMDVKKCGIQDTNSK







KQSDTHLEET






Inflammatory environments, like those induced by allograft transplants, attracts macrophages and inflammatory monocytes, among many other innate immune cells. The milk fat globule epidermal growth factor-8 (Mfge-8) is expressed by many murine tumours (Neutzner et al., Cancer Res. 67:6777-85 (2007)) and has been shown to contribute to local immune suppression by polarizing incoming monocytes to suppressive, M2-like macrophages (Soki et al., J Biol Chem. 289:24560-72 (2014)).


The amino acid sequences of mouse and human MFGE-8 are:











Mouse MFGE8



(SEQ ID NO: 13)



MQVSRVLAALCGMLLCASGLFAASGDFCDSSLCLNGGTCL







TGQDNDIYCLCPEGFTGLVCNETERGPCSPNPCYNDAKCL







VTLDTQRGDIFTEYICQCPVGYSGIHCETETNYYNLDGEY







MFTTAVPNTAVPTPAPTPDLSNNLASRCSTQLGMEGGAIA







DSQISASSVYMGFMGLQRWGPELARLYRTGIVNAWTASNY







DSKPWIQVNLLRKMRVSGVMTQGASRAGRAEYLKTFKVAY







SLDGRKFEFIQDESGGDKEFLGNLDNNSLKVNMFNPTLEA







QYIKLYPVSCHRGCTLRFELLGCELHGCSEPLGLKNNTIP







DSQMSASSSYKTWNLRAFGWYPHLGRLDNQGKINAWTAQS







NSAKEWLQVDLGTQRQVTGIITQGARDFGHIQYVASYKVA







HSDDGVQWTVYEQGSSKVFQGNLDNNSHKKNIFEKPFMAR







YVRVLPVSWHNRITLRLELLGC







Human MFGE8



(SEQ ID NO: 14)



MPRPRLLAALCGALLCAPSLLVALDICSKNPCHNGGLCEE







ISQEVRGDVFPSYTCTCLKGYAGNHCETKCVEPLGMENGN







IANSQIAASSVRVTFLGLQHWVPELARLNRAGMVNAWTPS







SNDDNPWIQVNLLRRMWVTGVVTQGASRLASHEYLKAFKV







AYSLNGHEFDFIHDVNKKHKEFVGNWNKNAVHVNLFETPV







EAQYVRLYPTSCHTACTLRFELLGCELNGCANPLGLKNNS







IPDKQITASSSYKTWGLHLFSWNPSYARLDKQGNFNAWVA







GSYGNDQWLQVDLGSSKEVTGIITQGARNFGSVQFVASYK







VAYSNDSANWTEYQDPRTGSSKIFPGNWDNHSHKKNLFET







PILARYVRILPVAWHNRIALRLELLGC






The potent killing potential of NK cells is also absolutely critical in graft rejection. NK cells can kill targets cells that lack MHC class I molecules, as well as other cells within an inflammatory setting. H2-M3, the murine homologue of human HLA-G has recently been shown to have a regulatory effect on NK cells, licensing them to ignore cells that lack “self molecules” (Andrews et al., Nat Immunol. 13:1171-7 (2012)). This is thought to be achieved by binding of HLA-G, immunosuppressive receptors on both NK and T-cells (Carosella et al., Adv Immunol. 127:33-144 (2015)). H2-M3 is the mouse ortholog of human HLA-G.


The amino acid sequences of mouse H2-M3 and the human counterpart, HLA-G, are:











Mouse H2-M3



(SEQ ID NO: 15)



SIEEIPRMEPRAPWMEKERPEYWKELKLKVKNIAQSARAN







LRTLLRYYNQSEGGSHILQWMVSCEVGPDMRLLGAHYQAA







YDGSDYITLNEDLSSWTAVDMVSQITKSRLESAGTAEYFR







AYVEGECLELLHRFLRNGKEILQRADPPKAHVAHHPRPKG







DVTLRCWALGFYPADITLTWQKDEEDLTQDMELVETRPSG







DGTFQKWAAVVVPSGEEQRYTCYVHHEGLTEPLALKWGRS







SQSSVVIMV







Human HLA-G



(SEQ ID NO: 16)



MVVMAPRTLFLLLSGALTLTETWAGSHSMRYFSAAVSRPG







RGEPRFIAMGYVDDTQFVRFDSDSACPRMEPRAPWVEQEG







PEYWEEETRNTKAHAQTDRMNLQTLRGYYNQSEASSHTLO







WMIGCDLGSDGRLLRGYEQYAYDGKDYLALNEDLRSWTAA







DTAAQISKRKCEAANVAEQRRAYLEGTCVEWLHRYLENGK







EMLQRADPPKTHVTHHPVFDYEATLRCWALGFYPAEIILT







WQRDGEDQTQDVELVETRPAGDGTFQKWAAVVVPSGEEQR







YTCHVQHEGLPEPLMLRWKQSSLPTIPIMGIVAGLVVLAA







VVTGAAVAAVLWRKKSSD






A set of transgenes that includes one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, H2-M3, Cd47, Cd200, FasL, Ccl21b, Mfge8, and Spi6A can be expressed in cells. The cells may be, for example, stem cells or a cell that is amenable to genome editing, such as a cell that can be used for therapy and/or differentiated into a therapeutic cell type. The stem cells may be, for example, embryonic stem (ES) cells or induced pluripotent stem (iPS) cells. The set of transgenes may comprise 1, 2, 3, 4, 5, 6, 7, or all 8 of these genes or may comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 of these genes. The cell may be further genetically modified to express one or more of TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and/or IFNγR1 d39. The TGF-β transgene may be modified to express the gene product in a membrane-bound form (i.e., such that the gene product is expressed on the cell surface of the allograft), using methods known to those skilled in the art. For example, a method for localizing TGF-β to the membrane is to co-express TGF-β with an additional transgene encoding the LRRC32 protein or any other polypeptide that results in localization of TGF-β to the cell membrane. This protein anchors TGF-β to the membrane. (Tran D Q et al., Proc Natl Acad Sci U.S.A 106:13445-50 (2009)).


The amino acid sequence of IFNγR1 d39 is:











(SEQ ID NO: 17)



MGPQAAAGRMILLVVLMLSAKVGSGALTSTEDPEPPSVPV







PTNVLIKSYNLNPVVCWEYQNMSQTPIFTVQVKVYSGSWT







DSCTNISDHCCNIYGQIMYPDVSAWARVKAKVGQKESDYA







RSKEFLMCLKGKVGPPGLEIRRKKEEQLSVLVFHPEVVVN







GESQGTMFGDGSTCYTFDYTVYVEHNRSGEILHTKHTVEK







EECNETLCELNISVSTLDSRYCISVDGISSFWQVRTEKSK







DVCIPPFHDDRKDSIWILVVAPLTVFTVVILVFAYWYTKK







NSFKRKSIMLPKSLLSVVKSATLETKPESKYSLVTPHQPA







VLESETVICEEPLSTVTAPDSPEAAEQEELSKETKALEAG







GSTSAMTPDSPPTPTQRRSFSLLSSNQSGPCSLTAYHSRN







GSDSGLVGSGSSSDLESLPNNNSETKMAEHDPPPVRKA






The genes may be human genes or murine genes. In an embodiment, the gene is of the same species as the recipient of the allograft recipient in which the cell is to be transplanted. In an embodiment, the gene is of any species in which the function of the gene is conserved or in which a designed biologic has the agonist function of the endogenous counterpart. Methods for introducing and expressing these transgenes in cells are described herein and are also known to those skilled in the art. Cells expressing these transgenes may be referred to as “cloaked” due to their ability to evade allorejection without systemic immunosuppression and without the need for immunosuppressive drugs.


It is contemplated herein that populations of cells derived from the above-described cloaked cells can also be used to produce a local immunosuppression when transplanted at a transplant site of an allogeneic recipient.


Before or after generating the cloaked cells of the disclosure, the cells can first be modified to be fail-safe cells. Fail-safe cells use cell division loci (CDLs) to control cell proliferation in animal cells. CDLs, as provided herein, are loci whose transcription product(s) are expressed during cell division. CDLs may be genetically modified, as described herein, to comprise a negative selectable marker and/or an inducible activator-based gene expression system, which allows a user to permit, ablate, and/or inhibit proliferation of the genetically modified cell(s) by adding or removing an appropriate inducer. Methods for making and using fail-safe cells are described, for example, in WO 2016/141480, the entire teachings of which are incorporated herein by reference. A cell may be made fail-safe first and then cloaked afterwards. Alternatively, a cell may be cloaked first and then made fail-safe afterwards.


The cell may be a vertebrate cell, for example, a mammalian cell, such as a human cell or a mouse cell. The cell may also be a vertebrate stem cell, for example, a mammalian stem cell, such as a human stem cell or a mouse stem cell. Preferably, the cell or stem cell is amenable to genetic modification. Preferably, the cell or stem cell is deemed by a user to have therapeutic value, meaning that the cell or stem cell may be used to treat a disease, disorder, defect or injury in a subject in need of treatment for same.


In some embodiments, the cell is a stem cell or progenitor cell (e.g., iPSC, embryonic stem cell, hematopoietic stem cell, mesenchymal stem cell, endothelial stem cell, epithelial stem cell, adipose stem or progenitor cells, germline stem cells, lung stem or progenitor cells, mammary stem cells, olfactory adult stem cells, hair follicle stem cells, multipotent stem cells, amniotic stem cells, cord blood stem cells, or neural stem or progenitor cells). In some embodiments, the stem cells are adult stem cells (e.g., somatic stem cells or tissue specific stem cells). In some embodiments, the stem or progenitor cell is capable of being differentiated (e.g., the stem cell is totipotent, pluripotent, or multipotent). In some embodiments, the cell is isolated from embryonic or neonatal tissue. In some embodiments, the cell is a fibroblast, monocytic precursor, B cell, exocrine cell, pancreatic progenitor, endocrine progenitor, hepatoblast, myoblast, preadipocyte, progenitor cell, hepatocyte, chondrocyte, smooth muscle cell, K562 human erythroid leukemia cell line, bone cell, synovial cell, tendon cell, ligament cell, meniscus cell, adipose cell, dendritic cells, or natural killer cell. In some embodiments, the cell is manipulated (e.g., converted or differentiated) into a muscle cell, erythroid-megakaryocytic cell, eosinophil, iPS cell, macrophage, T cell, islet beta-cell, neuron, cardiomyocyte, blood cell, endocrine progenitor, exocrine progenitor, ductal cell, acinar cell, alpha cell, beta cell, delta cell, PP cell, hepatocyte, cholangiocyte, or brown adipocyte. In some embodiments, the cell is a muscle cell (e.g., skeletal, smooth, or cardiac muscle cell), erythroid-megakaryocytic cell, eosinophil, iPS cell, macrophage, T cell, islet beta-cell, neuron, cardiomyocyte, blood cell (e.g., red blood cell, white blood cell, or platelet), endocrine progenitor, exocrine progenitor, ductal cell, acinar cell, alpha cell, beta cell, delta cell, PP cell, hepatocyte, cholangiocyte, or white or brown adipocyte. In some embodiments, the cell is a hormone-secreting cell (e.g., a cell that secretes insulin, oxytocin, endorphin, vasopressin, serotonin, somatostatin, gastrin, secretin, glucagon, thyroid hormone, bombesin, cholecystokinin, testosterone, estrogen, or progesterone, renin, ghrelin, amylin, or pancreatic polypeptide), an epidermal keratinocyte, an epithelial cell (e.g., an exocrine secretory epithelial cell, a thyroid epithelial cell, a keratinizing epithelial cell, a gall bladder epithelial cell, or a surface epithelial cell of the cornea, tongue, oral cavity, esophagus, anal canal, distal urethra, or vagina), a kidney cell, a germ cell, a skeletal joint synovium cell, a periosteum cell, a bone cell (e.g., osteoclast or osteoblast), a perichondrium cell (e.g., a chondroblast or chondrocyte), a cartilage cell (e.g., chondrocyte), a fibroblast, an endothelial cell, a pericardium cell, a meningeal cell, a keratinocyte precursor cell, a keratinocyte stem cell, a pericyte, a glial cell, an ependymal cell, a cell isolated from an amniotic or placental membrane, or a serosal cell (e.g., a serosal cell lining body cavities). In some embodiments, the cell is a somatic cell. In some embodiments, the cells are derived from skin or other organs, e.g., heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder, bone marrow, spleen, intestine, or stomach. The cells can be from humans or other mammals (e.g., rodent, non-human primate, bovine, or porcine cells). It is contemplated herein that cloaked cells may be of use in cell-based therapies wherein it may be desirable to evade allorejection at a localized transplant site.


In some embodiments, the cloaked cells described herein survive in a host without stimulating the host immune response for one week or more (e.g., one week, two weeks, one month, two months, three months, 6 months, one year, two years, three years, four years, five years or more, e.g., for the life of the cell and/or its progeny). The cells maintain expression of the cloaking transgenes for as long as they survive in the host (e.g., if cloaking transgenes are no longer expressed, the cloaked cells may be removed by the host's immune system). In some embodiments, the cloaked cells further express a transgene encoding a protein that allows the cloaked cells to be detected in vivo (e.g., a fluorescent protein, such as GFP or other detectable marker).


It is contemplated herein that the combination of cloaked and fail-safe cells may be of use in cell-based therapies wherein it may be desirable to evade allorejection at a localized transplant site, while also being able to eliminate cells exhibiting undesirable growth rates, irrespective of whether such cells are generated before or after grafting the cells into a host. The combined cloaking and fail-safe technologies allows for localized immunoprotection while addressing the risk that the recipient will develop a malignancy because the cells are providing local immunosuppression.


Methods of Producing Cloaked Cells


The compositions and methods described herein can be used to reduce rejection of allogenic cells through expression of cloaking transgenes. A wide array of methods has been established for the delivery of proteins to mammalian cells and for the stable expression of genes encoding proteins in mammalian cells, which can be used to produce the cloaked cells described herein.


Polynucleotides Encoding Cloaking Proteins or Therapeutic Agents


One platform that can be used to achieve therapeutically effective expression of cloaking proteins or therapeutic agents in mammalian cells is via the stable expression of a gene encoding a cloaking protein or therapeutic agent (e.g., by integration into the nuclear or mitochondrial genome of a mammalian cell, or by episomal concatemer formation in the nucleus of a mammalian cell). The gene is a polynucleotide that encodes the primary amino acid sequence of the corresponding protein. In order to introduce exogenous genes into a mammalian cell, genes can be incorporated into a vector. Vectors can be introduced into a cell by a variety of methods, including transformation, transfection, transduction, direct uptake, projectile bombardment, and by encapsulation of the vector in a liposomes. Examples of suitable methods of transfecting or transforming cells include calcium phosphate precipitation, electroporation, microinjection, infection, lipofection and direct uptake. Such methods are described in more detail, for example, in Green, et al., Molecular Cloning: A Laboratory Manual, Fourth Edition (Cold Spring Harbor University Press, New York 2014); and Ausubel, et al., Current Protocols in Molecular Biology (John Wiley & Sons, New York 2015), the disclosures of each of which are incorporated herein by reference.


Cloaking proteins or therapeutic agents can also be introduced into a mammalian cell by targeting vectors containing portions of a gene encoding a cloaking protein or therapeutic agent to cell membrane phospholipids. For example, vectors can be targeted to the phospholipids on the extracellular surface of the cell membrane by linking the vector molecule to a VSV-G protein, a viral protein with affinity for all cell membrane phospholipids. Such a construct can be produced using methods well known to those of skill in the field.


Recognition and binding of the polynucleotide encoding a cloaking protein or therapeutic agent by mammalian RNA polymerase is important for gene expression. As such, one may include sequence elements within the polynucleotide that exhibit a high affinity for transcription factors that recruit RNA polymerase and promote the assembly of the transcription complex at the transcription initiation site. Such sequence elements include, e.g., a mammalian promoter, the sequence of which can be recognized and bound by specific transcription initiation factors and ultimately RNA polymerase.


Polynucleotides suitable for use in the compositions and methods described herein also include those that encode a cloaking protein or therapeutic agent downstream of a mammalian promoter. Promoters that are useful for the expression of a cloaking protein or therapeutic agent in mammalian cells include constitutive promoters. Constitutive promoters include the CAG promoter, the cytomegalovirus (CMV) promoter, the EF1α promoter, and the PGK promoter. Alternatively, promoters derived from viral genomes can also be used for the stable expression of these agents in mammalian cells. Examples of functional viral promoters that can be used to promote mammalian expression of these agents include adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, promoter of moloney virus, Epstein barr virus (EBV) promoter, and the Rous sarcoma virus (RSV) promoter.


Once a polynucleotide encoding a cloaking protein or a therapeutic agent described herein below has been incorporated into the nuclear DNA of a mammalian cell, the transcription of this polynucleotide can be induced by methods known in the art. For example expression can be induced by exposing the mammalian cell to an external chemical reagent, such as an agent that modulates the binding of a transcription factor and/or RNA polymerase to the mammalian promoter and thus regulates gene expression. The chemical reagent can serve to facilitate the binding of RNA polymerase and/or transcription factors to the mammalian promoter, e.g., by removing a repressor protein that has bound the promoter. Alternatively, the chemical reagent can serve to enhance the affinity of the mammalian promoter for RNA polymerase and/or transcription factors such that the rate of transcription of the gene located downstream of the promoter is increased in the presence of the chemical reagent. Examples of chemical reagents that potentiate polynucleotide transcription by the above mechanisms include tetracycline and doxycycline. These reagents are commercially available (Life Technologies, Carlsbad, CA) and can be administered to a mammalian cell in order to promote gene expression according to established protocols.


Other DNA sequence elements that may be included in the nucleic acid vectors for use in the compositions and methods described herein include enhancer sequences. Enhancers represent another class of regulatory elements that induce a conformational change in the polynucleotide containing the gene of interest such that the DNA adopts a three-dimensional orientation that is favorable for binding of transcription factors and RNA polymerase at the transcription initiation site. Thus, polynucleotides for use in the compositions and methods described herein include those that encode a cloaking protein or therapeutic agent and additionally include a mammalian enhancer sequence. Many enhancer sequences are now known from mammalian genes, and examples include enhancers from the genes that encode mammalian globin, elastase, albumin, α-fetoprotein, and insulin. Enhancers for use in the compositions and methods described herein also include those that are derived from the genetic material of a virus capable of infecting a eukaryotic cell. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. Additional enhancer sequences that induce activation of eukaryotic gene transcription are disclosed in Yaniv, et al., Nature 297:17 (1982). An enhancer may be spliced into a vector containing a polynucleotide encoding a cloaking protein or therapeutic agent, for example, at a position 5′ or 3′ to this gene. In a preferred orientation, the enhancer is positioned at the 5′ side of the promoter, which in turn is located 5′ relative to the polynucleotide encoding a cloaking protein or therapeutic agent.


The nucleic acid vectors described herein may include a Woodchuck Posttranscriptional Regulatory Element (WPRE). The WPRE acts at the transcriptional level, by promoting nuclear export of transcripts and/or by increasing the efficiency of polyadenylation of the nascent transcript, thus increasing the total amount of mRNA in the cell. The addition of the WPRE to a vector can result in a substantial improvement in the level of transgene expression from several different promoters, both in vitro and in vivo.


In some embodiments, the nucleic acid vectors for use in the compositions and methods described herein include a reporter sequence, which can be useful in verifying gene expression, for example, in specific cells and tissues. Reporter sequences that may be provided in a transgene include DNA sequences encoding β-lactamase, β-galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art. When associated with regulatory elements which drive their expression, the reporter sequences provide signals detectable by conventional means, including enzymatic, radiographic, colorimetric, fluorescence or other spectrographic assays, fluorescent activating cell sorting assays and immunological assays, including enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and immunohistochemistry. For example, where the marker sequence is the LacZ gene, the presence of the vector carrying the signal is detected by assays for β-galactosidase activity. Where the transgene is green fluorescent protein or luciferase, the vector carrying the signal may be measured visually by color or light production in a luminometer.


Techniques for Introducing Transgenes into Cells


Transfection


Techniques that can be used to introduce a transgene, such as a cloaking transgene or a therapeutic transgene described herein, into a target cell (e.g., a mammalian cell) are well known in the art. For instance, electroporation can be used to permeabilize mammalian cells (e.g., human target cells) by the application of an electrostatic potential to the cell of interest. Mammalian cells, such as human cells, subjected to an external electric field in this manner are subsequently predisposed to the uptake of exogenous nucleic acids. Electroporation of mammalian cells is described in detail, e.g., in Chu et al., Nucleic Acids Research 15:1311 (1987), the disclosure of which is incorporated herein by reference. A similar technique, Nucleofection™ utilizes an applied electric field in order to stimulate the uptake of exogenous polynucleotides into the nucleus of a eukaryotic cell. Nucleofection™ and protocols useful for performing this technique are described in detail, e.g., in Distler et al., Experimental Dermatology 14:315 (2005), as well as in US 2010/0317114, the disclosures of each of which are incorporated herein by reference.


Additional techniques useful for the transfection of target cells include the squeeze-poration methodology. This technique induces the rapid mechanical deformation of cells in order to stimulate the uptake of exogenous DNA through membranous pores that form in response to the applied stress. This technology is advantageous in that a vector is not required for delivery of nucleic acids into a cell, such as a human target cell. Squeeze-poration is described in detail, e.g., in Sharei et al., Journal of Visualized Experiments 81:e50980 (2013), the disclosure of which is incorporated herein by reference.


Lipofection represents another technique useful for transfection of target cells. This method involves the loading of nucleic acids into a liposome, which often presents cationic functional groups, such as quaternary or protonated amines, towards the liposome exterior. This promotes electrostatic interactions between the liposome and a cell due to the anionic nature of the cell membrane, which ultimately leads to uptake of the exogenous nucleic acids, for instance, by direct fusion of the liposome with the cell membrane or by endocytosis of the complex. Lipofection is described in detail, for instance, in U.S. Pat. No. 7,442,386, the disclosure of which is incorporated herein by reference. Similar techniques that exploit ionic interactions with the cell membrane to provoke the uptake of foreign nucleic acids include contacting a cell with a cationic polymer-nucleic acid complex. Exemplary cationic molecules that associate with polynucleotides so as to impart a positive charge favorable for interaction with the cell membrane include activated dendrimers (described, e.g., in Dennig, Topics in Current Chemistry 228:227 (2003), the disclosure of which is incorporated herein by reference) polyethylenimine, and diethylaminoethyl (DEAE)-dextran, the use of which as a transfection agent is described in detail, for instance, in Gulick et al., Current Protocols in Molecular Biology 40:1:9.2:9.2.1 (1997), the disclosure of which is incorporated herein by reference. Magnetic beads are another tool that can be used to transfect target cells in a mild and efficient manner, as this methodology utilizes an applied magnetic field in order to direct the uptake of nucleic acids. This technology is described in detail, for instance, in US 2010/0227406, the disclosure of which is incorporated herein by reference.


Another useful tool for inducing the uptake of exogenous nucleic acids by target cells is laserfection, also called optical transfection, a technique that involves exposing a cell to electromagnetic radiation of a particular wavelength in order to gently permeabilize the cells and allow polynucleotides to penetrate the cell membrane. The bioactivity of this technique is similar to, and in some cases found superior to, electroporation.


Impalefection is another technique that can be used to deliver genetic material to target cells. It relies on the use of nanomaterials, such as carbon nanofibers, carbon nanotubes, and nanowires. Needle-like nanostructures are synthesized perpendicular to the surface of a substrate. DNA containing the gene, intended for intracellular delivery, is attached to the nanostructure surface. A chip with arrays of these needles is then pressed against cells or tissue. Cells that are impaled by nanostructures can express the delivered gene(s). An example of this technique is described in Shalek et al., PNAS 107: 1870 (2010), the disclosure of which is incorporated herein by reference.


Magnetofection can also be used to deliver nucleic acids to target cells. The magnetofection principle is to associate nucleic acids with cationic magnetic nanoparticles. The magnetic nanoparticles are made of iron oxide, which is fully biodegradable, and coated with specific cationic proprietary molecules varying upon the applications. Their association with the gene vectors (DNA, siRNA, viral vector, etc.) is achieved by salt-induced colloidal aggregation and electrostatic interaction. The magnetic particles are then concentrated on the target cells by the influence of an external magnetic field generated by magnets. This technique is described in detail in Scherer et al., Gene Therapy 9:102 (2002), the disclosure of which is incorporated herein by reference.


Another useful tool for inducing the uptake of exogenous nucleic acids by target cells is sonoporation, a technique that involves the use of sound (typically ultrasonic frequencies) for modifying the permeability of the cell plasma membrane permeabilize the cells and allow polynucleotides to penetrate the cell membrane. This technique is described in detail, e.g., in Rhodes et al., Methods in Cell Biology 82:309 (2007), the disclosure of which is incorporated herein by reference.


Microvesicles represent another potential vehicle that can be used to modify the genome of a target cell according to the methods described herein. For instance, microvesicles that have been induced by the co-overexpression of the glycoprotein VSV-G with, e.g., a genome-modifying protein, such as a nuclease, can be used to efficiently deliver proteins into a cell that subsequently catalyzes the site-specific cleavage of an endogenous polynucleotide sequence so as to prepare the genome of the cell for the covalent incorporation of a polynucleotide of interest, such as a gene or regulatory sequence. The use of such vesicles, also referred to as Gesicles, for the genetic modification of eukaryotic cells is described in detail, e.g., in Quinn et al., Genetic Modification of Target Cells by Direct Delivery of Active Protein [abstract]. In: Methylation changes in early embryonic genes in cancer [abstract], in: Proceedings of the 18th Annual Meeting of the American Society of Gene and Cell Therapy; 2015 May 13, Abstract No. 122.


Viral Infection


In addition to achieving high rates of transcription and translation, stable expression of an exogenous gene in a mammalian cell can be achieved by integration of the polynucleotide containing the gene into the nuclear genome of the mammalian cell. A variety of vectors for the delivery and integration of polynucleotides encoding exogenous proteins into the nuclear DNA of a mammalian cell have been developed. Examples of expression vectors are disclosed in, e.g., WO 1994/011026 and are incorporated herein by reference. Expression vectors for use in the compositions and methods described herein contain a cloaking transgene or therapeutic transgene, as well as, e.g., additional sequence elements used for the expression of these agents and/or the integration of these polynucleotide sequences into the genome of a mammalian cell.


Certain vectors that can be used for the expression of cloaking transgenes or therapeutic transgenes include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription. Other useful vectors for expression of cloaking transgenes or therapeutic transgenes contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of the mRNA that results from gene transcription. These sequence elements include, e.g., 5′ and 3′ untranslated regions and a polyadenylation signal site in order to direct efficient transcription of the gene carried on the expression vector. The expression vectors suitable for use with the compositions and methods described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker include genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, or nourseothricin.


Viral Vectors for Nucleic Acid Delivery


Viral genomes provide a rich source of vectors that can be used for the efficient delivery of a gene of interest into the genome of a target cell (e.g., a mammalian cell, such as a human cell). Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained within such genomes are typically incorporated into the nuclear genome of a mammalian cell by generalized or specialized transduction. These processes occur as part of the natural viral replication cycle, and do not require added proteins or reagents in order to induce gene integration. Examples of viral vectors include a retrovirus (e.g., Retroviridae family viral vector), adenovirus (e.g., Ad5, Ad26, Ad34, Ad35, and Ad48), parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses, such as picornavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, modified vaccinia Ankara (MVA), fowlpox and canarypox). Other viruses include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, human papilloma virus, human foamy virus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, avian C-type viruses, mammalian C-type, B-type viruses, D-type viruses, oncoretroviruses, HTLV-BLV group, lentivirus, alpharetrovirus, gammaretrovirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, Virology, Third Edition (Lippincott-Raven, Philadelphia, 1996)). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other examples of vectors are described, for example, U.S. Pat. No. 5,801,030, the disclosure of which is incorporated herein by reference as it pertains to viral vectors for use in gene therapy.


AAV Vectors for Nucleic Acid Delivery


In some embodiments, cloaking transgenes or therapeutic transgenes described herein are incorporated into rAAV vectors and/or virions in order to facilitate their introduction into a cell. rAAV vectors useful in the compositions and methods described herein are recombinant nucleic acid constructs that include (1) a promoter, (2) a heterologous sequence to be expressed (e.g., a cloaking transgene or therapeutic transgene described herein), and (3) viral sequences that facilitate integration and expression of the heterologous genes. The viral sequences may include those sequences of AAV that are required in cis for replication and packaging (e.g., functional ITRs) of the DNA into a virion. Such rAAV vectors may also contain marker or reporter genes. Useful rAAV vectors have one or more of the AAV WT genes deleted in whole or in part, but retain functional flanking ITR sequences. The AAV ITRs may be of any serotype suitable for a particular application. Methods for using rAAV vectors are described, for example, in Tal et al., J. Biomed. Sci. 7:279 (2000), and Monahan and Samulski, Gene Delivery 7:24 (2000), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.


The transgenes and vectors described herein (e.g., a promoter operably linked to a cloaking transgene or therapeutic transgene) can be incorporated into a rAAV virion in order to facilitate introduction of the polynucleotide or vector into a cell. The capsid proteins of AAV compose the exterior, non-nucleic acid portion of the virion and are encoded by the AAV cap gene. The cap gene encodes three viral coat proteins, VP1, VP2 and VP3, which are required for virion assembly. The construction of rAAV virions has been described, for instance, in U.S. Pat. Nos. 5,173,414; 5,139,941; 5,863,541; 5,869,305; 6,057,152; and 6,376,237; as well as in Rabinowitz et al., J. Virol. 76:791 (2002) and Bowles et al., J. Virol. 77:423 (2003), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.


rAAV virions useful in conjunction with the compositions and methods described herein include those derived from a variety of AAV serotypes including AAV 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, rh10, rh39, rh43, and rh74. Construction and use of AAV vectors and AAV proteins of different serotypes are described, for instance, in Chao et al., Mol. Ther. 2:619 (2000); Davidson et al., Proc. Natl. Acad. Sci. USA 97:3428 (2000); Xiao et al., J. Virol. 72:2224 (1998); Halbert et al., J. Virol. 74:1524 (2000); Halbert et al., J. Virol. 75:6615 (2001); and Auricchio et al., Hum. Molec. Genet. 10:3075 (2001), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.


Also useful in conjunction with the compositions and methods described herein are pseudotyped rAAV vectors. Pseudotyped vectors include AAV vectors of a given serotype (e.g., AAV9) pseudotyped with a capsid gene derived from a serotype other than the given serotype (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, etc.). Techniques involving the construction and use of pseudotyped rAAV virions are known in the art and are described, for instance, in Duan et al., J. Virol. 75:7662 (2001); Halbert et al., J. Virol. 74:1524 (2000); Zolotukhin et al., Methods, 28:158 (2002); and Auricchio et al., Hum. Molec. Genet. 10:3075 (2001).


AAV virions that have mutations within the virion capsid may be used to infect particular cell types more effectively than non-mutated capsid virions. For example, suitable AAV mutants may have ligand insertion mutations for the facilitation of targeting AAV to specific cell types. The construction and characterization of AAV capsid mutants including insertion mutants, alanine screening mutants, and epitope tag mutants is described in Wu et al., J. Virol. 74:8635 (2000). Other rAAV virions that can be used in methods described herein include those capsid hybrids that are generated by molecular breeding of viruses as well as by exon shuffling. See, e.g., Soong et al., Nat. Genet., 25:436 (2000) and Kolman and Stemmer, Nat. Biotechnol. 19:423 (2001).


Genome Editing


In addition to the above, a variety of tools have been developed that can be used for the incorporation of a gene of interest into a target cell, such as a mammalian cell. One such method that can be used for incorporating polynucleotides encoding target genes into target cells involves the use of transposons. Transposons are polynucleotides that encode transposase enzymes and contain a polynucleotide sequence or gene of interest flanked by 5′ and 3′ excision sites. Once a transposon has been delivered into a cell, expression of the transposase gene commences and results in active enzymes that cleave the gene of interest from the transposon. This activity is mediated by the site-specific recognition of transposon excision sites by the transposase. In some instances, these excision sites may be terminal repeats or inverted terminal repeats. Once excised from the transposon, the gene of interest can be integrated into the genome of a mammalian cell by transposase-catalyzed cleavage of similar excision sites that exist within the nuclear genome of the cell. This allows the gene of interest to be inserted into the cleaved nuclear DNA at the complementary excision sites, and subsequent covalent ligation of the phosphodiester bonds that join the gene of interest to the DNA of the mammalian cell genome completes the incorporation process. In certain cases, the transposon may be a retrotransposon, such that the gene encoding the target gene is first transcribed to an RNA product and then reverse-transcribed to DNA before incorporation in the mammalian cell genome. Exemplary transposon systems are the piggyback transposon (described in detail in, e.g., WO 2010/085699) and the sleeping beauty transposon (described in detail in, e.g., US 2005/0112764), the disclosures of each of which are incorporated herein by reference as they pertain to transposons for use in gene delivery to a cell of interest.


Another tool for the integration of target genes into the genome of a target cell is the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system, a system that originally evolved as an adaptive defense mechanism in bacteria and archaea against viral infection. The CRISPR/Cas system includes palindromic repeat sequences within plasmid DNA and an associated Cas9 nuclease. This ensemble of DNA and protein directs site specific DNA cleavage of a target sequence by first incorporating foreign DNA into CRISPR loci. Polynucleotides containing these foreign sequences and the repeat-spacer elements of the CRISPR locus are in turn transcribed in a host cell to create a guide RNA, which can subsequently anneal to a target sequence and localize the Cas9 nuclease to this site. In this manner, highly site-specific cas9-mediated DNA cleavage can be engendered in a foreign polynucleotide because the interaction that brings cas9 within close proximity of the target DNA molecule is governed by RNA:DNA hybridization. As a result, one can design a CRISPR/Cas system to cleave any target DNA molecule of interest. This technique has been exploited in order to edit eukaryotic genomes (Hwang et al., Nature Biotechnology 31:227 (2013)) and can be used as an efficient means of site-specifically editing target cell genomes in order to cleave DNA prior to the incorporation of a gene encoding a target gene. The use of CRISPR/Cas to modulate gene expression has been described in, for example, U.S. Pat. No. 8,697,359, the disclosure of which is incorporated herein by reference as it pertains to the use of the CRISPR/Cas system for genome editing. Alternative methods for site-specifically cleaving genomic DNA prior to the incorporation of a gene of interest in a target cell include the use of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). Unlike the CRISPR/Cas system, these enzymes do not contain a guiding polynucleotide to localize to a specific target sequence. Target specificity is instead controlled by DNA binding domains within these enzymes. The use of ZFNs and TALENs in genome editing applications is described, e.g., in Urnov et al., Nature Reviews Genetics 11:636 (2010); and in Joung et al., Nature Reviews Molecular Cell Biology 14:49 (2013), the disclosure of each of which are incorporated herein by reference as they pertain to compositions and methods for genome editing.


Additional genome editing techniques that can be used to incorporate polynucleotides encoding target genes into the genome of a target cell include the use of ARCUS™ meganucleases that can be rationally designed so as to site-specifically cleave genomic DNA. The use of these enzymes for the incorporation of genes encoding target genes into the genome of a mammalian cell is advantageous in view of the defined structure-activity relationships that have been established for such enzymes. Single chain meganucleases can be modified at certain amino acid positions in order to create nucleases that selectively cleave DNA at desired locations, enabling the site-specific incorporation of a target gene into the nuclear DNA of a target cell. These single-chain nucleases have been described extensively in, for example, U.S. Pat. Nos. 8,021,867 and 8,445,251, the disclosures of each of which are incorporated herein by reference as they pertain to compositions and methods for genome editing.


Expression of Cloaking Transgenes


The cloaking transgenes described herein (e.g., one of, or any combination of, PD-1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)) are expressed in an amount sufficient to produce a cloaking effect (e.g., in an amount sufficient to prevent rejection when injected into a subject, e.g., a mammalian subject, such as a mouse, rat, or human). Transgene expression can be considered to produce a cloaking effect if subcutaneous injection of cloaked cells generates a teratoma that is not removed by the subject's immune system. The cloaking transgenes are also expressed at a level that is sufficient to promote production of the proteins encoded by said transgenes. Protein production can be detected using routine methods known to those of skill in the art (e.g., immunohistochemistry, Western Blot analysis, or other methods that allow for visualization or proteins). Preferably, the expression of the cloaking transgenes is such that all 8 proteins encoded by the cloaking transgenes (PD-L1, H2-M3, Cd47, Cd200, FasL, Ccl21b, Mfge8, and Spi6) can be detected in cloaked cells (e.g., detected by immunohistochemistry using antibodies directed against the proteins encoded by the cloaking transgenes).


In some embodiments, cloaking transgenes are expressed at similar levels in cloaked cells to levels of endogenous gene expression in activated leukocytes, such as T cells (e.g., activated leukocytes from the same species, such as an activated leukocyte isolated from a lymph organ, for example expression in a cloaked mouse cell is similar to expression in an activated leukocyte isolated from a murine lymphoid organ). The expression of one or more cloaking transgenes (e.g., 1, 2, 3, 4, 5, 6, 7, or 8 of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)) is greater than or equal to expression of the endogenous gene in activated leukocytes (e.g., T cells) from the same species (e.g., expression level of the cloaking transgene is equal to the level of expression of the endogenous gene in activated leukocytes, or is 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10-fold or more higher than the level of expression of the endogenous gene in activated leukocytes). In some embodiments, all 8 cloaking transgenes are expressed at a level that is greater than or equal to the expression level of the endogenous gene in an activated leukocyte from the same species. Activated leukocytes can be isolated from lymphoid organs, or leukocytes, such as T cells, can activated in vitro using anti-CD3/CD28 beads or other methods employed by those of skill in the art (see, e.g., Frauwith and Thompson, J. Clin Invest 109:295-299 (2002); and Trickett and Kwan, J Immunol Methods 275:251-255 (2003)). Transgene expression in cloaked cells can also be compared to gene expression levels reported in profiling studies of activated T cells (see, e.g., Palacios et al., PLOSone 2:e1222 (2007)). In some embodiments, cloaking transgene expression is compared to expression of the endogenous gene in a wild-type version of the cell (e.g., a stem cell, e.g., an embryonic stem cell from the same species as the cloaked cell). The expression of one or more cloaking transgenes (e.g., 1, 2, 3, 4, 5, 6, 7, or 8 of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)) is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 500, 1,000-fold or more higher in cloaked cells compared to expression of the endogenous gene in unmodified wild-type cells of the same cell type as the cloaked cell (e.g., stem cells, such as embryonic stem cells from the same species). In some embodiments, all 8 cloaking transgenes are expressed at a level that is greater (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, or 100-fold higher or more) than the expression level of the endogenous gene in a wild-type version of the cell (e.g., a stem cell, e.g., an embryonic stem cell from the same species as the cloaked cell). Gene expression can be evaluated through direct comparison to isolated ES cells, or compared to stem cell expression (e.g., ES cell expression) in the Project Grandiose dataset (www.stemformatics.org/project_grandiose). Gene expression can be measured using techniques known in the art (e.g., quantitative polymerase chain reaction (qPCR)).


Methods of Providing a Local Immunosuppression at a Transplant Site


Also featured is a method of providing local immunosuppression at a transplant site.


The method comprises providing a cell; and expressing in the cell a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting and whose function is to mitigate function of graft attacking leukocyte and NK cell activation or act as a defense mechanism against attacking leukocytes.


The set of transgenes comprises one or more (e.g., two, three, four, five, six, seven, or all eight) of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6). In an embodiment, the set of transgenes genes comprises Pd-L1, H2-M3, Cd47, Cd200, FasL, Ccl21b, Mfge8, and Spi6.


Optionally, the method further comprises expressing one or more of the following transgenes in the cell: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and IFNγR1 d39. In an embodiment, the TGF-β or the biologic is local acting.


Techniques for introducing into animal cells various genetic modifications, such as transgenes are described herein and are generally known in the art.


In an embodiment of the method, the cell is a stem cell, a cell amenable to genome editing, and/or a source of therapeutic cell type (e.g., a cell that can be differentiated into a lineage restricted cell for cell therapy, or a cell of a desired target tissue). In an embodiment, the cell is an embryonic stem cell, an induced pluripotent stem cell, an adult stem cell, a tissue-specific stem cell, a hematopoietic stem cell, a mesenchymal stem cell, an endothelial stem cell, an epithelial stem cell, an adipose stem or progenitor cells, germline stem cell, a lung stem or progenitor cell, a mammary stem cell, an olfactory adult stem cell, a hair follicle stem cell, a multipotent stem cell, an amniotic stem cell, a cord blood stem cell, or a neural stem or progenitor cell. In some embodiments, the cell is derived from a target tissue, e.g., skin, heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder, bone marrow, spleen, intestine, or stomach. In some embodiments, the cell is a fibroblast, an epithelial cell, or an endothelial cell. The cell may be a vertebrate cell, for example, a mammalian cell, such as a human or mouse cell. In some embodiments, the cell that is modified to express one or more (e.g., two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) is a cell in the tissue or organ to be transplanted. In some embodiments, the cloaked cells (e.g., cloaked stem cells) are differentiated in vitro using methods known by those of skill in the art into a tissue or organ for transplantation.


In some embodiments, one million to one hundred billion cloaked cells (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010, 2×1010, 3×1010, 4×1010, 5×1010, 6×1010, 7×1010, 8×1010, 9×1010, or 1×1011 cloaked cells) are administered to or near a transplant site in a subject, or into an organ or tissue to be transplanted.


Techniques for transplanting the genetically modified cells into a transplant site of an allogeneic host are described herein and are generally known in the art.


Expression of Therapeutic Agents by Cloaked Cells


The cloaked cells described herein can be further modified to express a therapeutic agent. In some embodiments, the therapeutic agent is a protein. The therapeutic protein can be a wild type form of a protein that is deficient in a subject, such as a protein that is mutated or produced in insufficient quantity (e.g., produced at low levels or not produced) by the subject's cells. In some embodiments, the therapeutic protein is an inhibitory antibody (e.g., an antibody that blocks or neutralizes protein function). The cloaked cells may be modified to produce an inhibitory antibody to treat a subject having or at risk of developing a disease or condition related to overproduction or aberrant production of a protein (e.g., production by cells that do not normally produce the protein, production of a protein at a time or in a location at which the protein is not normally produced, or production of an excessive amount of a protein). In some embodiments, the therapeutic antibody is an agonist antibody (e.g., an activating antibody). The agonist antibody can act by binding to and activating an endogenous receptor (e.g., inducing or increasing signaling downstream of receptor activation or changing the conformation of the endogenous receptor to an open or active state). The cloaked cells may be modified to produce an agonist antibody to treat a subject having or at risk of developing a disease or condition related to under activation of a receptor or signaling pathway. The cloaked cells can be modified to produce the therapeutic protein or antibody using the methods described herein or using other methods known by those of skill in the art. Cloaked cells that produce a secreted protein or antibody can be delivered as circulating cells, injected into the tissue, organ, or body site in need of the therapeutic protein or antibody, or injected subcutaneously to produce a cloaked subcutaneous tissue. Cloaked cells that produce a transmembrane or membrane-bound protein, can be injected at or near the site of the endogenous cells that respond to the therapeutic protein.


In some embodiments, the cloaked cells described herein provide a wild-type copy of a gene that is mutated in the subject (e.g., the cloaked cell is a “wild-type cell” that does not have the genetic cause of the disease and that expresses one, two, three, four, five, six, seven or all eight of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6)). Such cells can be used to treat subjects having a disease or condition caused by a mutation in an endogenous gene (e.g., subjects having a metabolic disorder associated with one or more mutations described herein below).


A list of exemplary therapeutic agents that can be administered with or produced by cloaked cells and the associated diseases or conditions that can be treated using these therapeutic agents are provided in Table 2 below.









TABLE 2







Exemplary therapeutic agents that can be administered with or expressed


by cloaked cells to treat disease








Disease or Condition
Therapeutic Agent





Diabetes, altered glycemic states
Insulin, insulotropin, glucagon


Skeletal growth retardation
Human growth hormone


Anemia
Erythropoietin (EPO), hemoglobins


Obesity
Ob gene translation product (leptin)


Immunodeficiency (e.g., AIDS)
Adenosine deaminase, purine nucleoside



phosphorylase, CD-4


Hemophilia A
Factor VIII


Hemophilia B
Factor IX


Emphysema
α1-antitrypsin


Hypercholesterolemia
LDL receptor protein


Pernicious anemia
Intrinsic factor


Hypoalbuminemia
Albumin


Gaucher′s disease
B-glucosidase (glucocerebrosidase)


Cystic fibrosis
CF transmembrane conductance regulator


Cardiovascular disease
Tissue Plasminogen Activator (tPA),



urokinase, streptokinase, antithrombin III,



Apolipoproteins (e.g., APO B48, A1), Low



Density lipoprotein receptor, vascular



endothelial growth factor (VEGF)


Calcium mineral diseases
Calcitonin, parathyroid hormone (PTH), PTH-



like hormone


Severe Combined Immunodeficiency
Adenosine deaminase


(SCID)



Phenylketonuria
Phenylalanine hydroxylase


von Willebrand′s disease
von Willebrand Factor


Cancers, cancer suppression
Tumor Necrosis Factors (TNFs), cytokines,



anti-neoplastic agents (e.g., vincristine,



doxorubicin, tamoxifen, methotrexate),



interleukins (ILs), interferons (INFs), p53 and



related, anti-BRCAs, anti-VEGF (bevacizumab),



anti-Epidermal Growth Factor (EGF), oncogene



anti-sense RNAs, antibodies (e.g., Rituximab;



Daclizumab; Basiliximab; Palivizumab;



Infliximab; Trastuzumab; Gemtuzumab



ozogamicin; Alemtuzumab; Ibritumomab



tiuxetan; Adalimumab; Omalizumab;



Tositumomab-I-131; Efalizumab; Cetuximab;



Bevacizumab; Natalizumab; Tocilizumab;



Panitumumab; Ranibizumab; Eculizumab;



Certolizumab pegol; Golimumab; Canakinumab;



Ustekinumab; Ofatumumab; Denosumab;



Motavizumab; Raxibacumab; Belimumab;



Ipilimumab; Brentuximab Vedotin; Pertuzumab;



Ado-trastuzumab emtansine; or



Obinutuzumab), or checkpoint inhibitors (e.g.,



nivolumab, pidilizumab/CT-011,



pembrolizumab, ipilimumab, or tremelimumab)


Peripheral vascular disease
VEGF, endothelins


Neurodegenerative states, and post neural
Ciliary Neurotrophic Factor (CNTF), Brain


trauma conditions
Derived Neurite Factor (BDNF), Nerve Growth



Factor (NGF), tyrosine hydroxylase


Retarded fracture healing
Bone morphogenic proteins (BMP)


Lactose insufficiency
Lactase


Wound healing
Epidermal Growth Factors, Transforming



Growth Factors, Granulocyte-Colony



Stimulating Factors, Fibroblast Growth



Factors, Interferons, Interleukins, Insulin-like



growth Factors


Thrombosis, hypercoagulability
Antithrombins, urokinases, tPAs , hirudins,



streptokinase


Diabetes insipidus
Antidiuretic hormone (ADH)


Psychiatric Disorders
Selective Serotonin Reuptake Inhibitors, anti-



psychotic bio-substances


Pain Control
Endorphins


Endocrineopathies
Estrogens, Androgens, mineralocorticoids,



glucocorticoids, anabolic steroids, etc.


Hypothyroidism
Thyroid hormones, thyroglobulins


Muscular dystrophy
Dystrophin


Infections (bacterial, fungal, viral)
Anti-microbial polypeptides


Shock, Sepsis
Lipid Binding Protein (LBP)


Leukemia
L-asparaginase


Disorders of digestive, pancreatic states
Pepsin, trypsin, chymotrypsin, cholecystokinin,



sucrase, carboxypeptidase


Oxidative Stress, Neurodegenerative
Catalase


Disorders



Hypouricasemia, Gout
Uricase


Ehlers Danlos
Elastase


Thrombocytopenia
Thrombopoietin (TPO)


SCID/ADA deficiency
Adenosine deamidase


Porphyria
Porphobilinogen deaminase


Inborn errors of carboxylic and amino
Specific enzymes catalyzing transformations at


acid metabolism, (e.g., glutaric acidemia)
genetic block points, (e.g., glutaryl CoA



dehydrogenase)


Homocystinuria
Cystathionine B-synthase


Wilson′s Disease, Menke′s Disease
Specific copper transporting ATPase′s


Thalassemia
ß-globin


Sickle Cell Anemia
α-globin


Baldness
Sonic hedgehog gene products


Hashimoto′s Thyroiditis,
Thyroid hormone


Wet Age-Related Macular Degeneration or
VEGF trap (e.g., a soluble decoy receptor


Retinal Dystrophy
described in Holash et al., Proc Natl Acad Sci



U.S.A. 99:11383-11398, 2002, e.g., VEGF-



Trapparental, VEGF-TrapΔB1, VEGF-TrapΔB2,



VEGF-TrapR1R2, e.g., aflibercept), soluble forms



of VEGF receptors (e.g., soluble VEGFR-1 or



NRP-1), platelet factor-4, prolactin, SPARC,



VEGF inhibitory antibodies (e.g., bevacizumab



or ranibizumab).


Osteoarthritis or Rheumatoid Arthritis
TNFα inhibitors (adalimumab, etanercept,



infliximab, golimumab, certolizumab),



interleukin-6 (IL6) receptor inhibitors (e.g.,



tocilizumab), IL1 receptor inhibitors (e.g.,



anakinra), or other agents used to treat RA (e.g.,



abatacept, rituximab)


Inflammatory Bowel Disease, Crohn′s
TNFα inhibitors (adalimumab, etanercept,


disease, Ulcerative Colitis
infliximab, golimumab, certolizumab),



mesalazine, prednisone, azathioprine,



methotrexate


Addison′s Disease
Aldosterone, cortisol, glucocorticoids,



mineralocorticoids, androgens


Hurler syndrome
Alpha-L iduronidase


Niemann-Pick disease
Sphingomyelin phosphodiesterase1 (SMPD1),



NPC1 protein, or NPC2 protein


Tay-Sachs disease
beta-hexosaminidase A


Fabry disease
alpha galactosidase


Krabbe disease
Galactosylceramidase


Galactosemia
Galactokinase or galactose-1-phosphate



uridyltransferase


Maple syrup urine disease
Enzymes of the branched-chain alpha-keto acid



dehydrogenase complex


Phenylketonuria
Phenylalanine hydroxylase


Glycogen storage diseases (GSDs)
GSDO: Glycogen synthase (GYS2);



GSD1/von Gierke′s disease: Glucose-6-



phosphatase (G6PC);



GSD 2/Pompe′s disease: Acid alpha-



glucosidase (GAA);



GSD 3/Cori′s disease or Forbes′ disease:



Glycogen debranching enzyme (AGL);



GSD 4/Andersen disease: Glycogen branching



enzyme (GBE1);



GSD 5/McArdle disease: Muscle glycogen



phosphorylase (myophosphorylase) (PYGM);



GSD 6/Hers′ disease: Liver glycogen



phosphorylase (PYGL) or muscle



phosphoglycerate mutase (PGAM2);



GSD 7/Tarui′s disease: Muscle



phosphofructokinase (PKFM);



GSD 9: Glycogen phosphorylase kinase B



(PHKA2, PHKB, PHKG2, or PHKA1),



GSD 10: Enolase 3 (ENO3);



GSD 11: Muscle lactate dehydrogenase



(LDHA); Fanconi-Bickel syndrome: Glucose



transporter 2 (GLUT2);



GSD 12: Aldolase A (ALDOA);



GSD 13: ß-enolase (ENO3);



GSD 15: Glycogenin-1 (GYG1)


Mitochondrial disorders
Leber′s hereditary optic neuropathy (LHON):



NADH dehydrogenase;



Leigh syndrome: thiamine-diphosphate kinase,



thiamine triphosphate, or pyruvate



dehydrogenase;



Neuropathy, ataxia, retinitis pigmentosa, and



ptosis (NARP: ATP synthase;



Myoneurogenic gastrointestinal encephalopathy



(MNGIE): thymidine phosphorylase (TYMP);



Mitochondria myopathy, encephalomyopathy,



lactic acidosis, stroke-like symptoms (MELAS):



NADH dehydrogenase


Friedrich′s ataxia
Frataxin (FXN)


Peroxisomal disorders
Zellweger syndrome: Proteins encoded by



PEX1, PEX2, PEX3, PEX5, PEX6, PEX10,



PEX12, PEX13, PEX14, PEX16, PEX19, or



PEX26;



Adrenoleukodystrophy: protein encoded by



ABCD1


Metal metabolism disorders
Wilson disease: Wilson disease protein



(ATP7B); Hemochromatosis: Human



hemochromatosis protein (HFE)


Organic acidemias
Methylmalonic acidemia: methylmalonyl CoA



mutase, methylmalonyl CoA epimerase,



adenosylcobalamin



Propionic academia: propionyl-CoA carboxylase


Urea cycle disorders
Ornithine transcarbamylase (OTC), deficiency:



Ornithine transcarbamylase;



Arginase (ARG1) deficiency: Arginase;



Argininosuccinate lyase (ASL) deficiency:



Argininosuccinate lyase;



Argininosuccinate synthase 1 (ASS1)



deficiency: Argininosuccinate synthase 1;



Citrin deficiency: Citrin;



Carbamoyl phosphate synthase 1 (CPSI)



deficiency: Carbamoyl phosphate synthase 1;



N-acetylglutamate synthase (NAGS) deficiency:



N-acetylglutamate synthase;



Ornithine translocase (ORNT1) deficiency:



Ornithine translocase









Inducible Systems for Expression of Therapeutic Agents


If continuous administration of a therapeutic agent expressed by cloaked cells is needed to treat a disease or condition, the therapeutic agent can be expressed using a constitutive promoter described herein or known by those of skill in the art (e.g., CAG, CMV, or another constitutive promoter). If the therapeutic agent is needed intermittently (e.g., needed during a period of relapse or flare up that occurs during a disease or condition, but not needed when a subject is asymptomatic), it can be expressed by an inducible promoter, which provides the capability of expressing the therapeutic agent only when it is needed. One exemplary class of therapeutic agents that could be delivered using an inducible promoter is TNFα inhibitors. TNFα inhibitors are currently used to treat rheumatoid arthritis, but are only administered intermittently during flare-ups of joint inflammation as constitutive administration of TNFα can lead to systemic immunosuppression. If cloaked cells are modified to express TNFα inhibitors under the control of an inducible promoter, cloaked cells can be used to deliver TNFα intermittently, thus, obviating the need for repeated injections. Other therapeutic agents that have potentially adverse effects if administered continuously can also be expressed intermittently using inducible promoters as described herein. Exemplary inducible expression systems are described below.


Tetracycline Response Element


One widely used inducible expression system is based on tetracycline-controlled transcriptional activation. In this system, the antibiotic tetracycline, or one of its derivatives (e.g., doxycycline), is used to reversibly activate or inhibit gene expression. To use this system, a tetracycline response element (TRE) is placed upstream of a gene of interest (e.g., a therapeutic transgene to be expressed by cloaked cells), typically along with a minimal promoter that has very low basal expression. A protein called rtTA, which also needs to be expressed by the cloaked cells, binds to the TRE and activates transcription in the presence of tetracycline or doxycycline. When tetracycline or doxycycline is removed, rtTA no longer binds to the TRE and the gene of interest is no longer expressed. Advanced versions of this system, Tet-On Advanced transactivator (rtTA2s-M2) and Tet-On 3G, may be particularly useful for human therapy as they are human codon optimized and respond to low concentrations of doxycycline,


Light Inducible Systems


Another method for inducible activation of gene expression involves the use of optogenetics, which uses light sensitive proteins to manipulate gene expression. A recent development in optogenetics that can be used to inducibly express therapeutic agents in cloaked cells involves a class of proteins that undergo a conformational change and dimerize in response to blue light. These proteins have been fused to DNA-binding and transcriptional components that have been shown to bind to specific promoter sequences and activate transcription when brought together by exposure to blue light (Wang et al., Nat Methods, 9:266-269, 2012). This method of inducibly activating gene expression could be used to control the production of therapeutic agents in cloaked cells that are administered subcutaneously, as blue light can be shone onto the skin near the cloaked subcutaneous tissue to induce production of a therapeutic agent by the cloaked cells.


Radiogenetics


A third method of inducibly activating gene expression (e.g., expression of a therapeutic agent by cloaked cells) involves the use of radio waves. In one version of a radio wave-inducible expression system, the TRPV1 receptor is fused to a GFP binding domain and co-expressed with a form of ferritin that is linked to GFP (Stanley et al., Nat Med 21:92-98, 2015). The GFP-ferritin binds to the GFP binding domain of the TRPV1 receptor. When a radio wave of a specific frequency is applied to the cell, ferritin interacts with TRPV1 and allows for an influx of calcium, which activates the transcription factor NFAT. Therapeutic agents can be inducibly expressed using this system if they are operably linked to an NFAT-sensitive promoter element, such as SRE-CRE-NFATRE, and co-expressed with TRPV1-GFP and GFP-ferritin. Radio wave-induced expression provides the advantage of being able to induce expression in cells that are further from the outside of the body, as radio waves can pass through tissue. For example, radiogenetics could be used to regulate gene expression in the retina. This method could, therefore, be used to inducibly express therapeutic transgenes in cloaked cells with non-invasive and non-harmful radio waves.


Destabilization Domain System


Gene expression can also be regulated using destabilization domain systems. A transgene encoding a protein of interest (e.g., a therapeutic agent described herein) can also include destabilizing domains, such that the resulting protein product includes the protein of interest fused to a destabilizing domain. Exemplary destabilizing domains include mutants of the human FK506- and rapamycin-binding protein (FKBP12), which confer instability to the proteins to which they are fused. FKBP12 mutants include N-terminal mutants F15S, V24A, H25R, E60G, and L106P, and C-terminal mutants M66T, R71G, D100G, D100N, E102G, and K105I, as characterized in Banaszynski et al., Cell 126:995 (2006), the disclosure of which is incorporated herein by reference as it pertains to FKBP12 destabilizing domains. Destabilizing domains promote protein degradation. A small molecule synthetic ligand can be used to stabilize the destabilizing domain-containing proteins when expression of the protein of interest (e.g., a therapeutic agent) is desired. The small molecule ligand Shield-1 (Shld1) can be used to stabilize FKBP12 mutant-containing proteins by protecting them from degradation. Other destabilizing domains that can be used to regulate expression proteins of interest include mutants of the E. coli dihydrofolate reductase (ecDHFR) and mutants of the human estrogen receptor ligand binding domain (ERLBD), which confer instability resulting in degradation when fused to a protein of interest and can be stabilized by small molecule ligand trimethoprim (TMP), or by CMP8 or 4-hydroxytamoxifen (4OHT), respectively, as described in Iwamoto et al., Chem Biol. 17:981 (2010) and Miyazaki et al., J Am Chem Soc., 134:3942 (2012), the disclosures of each of which are incorporated herein by reference as they pertain to destabilization domain systems.


Cumate Switch Inducible System


Another method for inducible activation of gene expression involves the use of the cumate gene-switch system. In the repressor configuration of this system, regulation is mediated by the binding of the repressor (CymR) to the operator site (CuO), placed downstream of a strong constitutive promoter. Addition of cumate, a small molecule, relieves the repression, allowing for expression of the transgene. Alternatively, a reverse-cumate-Trans-Activator (rcTA) may be inserted upstream of a minimal CMV promoter that is operably linked to a transgene encoding a therapeutic agent. A 6-times repeat of a Cumate Operator (6×CuO) may be inserted just before the translational start (ATG) of the therapeutic transgene. In the absence of cumate, rcTA cannot bind to the 6×CuO, so the transgene encoding the therapeutic agent will not be transcribed because the 6×CuO is not active. When cumate is added, it will form a complex with rcTA, which allows for binding to 6×CuO and transcription of the transgene encoding the therapeutic agent (Mullick et al., 2006).


Ecdysone Inducible System


Another example of an inducible gene expression system is the ecdysone inducible system, in which a retinoid X receptor (RXR) and an N-terminal truncation of ecdysone receptor (EcR) fused to the activation domain of Vp16 (VpEcR) are inserted in the 5′ untranslated region of a gene expressed by the cloaked cell such that they are co-expressed by an endogenous promoter. An ecdysone responsive element (EcRE), with a downstream minimal promoter, can be inserted just upstream of the start codon of the transgene encoding the therapeutic agent. Co-expressed RXR and VpEcR can heterodimerize with each other. In the absence of ecdysone or synthetic drug analog muristerone A, dimerized RXR/VpEcR cannot bind to EcRE, so the transgene encoding the therapeutic agent is not transcribed. In the presence of ecdysone or muristerone A, dimerized RXR/VpEcR can bind to EcRE, such that the transgene encoding the therapeutic agent is transcribed (No et al., 1996). As ecdysone administration has no apparent effect on mammals, its use for regulating genes should be excellent for transient inducible expression of any gene.


Ligand-Reversible Dimerization System


In another example, the transgene encoding a therapeutic agent can be modified so that it is functionally divided in to parts/domains, such as a 5′ portion and a 3′ portion, and an FKBP peptide sequence can be inserted into each domain. An IRES (internal ribosomal entry site) sequence may be placed between the two domains, which allows for simultaneous transcription of the two different domains to generate two separate proteins. In the absence of a dimerization agent, the two separate domains of the therapeutic agent will be functionally inactive. Upon introduction of a dimerization agent, such as rapamycin or AP20187, the FKBP peptides will dimerize, bringing together the 5′ and 3′ domains of the therapeutic agent and reconstituting an active protein (Rollins et al., 2000).


Cell-Based Delivery of a Therapeutic Agent


Treatment of Age-Related Macular Degeneration or Retinal Dystrophy


In one example, cloaked cells can be modified to produce a VEGF inhibitor, such as VEGF trap (e.g., a soluble decoy receptor described in Holash et al., Proc Natl Acad Sci U.S.A. 99:11383-11398, 2002, incorporated herein by reference, such as aflibercept) to treat age-related macular degeneration (AMD) or retinal dystrophy. VEGF trap is a biologic that binds to and inhibits VEGF, an angiogenic protein that can promote the formation of aberrant blood vessels.


VEGF trap is used to treat wet AMD, which features aberrant growth of blood vessels beneath the retina that can lead to retinal detachment and progressive vision loss. To treat AMD, VEGF trap is typically delivered by regular injection into the eye. Cloaked cells can be modified to produce VEGF trap or another VEGF inhibitor by expression of a transgene encoding VEGF trap or another VEGF inhibitor operably linked to a constitutive or inducible promoter. Cloaked cells (e.g., stem cells) that express a VEGF inhibitor (e.g., VEGF trap) can be differentiated into retinal pigmented epithelium (RPE) cells before administration to the eye using methods known by those of skill in the art, or isolated RPE cells can be modified to express cloaking transgenes and a VEGF inhibitor. Twenty five thousand to one hundred thousand cloaked RPE cells (e.g., 25,000, 50,000, 75,000 or 100,000 cloaked RPE cells) expressing a VEGF inhibitor (e.g., VEGF trap) can be injected into the subretinal space of each eye to treat wet AMD or retinal dystrophy. Other VEGF inhibitors suitable for use in the compositions and methods described herein include soluble forms of VEGF receptors (e.g., soluble VEGFR-1 or NRP-1), platelet factor-4, prolactin, SPARC, and VEGF inhibitory antibodies (e.g., bevacizumab and ranibizumab).


Treatment of Parkinson's Disease


In another example, cloaked cells, such as dopaminergic neurons or cells (e.g., stem cells) that can be differentiated in vitro to produce dopaminergic neurons using methods known by those of skill in the art, can be administered to subjects suffering from Parkinson's disease, which is characterized by loss of dopaminergic neurons. Twenty five thousand to one hundred thousand cloaked dopaminergic neurons (e.g., 25,000, 50,000, 75,000 or 100,000 cloaked dopaminergic neurons) can be administered to the brain of a subject suffering from Parkinson's disease (e.g., stereotactically injected into the substantia nigra).


Treatment of Cardiac Infarction


The cloaked cells described herein can also be used to treat cardiac infarction (e.g., myocardial infarction, commonly known as a heart attack). Cardiac infarction occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. To treat subjects who have suffered a cardiac infarction, cloaked cells (e.g., stem cells) can be differentiated into cardiac muscle cells using methods known by those of skill in the art, or isolated cardiac muscle cells can be modified to express cloaking transgenes. Five hundred million to five billion cloaked cardiac muscle cells (e.g., 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, or 5×109 cloaked cardiac muscle cells) can be administered to a subject by injection into the cardiac muscle to treat a subject who has suffered a cardiac infarction (e.g., to replace dead or damaged cardiac muscle cells).


Treatment of Osteoarthritis and Rheumatoid Arthritis


In another example, the cloaked cells described herein can be used to treat osteoarthritis or rheumatoid arthritis. Osteoarthritis and rheumatoid arthritis (RA) are characterized by joint inflammation, and are commonly treated with anti-inflammatory therapeutics. To treat subjects suffering from osteoarthritis or RA, cloaked cells can be modified to express anti-inflammatory biologics, such as inhibitors of TNFα (e.g., TNFα inhibitory antibodies), which are already in clinical use for the treatment of RA. Cloaked cells can be modified to produce an anti-inflammatory biologic, such as a TNFα inhibitor, by expression of a transgene encoding an anti-inflammatory biologic operably linked to a constitutive or inducible promoter. Cloaked cells (e.g., stem cells) that express an anti-inflammatory biologic (e.g., a TNFα inhibitor) can be differentiated into articular fibroblasts before administration to a joint using methods known by those of skill in the art, or isolated articular fibroblasts can be modified to express cloaking transgenes and an anti-inflammatory biologic. One million to one hundred million cloaked articular fibroblasts (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108 cloaked articular fibroblasts) expressing an anti-inflammatory biologic can be injected into an arthritic or inflamed joint (depending on joint size) to treat osteoarthritis or RA. Anti-inflammatory biologics that can be expressed by cloaked cells to treat osteoarthritis or RA include TNFα inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab), interleukin-6 (IL6) receptor inhibitors (e.g., tocilizumab), IL1 receptor inhibitors (e.g., anakinra), or other agents used to treat RA (e.g., abatacept, rituximab).


Treatment of Diabetes


The cloaked cells can be used to treat diabetes (e.g., Type 1 or Type 2 diabetes). Type 1 diabetes results from a failure of the pancreas to produce enough insulin. Type 2 diabetes begins with insulin resistance, but a lack of insulin may develop as the disease progresses. To treat subjects suffering from diabetes, cloaked cells can be modified to express insulin, or insulin-expressing cells from a healthy subject (e.g., pancreatic beta cells from a subject without diabetes) can be modified to express one or more (e.g., one, two, three, four, five, six, seven or all eight) of cloaking transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) and administered to a subject with diabetes. Cloaked cells can be modified to produce insulin by expression of a transgene encoding insulin operably linked to a constitutive or inducible promoter. Cloaked cells (e.g., stem cells) that express insulin can be differentiated into insulin producing cells (e.g., pancreatic beta cells) prior to administration using methods known by those of skill in the art or can be administered without differentiation, or isolated pancreatic beta cells can be modified to express cloaking transgenes and, optionally, to express a transgene encoding insulin. Eight hundred million to three billion cloaked pancreatic beta cells (e.g., 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked pancreatic beta cells) expressing insulin (e.g., expressing insulin endogenously or expressing insulin due to expression of a transgene encoding insulin) to can be injected subcutaneously in a subject to create a cloaked subcutaneous tissue that produces insulin for treating diabetes.


Treatment of Hemophilia


In another example, the cloaked cells described herein can be used to treat hemophilia. Patients with hemophilia do not produce a functional Factor VIII protein, which is a critical blood component needed for blood clotting. These patients can have severe bleeding, and the standard of care involved multiple injections per week of a purified Factor VIII protein. To treat subjects suffering from hemophilia, cloaked cells can be modified to express an additional transgene that encodes Factor VIII. Factor VIII would be expressed constitutively in cloaked cells by being operably linked to a constitutive promoter, such as CMV or CAG. Cloaked cells (e.g., stem cells) that express Factor VIII can be differentiated into cells that produce blood coagulation factors (e.g., liver sinusoidal cells or endothelial cells) prior to administration using methods known by those of skill in the art or can be administered without differentiation, or isolated Factor VIII-expressing liver sinusoidal cells or endothelial cells from a healthy subject (e.g., a subject without hemophilia) can be modified to express one or more (e.g., one, two, three, four, five, six, seven or all eight) of cloaking transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) and administered to a subject with hemophilia. Isolated Factor VIII-expressing liver sinusoidal cells or endothelial cells from a healthy subject that are modified to express one or more cloaking transgenes, can be further modified to express a transgene encoding Factor VIII, if desired to ensure that Factor VIII is expressed at high levels. Eight hundred million to three billion cloaked cells (e.g., 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked cells) expressing Factor VIII (e.g., expressing Factor VIII endogenously or expressing Factor VIII due to expression of a transgene encoding Factor VIII) can be injected subcutaneously in a subject to create a cloaked subcutaneous tissue that produces Factor VIII for treating hemophilia.


Treatment of Metabolic Disorders


The cloaked cells of the invention can also be used to treat inherited metabolic disorders. In most inherited metabolic disorders, a single enzyme is not produced by the body or it is produced in a form that is defective. Inherited metabolic disorders include lysosomal storage disorders, such as Hurler syndrome (deficiency in alpha-L iduronidase), Niemann-Pick disease (mutations in SMPD1, NPC1, or NPC2), Tay-Sachs disease (mutation in HEXA), Gaucher's disease (mutation in GBA gene), Fabry disease (deficiency in alpha galactosidase due to mutation in GLA), and Krabbe disease (deficiency in galactosylceramidase due to mutations in GALC); Galactosemia (deficiency in Galactokinase or galactose-1-phosphate uridyltransferase); Maple syrup urine disease (deficiency in enzyme BCKD); Phenylketonuria (deficiency in enzyme PAH); glycogen storage diseases (GSDs), such as GSD0 (deficiency in glycogen synthase (GYS2)), GSD1/von Gierke's disease (deficiency in glucose-6-phosphatase (G6PC)), GSD 2/Pompe's disease (deficiency in acid alpha-glucosidase (GAA)), GSD 3/Cori's disease or Forbes' disease (deficiency in glycogen debranching enzyme AGL), GSD 4/Andersen disease (deficiency in glycogen branching enzyme (GBE1)), GSD 5/McArdle disease (deficiency in muscle glycogen phosphorylase (PYGM)), GSD 6/Hers' disease (deficiency in liver glycogen phosphorylase (PYGL) or muscle phosphoglycerate mutase (PGAM2)), GSD 7/Tarui's disease (deficiency in muscle phosphofructokinase (PKFM)), GSD 9 (deficiency in phosphorylase kinase (PHKA2, PHKB, PHKG2, or PHKA1)), GSD 10 (deficiency in enolase 3 (ENO3)), GSD 11 (deficiency in muscle lactate dehydrogenase (LDHA)), Fanconi-Bickel syndrome (deficiency in glucose transporter 2 (GLUT2)), GSD 12 (deficiency in aldolase A (ALDOA)), GSD 13 (deficiency in β-enolase (ENO3)), or GSD 15 (deficiency in glycogenin-1 (GYG1)); mitochondrial disorders, such as mitochondrial myopathy (Kearns-Sayre syndrome (KSS, caused by a deletion in mitochondrial DNA) and Chronic progressive external opthalmoplegia (CPEO, caused by a deletion or duplication in mitochondrial DNA or a mutation in ANT1, POLG, POLG2, or PEO1), diabetes mellitus and deafness (DAD, caused by a mutation in mitochondrial DNA at position 3243, which encodes tRNALeu (UUR)), Leber's hereditary optic neuropathy (LHON, caused by mutations in MT-ND1, MT-ND4, MT-ND4L, and MT-ND6), Leigh syndrome (associated with mutations in SURF1, MT-ATP6, MT-ND2, MT-ND3, MT-ND5, MT-ND6, BCS1L, NDUFA10, SDHA, NDUFS4, NDUFAF2, NDUFA2, NDUFAF6, COX15, NDUFS3, NDUFS8, FOXRED1, NDUFA9, NDUFA12, NDUFS7), Neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP, caused by mutations in MT-ATP6), myoneurogenic gastrointestinal encephalopathy (MNGIE, caused by mutations in TYMP), myoclonic epilepsy with ragged red fibers (MERRF, caused by mutation sin MT-TK, MT-TL1, MT-TH, MT-TS1, MT-TS2, or MT-TF), or mitochondria myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS, caused by mutations in MT-ND1, MT-ND5, MT-TH, MT-TL1, or MT-TV); Friedrich's ataxia (mutation in FXN); peroxisomal disorders, such as Zellweger syndrome (mutations in PEX1, PEX2, PEX3, PEX5, PEX6, PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, or PEX26) and adrenoleukodystrophy (mutations in ABCD1); metal metabolism disorders, such as Wilson disease (mutation in Wilson disease protein ATP7B) and hemochromatosis (mutation in human hemochromatosis protein HFE); organic acidemias, such as methylmalonic acidemia (mutations in MUT, MMAA, MMAB, MMADHC, or MCEE) and propionic academia (mutations in PCCA or PCCB); urea cycle disorders, such as ornithine transcarbamylase (OTC), deficiency, arginase (ARG1) deficiency, argininosuccinate lyase (ASL) deficiency, argininosuccinate synthase 1 (ASS1) deficiency, citrin deficiency, carbamoyl phosphate synthase 1 (CPSI) deficiency, N-acetylglutamate synthase (NAGS) deficiency, and ornithine translocase (ORNT1) deficiency.


To treat subjects suffering from a metabolic disorder, cloaked cells can be modified to express the wild-type form of the gene that is mutated in the subject or a transgene encoding the enzyme that is missing or deficient in the subject (see Table 2), or cells from a healthy subject (e.g., a subject that does not have a metabolic disorder) that express the wild-type form of the gene that is mutated in the subject or the enzyme that is deficient in the subject can be modified to express one or more (e.g., one, two, three, four, five, six, seven or all eight) of cloaking transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) and administered to a subject with a metabolic disorder. The wild-type form of the gene that is mutated in the subject or a transgene encoding the enzyme that is missing or deficient in the subject can be expressed constitutively in cloaked cells by being operably linked to a constitutive promoter, such as CMV or CAG, or can be inducibly expressed using one of the inducible expression systems described herein. Cloaked cells (e.g., stem cells) that are modified to express the wild-type form of the gene that is mutated in the subject or the enzyme that is missing or deficient in the subject can be differentiated into cells that normally express the gene or enzyme prior to administration using methods known by those of skill in the art or can be administered without differentiation, or isolated cells from a healthy subject that express the wild-type form of the gene or enzyme that is mutated or deficient in the subject can be modified to express one or more (e.g., one, two, three, four, five, six, seven or all eight) of cloaking transgenes PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) and administered to a subject with a metabolic disorder. If the subject has not already been diagnosed as having a particular mutation prior to treatment, the subject can be evaluated using standard methods to identify the mutated gene related to the metabolic disorder, to ensure that the cloaked cells express the corresponding wild-type gene. Eight hundred million to three billion cloaked cells (e.g., 8×108, 9×108, 1×101, 2×109, or 3×109 cloaked cells) expressing the wild-type form of the gene that is mutated in the subject can be injected subcutaneously to create a cloaked subcutaneous tissue that produces the corresponding wild-type protein.


Methods of Controlling Division of a Cloaked Cell


In an aspect, a method of controlling proliferation of cell at a transplant site in an allogeneic host is provided (e.g., to reduce the tumorigenic potential of a cell at the transplant site or to reduce proliferation of a cell that has become tumorigenic at a transplant site).


The method comprises: providing a cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host the cell or a population of such cells; genetically modifying in the cell a cell division locus/loci (CDL), the CDL being one or more loci whose transcription product(s) is expressed by dividing cells (e.g., all dividing cells containing one or more of the immunosuppressive transgenes), the genetic modification of the CDL comprising one or more of: a) an ablation link (ALINK) system, the ALINK system comprising a DNA sequence encoding a negative selectable marker that is transcriptionally linked to a DNA sequence encoding the CDL; and b) an inducible exogenous activator of regulation of a CDL (EARC) system, the EARC system comprising an inducible activator-based gene expression system that is operably linked to the CDL; permitting proliferation of the genetically modified cell comprising the ALINK system by maintaining the genetically modified cell comprising the ALINK system in the absence of an inducer of the negative selectable marker or ablating and/or inhibiting proliferation of the genetically modified cell comprising the ALINK system by exposing the cell comprising the ALINK system to the inducer of the negative selectable marker; and/or permitting proliferation of the genetically modified cell comprising the EARC system by exposing the genetically modified cell comprising the EARC system to an inducer of the inducible activator-based gene expression system or preventing or inhibiting proliferation of the genetically modified cell comprising the EARC system by maintaining the cell comprising the EARC system in the absence of the inducer of the inducible activator-based gene expression system; and transplanting the cell or a population of the cells at a transplantation site in an allogeneic host. Cells that have been modified to control cell division using one or more ALINK and/or EARC systems in one or more CDLs (e.g., 2, 3, 4, or more CDLs) may be referred to as “fail-safe cells”. The number of cells that can be grown from a single fail-safe cell (clone volume) before the cell loses activity of all of the systems (e.g., ALINKs or EARCs) that control cell division through genetic mutation (e.g., the number of cell divisions it would take for a cell to “escape” from control and exhibit uncontrollable cell proliferation based on mathematical modeling) determines the fail-safe volume. The fail-safe volume will depend on the number of ALINKs and the number of ALINK-targeted CDLs. The fail-safe property is further described in Table 3.









TABLE 3







Fail-safe cell volumes and their relationship to a human body were calculated


using mathematical modeling. The model did not take into account an event in which CDL


expression was co-lost with the loss of negative selectable marker activity, compromising cell


proliferation. Therefore the values are underestimates and were calculated assuming 106 forward


mutation rate for the negative selectable marker. The estimated number of cells in a human


body as 3.72 × 1013 was taken from (Bianconi et al., 2013).















Fail-safe






Genotype
volume
Relative (x) to a human
Estimated weight of


CDL #
ALINK #
in CDLs
(#cells)
body = 3.72 × 1013 cells
clones





1
1
het
     512
0.0000000000137
   1 μg


1
2
hom
16777216
0.000000451    
   31 mg


2
3
het, hom
1.374E+11
0.004          
 0.26 kg 


2
4
hom, hom
1.13E+15 
30               
2100 kg









In various embodiments, a CDL is a locus identified as an “essential gene” as set forth in Wang et al., 2015, which is incorporated herein by reference as if set forth in its entirety. Essential genes in Wang et al., 2015, were identified by computing a score (i.e., a CRISPR score) for each gene that reflects the fitness cost imposed by inactivation of the gene. In an embodiment, a CDL has a CRISPR score (CS) of less than about −1.0 (Table 5, column 5).


In various embodiments, a CDL is a locus/loci that encodes a gene product that is relevant to cell division and/or replication (Table 5, column 6). For example, in various embodiments, a CDL is a locus/loci that encodes a gene product that is relevant to one or more of: i) cell cycle; ii) DNA replication; iii) RNA transcription and/or protein translation; and iv) metabolism (Table 5, column 7).


In an embodiment, a CDL is one or more cyclin-dependent kinases that are involved with regulating progression of the cell cycle (e.g., control of G1/S G2/M and metaphase-to-anaphase transition), such as CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9 and/or CDK11 (Morgan, 2007). In an embodiment, a CDL is one or more cyclins that are involved with controlling progression of the cell cycle by activating one or more CDK, such as, for example, cyclinB, cyclinE, cyclinA, cyclinC, cyclinD, cyclinH, cyclinC, cyclinT, cyclinL and/or cyclinF (FUNG and POON, 2005). In an embodiment, a CDL is one or more loci involved in the anaphase-promoting complex that controls the progression of metaphase to anaphase transition in the M phase of the cell cycle (Peters, 2002). In an embodiment, a CDL is one or more loci involved with kinetochore components that control the progression of metaphase to anaphase transition in the M phase of the cell cycle (Fukagawa, 2007). In an embodiment, a CDL is one or more loci involved with microtubule components that control microtubule dynamics required for the cell cycle (Cassimeris, 1999).


In various embodiments, a CDL is a locus/loci involved with housekeeping. As used herein, the term “housekeeping gene” or “housekeeping locus” refers to one or more genes that are required for the maintenance of basic cellular function. Housekeeping genes are expressed in all cells of an organism under normal and patho-physiological conditions.


In various embodiments, a CDL is a locus/loci that encodes a gene product that is relevant to cell division and/or proliferation and has a CRISPR score of less than about −1.0. For example, in an embodiment, a CDL is a locus/loci that encodes a gene product that is relevant to one or more of: i) cell cycle; ii) DNA replication; iii) RNA transcription and/or protein translation; and iv) metabolism, and has a CRISPR score of less than about −1.0. In an embodiment, the CDL may also be a housekeeping gene.


In some embodiments, the CDL is Cdk1/CDK1, Top2A/TOP2A, Cenpa/CEPNA, Birc5/BIRC5, or Eef2/EEF2. In some embodiments, the CDL is Cdk1/CDK1. In some embodiments, the CDL is Top2A/TOP2A. In some embodiments, the CDL is Eef2/EEF2. In some embodiments, the CDLs are Cdk1/CDK1 and Top2A/TOP2A or Cdk1/CDK1 and Eef2/EEF2.


A cell can be modified to be a “fail-safe” cell by linking the expression of a CDL with that of a DNA sequence encoding a negative selectable marker, thereby allowing drug-induced ablation of mitotically active cells expressing both the CDL and the negative selectable marker. Ablation of proliferating cells may be desirable, for example, when cell proliferation is uncontrolled and/or accelerated relative to a cell's normal division rate (e.g., uncontrolled cell division exhibited by cancerous cells), or when therapeutic need for the cells has passed. Ablation of proliferating cells may be achieved via a genetic modification to the cell, referred to herein as an “ablation link” (ALINK), which links the expression of a DNA sequence encoding a negative selectable marker to that of a CDL, thereby allowing elimination or sufficient inhibition of ALINK-modified proliferating cells consequently expressing the CDL locus (sufficient inhibition being inhibition of cell expansion rate to a rate that is too low to contribute to tumour formation). In the presence of a pro-drug or other inducer of the negatively selectable system, cells expressing the negative selectable marker will stop proliferating or die, depending on the mechanism of action of the selectable marker. Cells may be modified to comprise homozygous, heterozygous, hemizygous or compound heterozygous ALINKS. In one embodiment, to improve fidelity of ablation, a negative selectable marker may be introduced into all alleles functional of a CDL. In one preferred embodiment, a negative selectable marker may be introduced into all functional alleles of a CDL. The fail-safe system can be used to eliminate all of the cloaked cells, if desired.


An ALINK may be inserted in any position of CDL, which allows co-expression of the CDL and the negative selectable marker.


In some embodiments, the ALINK system comprises a herpes simplex virus-thymidine kinase/ganciclovir system, a cytosine deaminase/5-fluorocytosine system, a carboxyl esterase/irinotecan system or an iCasp9/AP1903 system.


DNA encoding a negatively selectable marker (e.g., HSV-TK), may be inserted into a CDL (e.g., CDK1) in a host cell, such that expression of the negative selectable marker causes host cells expressing the negative selectable marker and, necessarily, the CDL, to be killed in the presence of an inducer (e.g., prodrug) of the negative selectable marker (e.g., ganciclovir (GCV)). In this example, host cells modified with the ALINK will produce thymidine kinase (TK) and the TK protein will convert GCV into GCV monophosphate, which is then converted into GCV triphosphate by cellular kinases. GCV triphosphate incorporates into the replicating DNA during S phase, which leads to the termination of DNA elongation and cell apoptosis (Halloran and Fenton, 1998).


A modified HSV-TK gene (PreuB et al., 2010) is disclosed herein as one example of DNA encoding a negative selectable marker that may be used in an ALINK genetic modification to selectively ablate cells comprising undesirable cell division rate.


It is contemplated herein that alternative and/or additional negative selectable systems could be used in the tools and/or methods provided herein. Various negative selectable marker systems are known in the art (e.g., dCK.DM (Neschadim et al., 2012)).


For example, various negative selectable system having clinical relevance have been under active development in the field of “gene-direct enzyme/prodrug therapy” (GEPT), which aims to improve therapeutic efficacy of conventional cancer therapy with no or minimal side-effects (Hedley et al., 2007; Nawa et al., 2008). Frequently, GEPT involves the use of viral vectors to deliver a gene into cancer cells or into the vicinity of cancer cells in an area of the cancer cells that is not found in mammalian cells and that produces enzymes, which can convert a relatively non-toxic prodrug into a toxic agent.


HSV-TK/GCV, cytosine deaminase/5-fluorocytosine (CD/5-FC), and carboxyl esterase/irinotecan (CE/CPT-11) are examples of negative selectable marker systems being evaluated in GEPT pre- and clinical trials (Danks et al., 2007; Shah, 2012).


To overcome the potential immunogenicity of a Herpes Simplex Virus type 1 thymidine kinase/ganciclovir (TK/GCV) system, a “humanized” suicide system has been developed by engineering the human deoxycytidine kinase enzyme to become thymidine-active and to work as a negative selectable (suicide) system with non-toxic prodrugs: bromovinyl-deoxyuridine (BVdU), L-deoxythymidine (LdT) or L-deoxyuridine (LdU) (Neschadim et al., 2012).


The CD/5-FC negative selectable marker system is a widely used “suicide gene” system. Cytosine deaminase (CD) is a non-mammalian enzyme that may be obtained from bacteria or yeast (e.g., from Escherichia coli or Saccharomyces cerevisiae, respectively) (Ramnaraine et al., 2003). CD catalyzes conversion of cytosine into uracil and is an important member of the pyrimidine salvage pathway in prokaryotes and fungi, but it does not exist in mammalian cells. 5-fluorocytosine (5-FC) is an antifungal prodrug that causes a low level of cytotoxicity in humans (Denny, 2003). CD catalyzes conversion of 5-FC into the genotoxic agent 5-FU, which has a high level of toxicity in humans (Ireton et al., 2002).


The CE/CPT-11 system is based on the carboxyl esterase enzyme, which is a serine esterase found in a different tissues of mammalian species (Humerickhouse et al., 2000). The anti-cancer agent CPT-11 is a prodrug that is activated by CE to generate an active referred to as 7-ethyl-10-hydroxycamptothecin (SN-38), which is a strong mammalian topoisomerase I inhibitor (Wierdl et al., 2001). SN-38 induces accumulation of double-strand DNA breaks in dividing cells (Kojima et al., 1998).


Another example of a negative selectable marker system is the iCasp9/AP1903 suicide system, which is based on a modified human caspase 9 fused to a human FK506 binding protein (FKBP) to allow chemical dimerization using a small molecule AP1903, which has tested safely in humans. Administration of the dimerizing drug induces apoptosis of cells expressing the engineered caspase 9 components. This system has several advantages, such as, for example, including low potential immunogenicity, since it consists of human gene products, the dimerizer drug only effects the cells expressing the engineered caspase 9 components (Straathof et al., 2005). The iCasp/AP1903 suicide system is being tested in clinical settings (Di Stasi et al., 2011).


It is contemplated herein that the negative selectable marker system of the ALINK system could be replaced with a proliferation antagonist system. The term “proliferation antagonist” as used herein, refers to a natural or engineered compound(s) whose presence inhibits (completely or partially) division of a cell. For example, OmomycER is the fusion protein of MYC dominant negative Omomyc with mutant murine estrogen receptor (ER) domain. When induced with tamoxifen (TAM), the fusion protein OmomycER localizes to the nucleus, where the dominant negative Omomyc dimerizes with C-Myc, L-Myc and N-Myc, sequestering them in complexes that are unable to bind the Myc DNA binding consensus sequences (Soucek et al., 2002). As a consequence of the lack of Myc activity, cells are unable to divide (Oricchio et al., 2014). Another example of a proliferation antagonist is A-Fos, a dominant negative to activation protein-1 (AP1) (a heterodimer of the oncogenes Fos and Jun) that inhibits DNA binding in an equimolar competition (Olive et al., 1997). A-Fos can also be fused to ER domain, rendering its nuclear localization to be induced by TAM. OmomycER/tamoxifen or A-FosER/tamoxifen could be a replacement for TK/GCV to be an ALINK.


A cell can also be modified to be “fail-safe” by operably linking the CDL with an EARC, such as an inducible activator-based gene expression system. Under these conditions, the CDL will only be expressed (and the cell can only divide) in the presence of the inducer of the inducible activator-based gene expression system. Under these conditions, EARC-modified cells stop dividing, significantly slow down, or die in the absence of the inducer, depending on the mechanism of action of the inducible activator-based gene expression system and CDL function.


Cells may be modified to comprise homozygous or compound heterozygous EARCs or may be altered such that only EARC-modified alleles can produce functional CDLs. In an embodiment, an EARC modification may be introduced into all alleles of a CDL, for example, to provide a mechanism for cell division control.


An EARC may be inserted in any position of CDL that permits co-expression of the CDL and the activator component of the inducible system in the presence of the inducer.


In an embodiment, an “activator” based gene expression system is preferable to a “repressor” based gene expression system. For example, if a repressor is used to suppress a CDL a loss of function mutation of the repressor could release CDL expression, thereby allowing cell proliferation. In a case of an activation-based suppression of cell division, the loss of activator function (mutation) would shut down CDL expression, thereby disallowing cell proliferation.


In some embodiments, the EARC system is a dox-bridge system, a cumate switch inducible system, an ecdysone inducible system, a radio wave inducible system, or a ligand-reversible dimerization system.


A dox-bridge may be inserted into a CDL (e.g., CDK1) in a host cell, such that in the presence of an inducer (e.g., doxycycline or “DOX”) the dox-bridge permits CDL expression, thereby allowing cell division and proliferation. Host cells modified with a dox-bridge EARC may comprise a reverse tetracycline Trans-Activator (rtTA) gene (Urlinger et al., 2000) under the transcriptional control of a promoter, which is active in dividing cells (e.g., in the CDL). This targeted insertion makes the CDL promoter no longer available for CDL transcription. To regain CDL transcription, a tetracycline responder element promoter (for example TRE (Agha-Mohammadi et al., 2004)) is inserted in front of the CDL transcript, which will express the CDL gene only in a situation when rtTA is expressed and doxycycline is present. When the only source of CDL expression is dox-bridged alleles, there is no CDL gene expression in the absence of doxycycline. The lack of CDL expression causes the EARC-modified cells to be compromised in their proliferation, either by death, stopping cell division, or by rendering the cell mitotic rate so slow that the EARC-modified cell could not contribute to tumor formation.


The term “dox-bridge” as used herein, refers to a mechanism for separating activity of a promoter from a target transcribed region by expressing rtTA (Gossen et al., 1995) by the endogenous or exogenous promoter and rendering the transcription of target region under the control of TRE. As used herein, “rtTA” refers to the reverse tetracycline transactivator elements of the tetracycline inducible system (Gossen et al., 1995) and “TRE” refers to a promoter consisting of TetO operator sequences upstream of a minimal promoter. Upon binding of rtTA to the TRE promoter in the presence of doxycycline, transcription of loci downstream of the TRE promoter increases. The rtTA sequence may be inserted in the same transcriptional unit as the CDL or in a different location of the genome, so long as the transcriptional expression's permissive or non-permissive status of the target region is controlled by doxycycline. A dox-bridge is an example of an EARC.


Introduction of an EARC system into the 5′ regulatory region of a CDL is also contemplated herein.


It is contemplated herein that alternative and/or additional inducible activator-based gene expression systems could be used in the tools and or methods provided herein to produce EARC modifications. Various inducible activator-based gene expression systems are known in the art.


For example, destabilizing protein domains (Banaszynski et al., 2006) fused with an acting protein product of a coding CDL could be used in conjunction with a small molecule synthetic ligand to stabilize a CDL fusion protein when cell division and/or proliferation is desirable. In the absence of a stabilizer, destabilized-CDL-protein will be degraded by the cell, which in turn would stop proliferation. When the stabilizer compound is added, it would bind to the destabilized-CDL-protein, which would not be degraded, thereby allowing the cell to proliferate.


For example, transcription activator-like effector (TALE) technology (Maeder et al., 2013) could be combined with dimerizer-regulated expression induction (Pollock and Clackson, 2002). The TALE technology could be used to generate a DNA binding domain designed to be specific to a sequence, placed together with a minimal promoter replacing the promoter of a CDL. The TALE DNA binding domain also extended with a drug dimerizing domain. The latter can bind to another engineered protein having corresponding dimerizing domain and a transcriptional activation domain.


For example, a reverse-cumate-Trans-Activator (rcTA) may be inserted in the 5′ untranslated region of the CDL, such that it will be expressed by the endogenous CDL promoter. A 6-times repeat of a Cumate Operator (6×CuO) may be inserted just before the translational start (ATG) of CDL. In the absence of cumate in the system, rcTA cannot bind to the 6×CuO, so the CDL will not be transcribed because the 6×CuO is not active. When cumate is added, it will form a complex with rcTA, enabling binding to 6×CuO and enabling CDL transcription (Mullick et al., 2006).


For example, a retinoid X receptor (RXR) and an N-terminal truncation of ecdysone receptor (EcR) fused to the activation domain of Vp16 (VpEcR) may be inserted in the 5′ untranslated region of a CDL such that they are co-expressed by an endogenous CDL promoter. Ecdysone responsive element (EcRE), with a downstream minimal promoter, may also be inserted in the CDL, just upstream of the starting codon. Co-expressed RXR and VpEcR can heterodimerize with each other. In the absence of ecdysone or a synthetic drug analog muristerone A, dimerized RXR/VpEcR cannot bind to EcRE, so the CDL is not transcribed. In the presence of ecdysone or muristerone A, dimerized RXR/VpEcR can bind to EcRE, such that the CDL is transcribed (No et al., 1996).


For example, a transient receptor potential vanilloid-1 (TRPV1), together with ferritin, may be inserted in the 5′ untranslated region of a CDL and co-expressed by an endogenous CDL promoter. A promoter inducible by NFAT (NFATre) may also be inserted in the CDL, just upstream of the starting codon. In a normal environment, the NFAT promoter is not active. However, upon exposure to low-frequency radio waves, TRPV1 and ferritin create a wave of Ca++ entering the cell, which in turn converts cytoplasmatic-NFAT (NFATc) to nuclear-NFAT (NFATn), that ultimately will activate the NFATre and transcribe the CDL (Stanley et al., 2015).


For example, a CDL may be functionally divided in to parts/domains: 5′-CDL and 3′CDL, and a FKBP peptide sequence may be inserted into each domain. An IRES (internal ribosomal entry site) sequence may be placed between the two domains, which will be transcribed simultaneously by a CDL promoter but will generate two separate proteins. Without the presence of an inducer, the two separate CDL domains will be functionally inactive. Upon introduction of a dimerization agent, such as rapamycin or AP20187, the FKBP peptides will dimerize, bringing together the 5′ and 3′ CDL parts and reconstituting an active protein (Rollins et al., 2000).


In an embodiment of the method, the genetically modified cell comprises: a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting and whose function is to mitigate function of graft attacking leukocyte and NK cell activation or act as a defense mechanism against attacking leukocytes.


Methods for genetically modifying cell to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host the cell or a population of such cells are described, for example, in WO 2016/141480, the entire teachings of which are incorporated herein by reference.


The set of transgenes comprises one or more of the following genes: PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6). In an embodiment, the set of transgenes genes comprises PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6).


Optionally, the method further comprises expressing one or more of the following transgenes in the cell: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and IFNγR1 d39. In an embodiment, the TGF-β or the biologic is local acting in the graft environment.


Techniques for introducing into animal cells various genetic modifications, such as transgenes are described herein and are generally known in the art.


In an embodiment of the method, the cell is a stem cell, a cell amenable to genome editing, or a cell that can serve as a source of a therapeutic cell type (e.g., a cell that can be directed to differentiate into a lineage restricted or terminally differentiated cell that can be used for cell therapy, or a cell of a desired target tissue). In an embodiment, the cell is an embryonic stem cell, an induced pluripotent stem cell, an adult stem cell, a tissue-specific stem cell, a hematopoietic stem cell, a mesenchymal stem cell, an endothelial stem cell, an epithelial stem cell, an adipose stem or progenitor cells, germline stem cell, a lung stem or progenitor cell, a mammary stem cell, an olfactory adult stem cell, a hair follicle stem cell, a multipotent stem cell, an amniotic stem cell, a cord blood stem cell, or a neural stem or progenitor cell. In some embodiments, the cell is derived from a target tissue, e.g., skin, heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder, bone marrow, spleen, intestine, or stomach. In some embodiments, the cell is a fibroblast, an epithelial cell, or an endothelial cell. The cell may be a vertebrate cell, for example a mammalian cell, such as a human or mouse cell.


Techniques for transplanting the genetically modified cells into a transplant site of an allogeneic host are described herein and are generally known in the art.


In various embodiments of any of the methods of the disclosure, the host has a degenerative disease or a condition that can be treated with cell therapy. Examples of such diseases or conditions include, but are not limited to: blindness, arthritis (e.g., osteoarthritis or rheumatoid arthritis), ischemia, diabetes (e.g., Type 1 or Type 2 diabetes), multiple sclerosis, spinal cord injury, stroke, cancer, a lung disease, a blood disease, a neurological disease, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS, an enzyme or hormone deficiency, a metabolic disorder (e.g., a lysosomal storage disorder, Galactosemia, Maple syrup urine disease, Phenylketonuria, a glycogen storage disease, a mitochondrial disorder, Friedrich's ataxia, a peroxisomal disorder, a metal metabolism disorder, or an organic academia), an autoimmune disease (e.g., Psoriasis, Systemic Lupus Erythematosus, Grave's disease, Inflammatory Bowel Disease, Addison's Diseases, Sjogren's Syndrome, Hashimoto's Thyroiditis, Vasculitis, Autoimmune Hepatitis, Alopecia Areata, Autoimmune pancreatitis, Crohn's Disease, Ulcerative colitis, Dermatomyositis), age-related macular degeneration, retinal dystrophy, an infectious disease, hemophilia, a degenerative disease (e.g., Charcot-Marie-Tooth disease, chronic obstructive pulmonary disease, chronic traumatic encephalopathy, Creutzfeldt-Jakob disease, Cystic Fibrosis, Cytochrome C Oxidase deficiency, Ehlers-Danlos syndrome, essential tremor, Fribrodisplasia Ossificans Progressiva, infantile neuroaxonal dystrophy, keratoconus, keratoglobus, muscular dystrophy, neuronal ceroid lipofuscinosis, a prior disease, progressive supranuclear palsy, sandhoff disease, spinal muscular atrophy, retinitis pigmentosa), or an age-related disease (e.g., atherosclerosis, cardiovascular disease (e.g., angina, myocardial infarction), cataracts, osteoporosis, or hypertension).


Pharmaceutical Compositions


The cloaked cells described herein may be incorporated into a vehicle for administration into a patient, such as a human patient receiving a transplant or suffering from a disease or condition described herein. Pharmaceutical compositions containing cloaked cells can be prepared using methods known in the art. For example, such compositions can be prepared using, e.g., physiologically acceptable carriers, excipients or stabilizers (Remington: The Science and Practice of Pharmacology 22nd edition, Allen, L. Ed. (2013); incorporated herein by reference), and in a desired form, e.g., in the form of aqueous solutions.


The cloaked cells described herein can be administered in any physiologically compatible carrier, such as a buffered saline solution. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and/or dispersion media. The use of such carriers and diluents is well known in the art. Other examples include liquid media, for example, Dulbeccos modified eagle's medium (DMEM), sterile saline, sterile phosphate buffered saline, Leibovitz's medium (L15, Invitrogen, Carlsbad, Calif.), dextrose in sterile water, and any other physiologically acceptable liquid. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. The solution is preferably sterile and fluid to the extent that easy syringability exists. Preferably, the solution is stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi through the use of, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosol, and the like. Solutions of the invention can be prepared by using a pharmaceutically acceptable carrier or diluent and, as required, other ingredients enumerated above, followed by filtered sterilization, and then incorporating the cloaked cells as described herein.


For example, a solution containing a pharmaceutical composition described herein may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations may meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biologics standards.


Pharmaceutical compositions comprising cloaked cells in a semi-solid or solid carrier are typically formulated for surgical implantation at the site of transplantation or at the affected site of a disease or condition in the subject. It will be appreciated that liquid compositions also may be administered by surgical procedures. In particular embodiments, semi-solid or solid pharmaceutical compositions may comprise semi-permeable gels, matrices, cellular scaffolds and the like, which may be non-biodegradable or biodegradable. For example, in certain embodiments, it may be desirable or appropriate to sequester the cloaked cells from their surroundings, yet enable the cells to secrete and deliver biological molecules (e.g., a therapeutic agent listed in Table 2) to surrounding cells.


In other embodiments, different varieties of degradable gels and networks are utilized for the pharmaceutical compositions of the invention. For example, degradable materials include biocompatible polymers, such as poly(lactic acid), poly(lactic acid-co-glycolic acid), methylcellulose, hyaluronic acid, collagen, and the like.


In another embodiment, one or more hydrogels are used for the pharmaceutical compositions. The one or more hydrogels may include collagen, atelocollagen, fibrin constructs, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, and poly(ethylene oxide). Further, the hydrogel may be formed of poly(2-hydroxyethyl methacrylate), poly(acrylic acid), self-assembling peptides (e.g., RAD16), poly(methacrylic acid), poly(N-vinyl-2-pyrrolidinone), poly(vinyl alcohol) and their copolymers with each other and with hydrophobic monomers such as methyl methacrylate, vinyl acetate, and the like. Also preferred are hydrophilic polyurethanes containing large poly(ethylene oxide) blocks. Other preferred materials include hydrogels comprising interpenetrating networks of polymers, which may be formed by addition or by condensation polymerization, the components of which may comprise hydrophilic and hydrophobic monomers such as those just enumerated. In situ-forming degradable networks are also suitable for use in the invention (see, e.g., Anseth, K S et al. J. Controlled Release, 2002; 78:199-209; Wang, D. et al., Biomaterials, 2003; 24:3969-3980; U.S. Patent Publication 2002/0022676). These in situ forming materials are formulated as fluids suitable for injection; then may be induced to form a hydrogel by a variety of means such as change in temperature, pH, and exposure to light in situ or in vivo. In one embodiment, the construct contains fibrin glue containing gels. In another embodiment, the construct contains atelocollagen containing gels.


A polymer used to form a matrix may be in the form of a hydrogel. In general, hydrogels are cross-linked polymeric materials that can absorb more than 20% of their weight in water while maintaining a distinct three-dimensional structure. This definition includes dry cross-linked polymers that will swell in aqueous environments, as well as water-swollen materials. A host of hydrophilic polymers can be cross-linked to produce hydrogels, whether the polymer is of biological origin, semi-synthetic or wholly synthetic. The hydrogel may be produced from a synthetic polymeric material. Such synthetic polymers can be tailored to a range of properties and predictable lot-to-lot uniformity, and represent a reliable source of material that generally is free from concerns of immunogenicity. The matrices may include hydrogels formed from self assembling peptides, such as those discussed in U.S. Pat. Nos. 5,670,483 and 5,955,343, U.S. Patent Application No. 2002/0160471, and PCT Application No. WO 02/062969.


Properties that make hydrogels valuable in drug delivery applications include the equilibrium swelling degree, sorption kinetics, solute permeability, and their in vivo performance characteristics. Permeability to compounds depends, in part, upon the swelling degree or water content and the rate of biodegradation. Since the mechanical strength of a gel may decline in proportion to the swelling degree, it is also well within the contemplation of the present invention that the hydrogel can be attached to a substrate so that the composite system enhances mechanical strength. In some embodiments, the hydrogel can be impregnated within a porous substrate, so as to gain the mechanical strength of the substrate, along with the useful delivery properties of the hydrogel.


In other embodiments, the pharmaceutical composition comprises a biocompatible matrix made of natural, modified natural or synthetic biodegradable polymers, including homopolymers, copolymers and block polymers, as well as combinations thereof.


Examples of suitable biodegradable polymers or polymer classes include any biodegradable polymers discussed within this disclosure, including but not limited to, fibrin, collagen types I, II, III, IV and V, elastin, gelatin, vitronectin, fibronectin, laminin, thrombin, poly(aminoacid), oxidized cellulose, tropoelastin, silk, ribonucleic acids, deoxyribonucleic acids; proteins, polynucleotides, gum arabic, reconstituted basement membrane matrices, starches, dextrans, alginates, hyaluron, chitin, chitosan, agarose, polysaccharides, hyaluronic acid, poly(lactic acid), poly(glycolic acid), polyethylene glycol, decellularized tissue, self-assembling peptides, polypeptides, glycosaminoglycans, their derivatives and mixtures thereof. Suitable polymers also include poly(lactide) (PLA) which can be formed of L(+) and D(−) polymers, polyhydroxybutyrate, polyurethanes, polyphoshazenes, poly(ethylene glycol)-poly(lactide-co-glycolide) co-polymer, degradable polycyanoacrylates and degradable polyurethanes. For both glycolic acid and lactic acid, an intermediate cyclic dimer is may be prepared and purified prior to polymerization. These intermediate dimers are called glycolide and lactide, respectively.


Other useful biodegradable polymers or polymer classes include, without limitation, aliphatic polyesters, poly(alkylene oxalates), tyrosine derived polycarbonates, polyiminocarbonates, polyorthoesters, polyoxaesters, polyamidoesters, polyoxaesters containing amine groups, poly(propylene fumarate), polyfumarates, polydioxanones, polycarbonates, polyoxalates, poly(alpha-hydroxyacids), poly(esters), polyurethane, poly(ester urethane), poly(ether urethane), polyanhydrides, polyacetates, polycaprolactones, poly(orthoesters), polyamino acids, polyamides and blends and copolymers thereof. Additional useful biodegradable polymers include, without limitation stereopolymers of L- and D-lactic acid, copolymers of bis(para-carboxyphenoxy)propane and sebacic acid, sebacic acid copolymers, copolymers of caprolactone, poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol copolymers, copolymers of polyurethane and poly(lactic acid), copolymers of alpha-amino acids, copolymers of alpha-amino acids and caproic acid, copolymers of alpha-benzyl glutamate and polyethylene glycol, copolymers of succinate and poly(glycols), polyphosphazene, poly(hydroxyalkanoates) and mixtures thereof. Binary and ternary systems also are contemplated.


In general, the material used to form a matrix is desirably configured so that it: (1) has mechanical properties that are suitable for the intended application; (2) remains sufficiently intact until tissue has in-grown and healed; (3) does not invoke an inflammatory or toxic response; (4) is metabolized in the body after fulfilling its purpose; (5) is easily processed into the desired final product to be formed; (6) demonstrates acceptable shelf-life; and (7) is easily sterilized.


In another embodiment, the population of cloaked cells can be administered by use of a scaffold. The composition, shape, and porosity of the scaffold may be any described above. Typically, these three-dimensional biomaterials contain the living cells attached to the scaffold, dispersed within the scaffold or incorporated in an extracellular matrix entrapped in the scaffold. Once implanted into the target region of the body, these implants become integrated with the host tissue, wherein the transplanted cells gradually become established.


Non-limiting examples of scaffolds that may be used include textile structures, such as weaves, knits, braids, meshes, non-wovens, and warped knits; porous foams, semi-porous foams, perforated films or sheets, microparticles, beads, and spheres and composite structures being a combination of the above structures. Nonwoven mats may, for example, be formed using fibers comprised of a synthetic absorbable copolymer of glycolic and lactic acids (PGA/PLA), sold under the tradename VICRYL sutures (Ethicon, Inc., Somerville, N.J.). Foams, composed of, for example, poly(epsilon-caprolactone)/poly(glycolic acid) (PCL/PGA) copolymer, formed by processes such as freeze-drying, or lyophilized, as discussed in U.S. Pat. No. 6,355,699, also may be utilized.


In another embodiment, the framework is a felt, which can be composed of a multifilament yarn made from a bioabsorbable material. The yarn can be made into a felt using standard textile processing techniques consisting of crimping, cutting, carding and needling. In another embodiment, cells are seeded onto foam scaffolds that may be used as composite structures.


The framework may be molded into a useful shape, such as to fill a tissue void. The framework can therefore be shaped to not only provide a channel for neural growth, but also provide a scaffold for the supporting and surrounding tissues, such as vascular tissue, muscle tissue, and the like. Furthermore, it will be appreciated that the population of cells may be cultured on pre-formed, non-degradable surgical or implantable devices.


Pharmaceutical compositions may include preparations made from cloaked cells that are formulated with a pharmaceutically acceptable carrier or medium. Suitable pharmaceutically acceptable carriers include any discussed within this disclosure, including but not limited to, water, salt solution (such as Ringer's solution), alcohols, oils, gelatins, polyvinyl pyrrolidine, carbohydrates such as lactose, amylose, or starch, fatty acid esters, and hydroxymethylcellulose. Such preparations can be sterilized, and if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, and coloring agents. Pharmaceutical carriers suitable for use in the present invention are known in the art and are described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, Pa.) and WO 96/05309.


Methods of Treatment


The cloaked cells and compositions described herein may be administered to a subject in need thereof (e.g., a subject who is receiving or has received a transplant, or a subject having a disease or condition described herein) by a variety of routes, such as local administration to or near the site of a transplant, local administration to the site affected by the disease or condition (e.g., injection to a joint for treating RA, injection into the subretinal space for treating wet AMD, direct administration to the central nervous system (CNS) (e.g., intracerebral, intraventricular, intrathecal, intracisternal, or stereotactic administration) for treating a neurological disease, such as Parkinson's disease, direct injection into the cardiac muscle for treating cardiac infarction), intravenous, parenteral, intradermal, transdermal, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intraarterial, intravascular, inhalation, perfusion, lavage, and oral administration. The most suitable route for administration in any given case will depend on the particular cells or composition administered, the patient, pharmaceutical formulation methods, administration methods (e.g., administration time and administration route), the patient's age, body weight, sex, severity of the disease being treated, the patient's diet, and the patient's excretion rate. Compositions may be administered once, or more than once (e.g., once annually, twice annually, three times annually, bi-monthly, or monthly). For local administration, the cloaked cells may be administered by any means that places the population of cells in a desired location, including catheter, syringe, shunt, stent, microcatheter, pump, implantation with a device, or implantation with a scaffold.


As described herein, before administration, the population of cells can be incubated in the presence of one or more factors, or under conditions, that stimulate stem cell differentiation into a desired cell type (e.g., a neuron, a cardiac muscle cell, an RPE cell, an insulin producing cell, a blood coagulation factor producing cell, an articular fibroblast, or other cell types described herein). Such factors are known in the art and the skilled artisan will appreciate that determination of suitable conditions for differentiation can be accomplished with routine experimentation. Such factors include growth or trophic factors, chemokines, cytokines, cellular products, demethylating agents, and other stimuli which are known to stimulate differentiation, for example, of stem cells along angiogenic, hemangiogenic, vasculogenic, skeletal muscle, vascular smooth muscle, pericyte, neuronal, or vascular endothelial pathways or lineages. Alternatively, the composition administered to the patient includes a population of cloaked cells with one or more factors that stimulate cell differentiation into a desired cell type, where the cell differentiation occurs in vivo at the tissue site. In some embodiments, the cloaked cells can be differentiated into an organ or tissue in vitro using methods known by those of skill in the art and administered to a subject in need of an organ or tissue transplant.


In some embodiments, cells of a specific cell type are collected from the patient or from a donor (e.g., from an HLA-matched or mis-matched donor that is, e.g., free of the disease or condition), modified to express one or more (e.g., one, two, three, four, five, six, seven, or eight) cloaking transgenes, and subsequently administered to a subject. Such an approach is useful for treating subjects carrying a mutation in a particular gene, as the cloaked donor cells can endogenously express the wild-type version of the gene, or for subjects deficient in a particular secreted protein or enzyme (e.g., using cloaked donor cells that endogenously express the protein or enzyme that is deficient in the subject). This approach can also be used for treatment of subjects receiving an organ or tissue transplant, as cells in the organ or tissue transplant can be modified to express one or more (e.g., one, two, three, four, five, six, seven, or eight) of the cloaking transgenes before the transplant is performed.


Subjects that may be treated as described herein are subjects that have received a transplant, or subjects having a disease or condition described herein (e.g., wet AMD or retinal dystrophy, a neurodegenerative disease, such as Parkinson's disease, cardiac infarction, osteoarthritis or RA, diabetes, hemophilia, a metabolic disorder, or a disease or condition listed in Table 2). The cells, compositions, and methods described herein can be used to treat a disease or condition caused by or associated with loss of cells, a mutation or deficiency in a protein, or aberrant production of a protein, which could be treated using cell replacement protein or cellular therapy, production of a therapeutic protein, production of an agonist antibody, or production of an inhibitory antibody. The methods described herein may include a step of screening a subject for mutations in genes associated with deficient protein production prior to treatment with or administration of the compositions described herein. A subject can be screened for a genetic mutation using standard methods known to those of skill in the art (e.g., genetic testing). The methods described herein may also include a step of evaluating the symptoms of the disease or condition in a subject prior to treatment with or administration of the cloaked cells or compositions described herein. The subject can then be evaluated using the same diagnostic tests after administration of the cloaked cells or compositions to determine whether the subject's condition has improved. The compositions and methods described herein may be administered as a preventative treatment to patients who have received a tissue or organ transplant before the patient shows any signs of tissue or organ rejection.


The cloaked cells, compositions, and methods described herein can be used to replace dead or dying cells in a subject (e.g., to replace neurons in a subject suffering from a neurodegenerative disease, or to replace cardiac muscle cells in a subject who has had a myocardial infarction). The cloaked cells, compositions, and methods described herein can also be used to provide immunosuppression in the region of a tissue or organ transplant, or to reduce the risk of rejection of the tissue or organ transplant. Cloaked cells that express a therapeutic agent, such as a protein or agonist antibody, compositions including such cells, or methods of administering such cells, may be used to replace or supply wild type versions of proteins that are mutated or deficient in a subject (e.g., proteins that are produced but do not function correctly due to a genetic mutation, such as truncated proteins or proteins with altered charge, polarity, or binding properties; or proteins that are not produced or that are produced in insufficient quantities, e.g., deficient protein production that is associated with a disease or condition in Table 2). Cloaked cells that express a therapeutic agent, such as an inhibitory or neutralizing antibody, compositions including such cells, or methods of administering such cells, may be used to block or neutralize proteins that are overexpressed in a subject or proteins that are aberrantly produced (e.g., proteins that are produced in at a time or in a location that differs from production of that protein in healthy subjects, e.g., aberrant protein production that is associated with a disease or condition listed in Table 2).


Treatment may include administration of cloaked cells or a composition containing cloaked cells in various unit doses. Each unit dose will ordinarily contain a predetermined-quantity of the cloaked cells described herein. The quantity to be administered, and the particular route of administration and formulation, are within the skill of those in the clinical arts. A unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time. Dosing may be performed using a catheter, syringe, shunt, stent, microcatheter, pump, implantation with a device, or implantation with a scaffold. The number of cells administered may vary depending on whether the cells are administered to a tissue, organ, or body site associated with a disease or injury, or are administered subcutaneously to produce a cloaked subcutaneous tissue. For administration to a tissue, organ, or body site, the cloaked cells may be administered to the patient at a dose of, for example 1×104 cells to 1×1010 cells (e.g., 1×104, 2×104, 3×104, 4×104, 5×104, 6×104, 7×104, 8×104, 9×104, 1×105, 2×105, 3×105, 4×105, 5×105, 6×105, 7×105, 8×105, 9×105, 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010 cells). The number of cells administered will depend on the size of the recipient tissue, organ, or body site. For example, 2.5×104 to 1×105 cells (e.g., 2.5×104, 3×104, 4×104, 5×104, 6×104, 7×104, 8×104, 9×104, or 1×105 cells) can be administered (e.g., injected) to the subretinal space of the eye or to a specific brain region; 1×106 to 1×108 cells (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108 cells) can be administered (e.g., injected) to a joint, with the quantity of cells depending on the size of the joint; and 5×108 to 5×109 cells (e.g., 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, or 5×109 cells) can be administered to the cardiac muscle. For creating cloaked subcutaneous tissue, 8×108 cells to 3×109 cells (e.g., 8×108, 9×108, 1×109, 2×109, 3×109 cells) can be administered (e.g., injected) subcutaneously. Cloaked cells can be administered in two or more doses (e.g., two, three, four, five, or more different doses, e.g., to joints of different sizes in a patient with RA) or at the same dose two or more times (e.g., two, three, four, five, six, or more times over the course of an hour, day, week, month, or year). In some embodiments, the cloaked cells described herein are administered as a tissue (e.g., a tissue that has been grown and/or differentiated in vitro from cloaked cells). In some embodiments, the cloaked tissue is administered (e.g., implanted) with a gel, biocompatible matrix, or scaffold.


The compositions described herein are administered in an amount sufficient to prevent or reduce transplant rejection or to improve symptoms of a disease or condition listed in Table 2 (e.g., to reduce symptoms of osteoarthritis or RA (e.g., reduce inflammation, joint pain, stiffness, or immobility); reduce symptoms of retinal dystrophy or wet AMD (e.g., improve vision, slow or reduce vascularization of the eye); reduce symptoms of Parkinson's disease (e.g., reduce tremors, rigidity, bradykinesia, or improve posture or gait); reduce symptoms of diabetes (e.g., improve insulin levels, reduce the need for regular insulin injections); reduce symptoms of cardiac infarction (e.g., improve heart function, reduce infarct size); reduce symptoms of hemophilia (e.g., increase level of blood coagulation factors, such as Factor VIII, reduce excessive bleeding, reduce bruising, reduce nosebleeds, reduce joint pain or swelling); or reduce symptoms of metabolic disorders (e.g., increase appetite, growth, or weight gain, or reduce lethargy, weight loss, jaundice, seizures, abdominal pain, or vomiting)). Transplant rejection may be evaluated using standard methods known by those of skill in the art and may be reduced by 5% or more (e.g., 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more) compared to rates of transplant rejection typically observed without treatment. In some embodiments, administration of the cloaked cells or compositions described herein results in an equivalent outcome in transplant rejection as that observed in subjects administered immunosuppressive agent(s). Symptoms of diseases and conditions described herein can be evaluated using standard methods known to those of skill in the art and may be reduced (e.g., the subject's condition may be improved) by 5% or more (e.g., 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more) compared to symptoms prior to administration of the cloaked cells or compositions described herein. These effects may occur, for example, within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, or more, following administration of the compositions described herein. The patient may be evaluated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months or more following administration of the cloaked cell or composition depending on the dose and route of administration used for treatment. Depending on the outcome of the evaluation, the patient may receive additional treatments.


Combination Therapy


In some embodiments, the cloaked cells described herein are administered in combination with one or more additional therapeutic agents. The additional therapeutic agent(s) can be administered prior to administration of the cloaked cells, after administration of the cloaked cells, or concurrently with administration of the cloaked cells. The cloaked cells and additional therapeutic agents can also be administered simultaneously via co-formulation. The cloaked cells and therapeutic agent(s) can also be administered sequentially, such that the action of the cloaked cells and therapeutic agent(s) overlaps and their combined effect is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with the cloaked cells or therapeutic agent delivered alone or in the absence of the other. The effect of the cloaked cells and therapeutic agent(s) can be partially additive, wholly additive, or greater than additive (e.g., synergistic). Sequential or substantially simultaneous administration of cloaked cells and therapeutic agent(s) can be effected by any appropriate route including, but not limited to oral routes, intravenous routes, intramuscular routes, local routes, or subcutaneous routes. The cloaked cells and therapeutic agent(s) can be administered by the same route or by different routes. For example, cloaked cells may be administered by subcutaneous injection while the additional therapeutic agent is administered orally. The cloaked cells may be administered immediately, up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to, 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to hours 16, up to 17 hours, up 18 hours, up to 19 hours up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours up to 24 hours or up to 1-7, 1-14, 1-21 or 1-30 days before or after the additional therapeutic agent.


In one example, the additional therapeutic agent is an immunosuppressive agent(s) commonly given for organ or tissue transplant. The immunosuppressive agent(s) may be an agent that is given immediately after transplantation to prevent acute rejection (e.g., methylprednisolone, atgam, thymoglobulin, OKT3, basiliximab, or daclizumab) or an immunosuppressive agent(s) used for maintenance (e.g., prednisone, a calcineurin inhibitor (e.g., cyclosporine, tacrolimus), Mycophenolate Mofetil, Azathioprine or Rapamycin). Other immunosuppressive agents given after organ transplantation include corticosteroids (e.g., methylprednisolone, dexamethasone, prednisolone), cytotoxic immunosuppressants (e.g., azathioprine, chlorambucil, cyclophosphamide, mercaptopurine, methotrexate), immunosuppressant antibodies (e.g., antithymocyte globulins, basiliximab, infliximab), sirolimus derivatives (e.g., everolimus, sirolimus), and anti-proliferative agents (e.g., mycophenolate mofetil, mycophenolate sodium, and azathioprine). In this case, the cloaked cell(s) is administered to or near the transplant site, or the tissue to be transplanted is modified to express one or more (e.g., one, two, three, four, five, six, seven, or eight) cloaking transgenes, and the immunosuppressive agent(s) is administered as an additional source of immunosuppression, if needed.


For use in treating inflammatory and autoimmune related diseases or conditions, the additional agent may be a disease-modifying anti-rheumatic drug (DMARD), a biologic response modifier (a type of DMARD), a corticosteroid, or a nonsteroidal anti-inflammatory medication (NSAID). In some embodiments, the additional agent is prednisone, prednisolone, methylprednisolone, methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, cyclophosphamide, azathioprine, or a biologic such as tofacitinib, adalimumab, abatacept, anakinra, kineret, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab. In some embodiments, the additional agent is 6-mercaptopurine, 6-thioguanine, abatacept, adalimumab, alemtuzumab (Lemtrada), an aminosalicylate (5-aminoalicylic acid, sulfasalazine, mesalamine, balsalazide, olsalazine), an antibiotic, an anti-histamine, Anti-TNFα (infliximab, adalimumab, certolizumab pegol, natalizumab), azathioprine, belimumab, beta interferon, a calcineurin inhibitor, certolizumab, a corticosteroids, cromolyn, cyclosporin A, cyclosporine, dimethyl fumarate (tecfidera), etanercept, fingolimod (Gilenya), fumaric acid esters, glatiramer acetate (Copaxone), golimumab, hydroxyurea, IFNγ, IL-11, infliximab, leflunomide, leukotriene receptor antagonist, long-acting beta2 agonist, mitoxantrone, mycophenolate mofetil, natalizumab (tysabri), ocrelizumab, pimecrolimus, a probiotic (VSL #3), a retinoid, rituximab, salicylic acid, short-acting beta2 agonist, sulfasalazine, tacrolimus, teriflunomide (Aubagio), theophylline, tocilizumab, ustekinumab (anti-IL-12/IL-23), or vedolizumab (Anti alpha3 beta7 integrin). In this case, the cloaked cell(s) could be administered to replace a tissue or organ damaged by the inflammatory or autoimmune-related disease or condition. In another example, the cloaked cell(s) administered could be modified to express a biologic therapeutic agent (e.g., an antibody) directed to treatment of a particular inflammatory or autoimmune-related disease or condition, and the additional agent could be a compound or general anti-inflammatory agent (e.g., an NSAID or corticosteroid).


For example, if the disease is rheumatoid arthritis, the additional agent may be one or more of: prednisone, prednisolone and methylprednisolone, methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, cyclophosphamide and azathioprine, tofacitinib, adalimumab, abatacept, anakinra, kineret, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab. The cloaked cell(s) administered could be cartilage or bone producing cells of the joints. In some embodiments, the cloaked cell(s) can be modified to produce an anti-TNFα antibody and can be administered in combination with an anti-inflammatory agent (e.g., a corticosteroid).


In another example, for use in treating AMD or retinal dystrophy, the additional therapeutic agent may be an additional biologic agent (e.g., bevacuzimab, ranibizumab, or aflibercept), photodynamic therapy, or photocoagulation. The cloaked cell(s) administered could be retinal cells (e.g., RPE cells). In some embodiments, the cloaked cell(s) can be modified to produce a VEGF inhibitor and can be administered in combination with photodynamic therapy or photocoagulation.


For use in treating Parkinson's disease, the cloaked cells described herein can be administered with carbidopa-levodopa, a dopamine agonist (e.g., pramipexole, ropinirole, rotigotine, or apomorphine), an MAO-B inhibitor (e.g., selegiline or rasagiline), a catechol-O-methyltransferase inhibitor (e.g., entacapone or tolcapone), anticholinergic (e.g., benztropine or trihexyphenidyl), amantadine, or deep brain stimulation. The cloaked cell(s) administered could be dopaminergic neurons.


Additional agents for treating cardiac infarction include anticoagulants (e.g., rivaroxaban, dabigatran, apixaban, heparin, warfarin), anti-platelet agents (e.g., aspirin, clopidogrel, dipyramidole, prasugrel, ticagrelor), angiotensin-converting enzyme inhibitors (e.g., benazepril, captopril, enalapril, fosinopril, Lisinopril, moexipril, perindopril, quinapril, Ramipril, trandolapril), angiotensin II receptor blockers (e.g., candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan), angiotensin receptor neprilysin inhibitors (e.g., sacubitril/valsartan), beta blockers (e.g., acebutelol, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol), combined alpha and beta blockers (e.g., carvedilol, labetalol hydrochloride), calcium channel blockers (e.g., amlodipine, diltiazem, felodipine, nifedipine, nimodipine, nisoldipine, verapamil), cholesterol lowering medication (e.g., statins (e.g., atorvastatin, rosuvastatin), nicotinic acids (e.g., lovastatin), cholesterol absorption inhibitors (e.g., ezetimibe/simvastatin)), digitalis preparation (e.g., lanoxin), diuretics (e.g., amiloride, bumentanide, chlorothiazide, chlorthalidone, furosemide, hydro-chlorothiazide, indipamide, spironolactone), vasodilators (e.g., isosorbide dinitrate, nesiritide, hydralazine, nitrates, minoxidil), dual anti-platelet therapy (e.g., aspirin and a P2Y12 inhibitor), or a cardiac procedure (e.g., an angioplasty, artificial heart valve surgery, atherectomy, bypass surgery, cardiomyoplasty, heart transplant, minimally invasive heart surgery, radiofrequency ablation, stent procedure, or transmyocardial revascularization). The cloaked cell(s) administered could be cardiac muscle cells.


For use in treating infectious disease, the additional agent may be an antiviral compound (e.g., vidarabine, acyclovir, gancyclovir, valgancyclovir, nucleoside-analog reverse transcriptase inhibitor (NRTI) (e.g., AZT (Zidovudine), ddl (Didanosine), ddC (Zalcitabine), d4T (Stavudine), or 3TC (Lamivudine)), non-nucleoside reverse transcriptase inhibitor (NNRTI) (e.g., (nevirapine or delavirdine), protease inhibitor (saquinavir, ritonavir, indinavir, or nelfinavir), ribavirin, or interferon); an antibacterial compound; an antifungal compound; an antiparasitic compound. The cloaked cell(s) administered could be immune cells (e.g., cell that could assist in fighting the infectious disease, e.g., a cloaked T cell or B cell).


For use in treating diabetes, the additional agent may be insulin, a sulfonylurea (e.g., chlorpropamide, glipizide, glyburide, glimepiride), a biguanide (e.g., metformin), a meglitinide (e.g., repaglinide, nateglinide), a thiazolidinedione (e.g., rosiglitazone, pioglitazone), a DPP-4 inhibitor (sitagliptin, saxagliptin, linagliptin, alogliptin), an SGLT2 inhibitor (e.g., canagliflozin, dapagliflozin), an alpha-glucosidase inhibitor (e.g., acarbose, miglitol), a bile acid sequestrant (e.g., colesevelam), aspirin, or a dietary regimen. The cloaked cell(s) administered could be pancreatic beta cells, which can optionally be modified to express a transgene encoding insulin.


For use in treating hemophilia, the additional therapeutic agent may be a clotting factor, desmopressin, a clot-preserving medication (e.g., an anti-fibrinolytic, e.g., aprotinin, aminocaproic acid, fibrigongen, or tranexamic acid), a fibrin sealant, or physical therapy. The cloaked cell(s) administered could be liver sinusoidal cells or endothelial cells, which can optionally be modified to express a transgene encoding Factor VIII.


For treatment of a metabolic deficiency or disorder, the additional therapeutic agent may be a coenzyme (e.g., biotin, hydroxycobalamine, riboflavin, pyridoxine, folate, thiamin, ubichinone, tetrahydrobiopterine), a bone marrow transplant, an organ transplant (e.g., a liver, kidney, or heart transplant), hemodialysis, hemofiltration, exchange transfusion, peritoneal dialysis, medium-chain triacylglycerols, miglustat, enzyme supplementation therapy, or dietary restriction (e.g., low protein or phenylalanine-restricted diet for subjects with phenylketonuria), The cloaked cell(s) can be cells that carry a wild-type copy of the gene that is mutated in a subject with a metabolic disorder or cells that endogenously produce the enzyme that is deficient in subject with a metabolic disorder (e.g., a liver cell, kidney cell, heart cell, or any other cell that carries a wild-type copy of a gene that is mutated in a subject with a metabolic disorder or produces an enzyme that is deficient in a subject with a metabolic disorder).


For use in treating cancer, the additional agent may be a checkpoint inhibitor, a chemotherapeutic drug, a biologic drug, a non-drug therapy (e.g., radiation therapy, cryotherapy, hyperthermia, or surgical excision or tumor tissue), or an anti-cancer vaccine. The cloaked cell(s) could be an immune cell that could help fight the cancer (e.g., a macrophage, natural killer cell, dendritic cell, or T cell).


Checkpoint inhibitors can be broken down into at least 4 major categories: i) agents such as antibodies that block an inhibitory pathway directly on T cells or natural killer (NK) cells (e.g., PD-1 targeting antibodies such as nivolumab, pidilizumab/CT-011, and pembrolizumab, antibodies targeting TIM-3, and antibodies targeting LAG-3, 2B4, CD160, A2aR, BTLA, CGEN-15049, or KIR), ii) agents such as antibodies that activate stimulatory pathways directly on T cells or NK cells (e.g., antibodies targeting OX40, GITR, or 4-1BB), iii) agents such as antibodies that block a suppressive pathway on immune cells or rely on antibody-dependent cellular cytotoxicity to deplete suppressive populations of immune cells (e.g., CTLA-4 targeting antibodies such as ipilimumab or tremelimumab, antibodies targeting VISTA, and antibodies targeting PD-L2 (e.g., a PDL2/lg fusion protein such as AMP 224), Gri, or Ly6G), and iv) agents such as antibodies or small molecules that block a suppressive pathway directly on cancer cells or that rely on antibody-dependent cellular cytotoxicity to enhance cytotoxicity to cancer cells (e.g., rituximab, antibodies or small molecules targeting PD-L1 (e.g., MPDL3280A/RG7446; MED14736; MSB0010718C; BMS 936559), and antibodies or small molecule inhibitors targeting B7-H3 (e.g., MGA271), B7-H4, Gal-9, or MUC1). In one embodiment, the inhibitor of checkpoint is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of HVEM, CD160, CHK 1, CHK2, B-7 family ligands, or a combination thereof. Such agents described herein can be designed and produced, e.g., by conventional methods known in the art (e.g., Templeton, Gene and Cell Therapy, 2015; Green and Sambrook, Molecular Cloning, 2012). In one embodiment, the inhibitor of checkpoint is an inhibitory antibody (e.g., a monospecific antibody such as a monoclonal antibody). The antibody may be, e.g., humanized or fully human. In other embodiments, the inhibitor of checkpoint is a fusion protein, e.g., an Fc-receptor fusion protein. In some embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with a checkpoint protein. In other embodiments, the inhibitor of checkpoint is an agent, such as an antibody, that interacts with the ligand of a checkpoint protein.


Chemotherapeutic agents include alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodopyyllotoxins, antibiotics, L-asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog. Also included is 5-fluorouracil (5-FU), leucovorin (LV), irenotecan, oxaliplatin, capecitabine, paclitaxel and doxetaxel. Non-limiting examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammaII and calicheamicin omegaII; dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., paclitaxel; chloranbucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Two or more chemotherapeutic agents can be used in a cocktail to be administered in combination with the cloaked cells described herein. Suitable dosing regimens of combination chemotherapies are known in the art.


Anti-cancer biologics include cytokines (e.g., interferon or an interleukin (e.g., IL-2)) used in cancer treatment. In other embodiments the biologic is an anti-angiogenic agent, such as an anti-VEGF agent, e.g., bevacizumab. In some embodiments the biologic is an immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a humanized antibody, a fully human antibody, an Fc fusion protein or a functional fragment thereof) that agonizes a target to stimulate an anti-cancer response, or antagonizes an antigen important for cancer. Such agents include Rituximab; Daclizumab; Basiliximab; Palivizumab; Infliximab; Trastuzumab; Gemtuzumab ozogamicin; Alemtuzumab; Ibritumomab tiuxetan; Adalimumab; Omalizumab; Tositumomab-1-131; Efalizumab; Cetuximab; Bevacizumab; Natalizumab; Tocilizumab; Panitumumab; Ranibizumab; Eculizumab; Certolizumab pegol; Golimumab; Canakinumab; Ustekinumab; Ofatumumab; Denosumab; Motavizumab; Raxibacumab; Belimumab; Ipilimumab; Brentuximab Vedotin; Pertuzumab; Ado-trastuzumab emtansine; and Obinutuzumab. Also included are antibody-drug conjugates.


Kits


The invention also features a kit containing the cloaked cells described herein (e.g., cloaked cells expressing a set of the cloaking transgenes described herein (e.g., 1, 2, 3, 4, 5, 6, 7, or 8 of PD-L1, H2-M3, Cd47, Cd200, FasL, Ccl21b, Mfge8, and Spi6), optionally further expressing one or more of the following transgenes: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, and IFNγR1 d39). In some embodiments, the cloaked cells are further modified to contain one or more systems for regulating cell division (e.g., an ALINK or EARC system), and/or a therapeutic agent (e.g., a transgene encoding a protein or antibody). The cloaked cells may be provided in a pharmaceutical composition. The kit may further include a syringe for administration of the cloaked cells or pharmaceutical composition and instructions for administering the cloaked cells or pharmaceutical composition for treating a disease or condition described herein.


EXAMPLES

The following examples are provided to further illustrate some embodiments of the present invention, but are not intended to limit the scope of the invention; it will be understood by their exemplary nature that other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.


Example 1: Materials and Methods

Construction of Vectors that Express Target Genes Essential for Allo-Tolerance


Plasmids containing the cDNA sequences of genes involved in allo-tolerance were obtained as follows:

    • PD-L1: Mount Sinai Hospital, clone #V102001
    • FasL: Mount Sinai Hospital, #75719
    • Cd47: Mount Sinai Hospital, #V75535
    • Cd200: GE Dharmacon, ID #17470
    • H2-M3: Mount Sinai Hospital, clone #8188
    • Ccl21: Mount Sinai Hospital, clone #V77120
    • Mfge8: Mount Sinai Hospital, clone #V72614
    • Spi6: Mount Sinai Hospital, clone #V8907


Expression vectors that contain these Genes of Interest (GOI), or the luciferase enzyme, were generated using the Gateway cloning system (Thermo Fisher). Cd47, Ccl21, Mfge8 and Spi6 cDNAs were acquired in a form that contained cDNA-flanking attB sites. For H2-M3, Cd200, FasL, and PD-L1, primers were designed to amplify the cDNA sequence, and add attB sites (FIG. 15(a)). Following PCR amplification, attB-containing cDNA was recombined into pDONR221 vectors (Thermo Fisher, #1256017) by the BP (recombination between attB and attP sites) reaction to create entry (pENTRY) clones (FIG. 15(b)). The BP reaction entails mixing the attB-flanked transgene cDNA with the pDONR221 plasmid in a 1 mL tube, along with buffers and the BP enzyme provided by Invitrogen, where the BP enzyme recombines the GOI into the docking site of the pDONR221 plasmid. Insertion of the transgene into the pDONR221 plasmid was verified by DNA sequencing (TCAG Sequencing Facility at the Centre for Applied Genomics, Toronto). pENTRY clones that contained the GOI were then recombined into destination vectors via the gateway LR (recombination between attL and attR sites) reaction (FIG. 15(c)). The LR reaction entails mixing the GOI-containing pDONR221 plasmid and the destination vector in a 1 mL tube, along with buffers and the LR enzyme provided by Invitrogen, where the LR enzyme recombines the GOI cassette from the pDONR221 plasmid into the docking site of the destination plasmid. Destination vectors, which were used for all transgene constructions, contain a CAGG promoter followed by a Gateway entry site, internal ribosomal entry site (IRES) and either a Puromycin resistance selectable marker or a green fluorescent protein (GFP) reporter. The entire cassette is flanked by transposable PB sites. Following LR recombination, the final destination vectors containing the GOI (FIG. 15(d)) were verified by restriction enzyme digestion.


ES Cell Culture, Transfection, Selection and Cloning


Mouse ES cells derived from the inbred C57BL/6N mouse strain (Gertsenstein 2010) were cultured in DMEM high glucose supplemented with 15% fetal bovine serum (FBS, tested for compatibility with ES cell cultures) and standard amounts of Sodium Pyruvate, non-essential amino acid (NEAA), Glutamax, Penicillin/Streptomycin, Beta-mercapto-ethanol and leukemia inhibitory factor (LIF) (Behringer et al 2014). Cells were cultured on a feeder layer of MitomycinC-inactivated Murine Embryonic Fibroblasts (MEFs). Cultures were kept in a standard cell culture incubator at 37° C. and 5% CO2.


Transfection was performed using JetPRIME reagent (Polyplus, catalog #14-07) per manufacturer protocol, and was done in three steps: 1) transfection with PD-L1-IRES-GFP destination vector only, 2) transfection with all the other transgenes carrying a Puromycin selectable marker, and 3) transfection with an eLuciferase-IRES-GFP transgene.


Step 1: Following transfection with PD-L1-IRES-GFP, cells were plated at low density so that after multiple rounds of proliferation 5-6 days later, individual cell clones—existing as cell aggregates (colonies)—were selected based on the intensity of GFP expression and then expanded as a clonal cell culture. The clone with the highest and most consistent GFP expression was chosen for the next step.


Step 2: 24 hours after transfection with transgenes containing a Puromycin selection marker, Puromycin was added to the culture media. On the third day, cells were plated at clonal density and Puromycin selection was continued until individual colonies were picked and expanded as clones. A large number of these clones were screened in vivo and the one capable of forming a teratoma in an allogeneic setting was designated “NT2”.


Step 3: NT2 was transfected with PB-CAG-eLuciferase-IRES-GFP as described above and plated at clonal density. GFP+ clones were picked and expanded. 10 clones with high levels of GFP expression were chosen for further studies.


Evaluation of Transgene Expression Levels


RNA was isolated from cultures grown on 30 mm culture plates, as well as from tumours grown in vivo. Cells were dissociated with Trypsin, centrifuged, and the supernatant removed. The cell pellet was immediately frozen on dry ice and stored at −80° C. Tumour tissues were dissected, immediately frozen on dry ice and stored at −80° C. RNA was isolated per standard protocols using Sigma GeneElute Total RNA Miniprep kit #RTN350. cDNA was obtained by reverse transcriptase reaction using the Qiagen Quantifast Reverse Transcriptase kit #205313. Quantitative PCR was performed using Sensifast mastermix from Bioline, #Bio-98020, gene specific primers and RNA at a 1:50 dilution. Samples were plated in 384 well plates using the Eppendorf epMotion 5070 robot and the quantitative PCR was performed on BioRad CFX384 Real-Time System C1000 Thermal cycler according to standard protocols. qPCR data was captured by BioRad CFX Manager 3.1 software and expression levels calculated with Microsoft Excel.


Teratoma Assay


Matrigel Matrix High Concentration (Corning cat #354248) was diluted 1:1 with cold DMEM media on ice. 5×107 cells were suspended into 500 uL of DMEM and equal volume of Matrigel. 100 ul 5×107 cells of the suspension was injected subcutaneously into each dorsal flank of B6N (isogenic) or FVB/N (allogeneic) mice. The resulting teratomas formed 2-4 weeks after injection. Teratoma size was measured using calipers, and the volume was calculated with the formula V=(L×W×H)/2. The tumours were allowed to grow to approximately 500 mm2, a size that is well-tolerated and also well-suited for downstream experiments. All of the transgenes were delivered into cells that contain “Fail-safe system” (as described, for example, in WO 2016/141480, the entire contents of which are incorporated herein by reference. This genetic system allows for the complete inhibition of cell division with the administration of Ganciclovir (GCV). Once teratomas from the previously described experiments reached 500 mm2, mice were injected into the peritoneal cavity with 50 mg/kg GCV every 2-3 days for 2-3 weeks. This treatment regimen resulted in an initial brief shrinkage of the tumours, followed by stabilization of tumour size at 400-500 mm2 after 2-3 weeks of treatment. At the endpoint of the experiment, mice were sacrificed and tumours were dissected. A small portion of tissue was snap-frozen for RNA extraction while the rest was fixed in 4% paraformaldehyde.


Bioluminescence Imaging


Mice that developed teratomas derived from cells transfected with the eLuciferase transgene were injected with 30 mg/mL VivoGlo Luciferin at 100 uL/25 g body mass (Promega #P104C) 10 min before imaging. Animals were anaesthetized with Isoflurane and placed in an IVIS Lumina II imager (Caliper Life Sciences) driven by Living Image software. Exposure times were set between 5 seconds and 5 minutes depending on signal intensity.


Histology


Fixed tumours were embedded in paraffin, sectioned and stained with Hematoxylin/Eosin for histological analysis at the CMHD Pathology Core. Histology images were processed with NDPview2 software.


Example 2: Generation of Cloaked Cells

Transgenes encoding the genes in Table 1 were cloned into expression vectors and sequence verified both by polymerase chain reaction (PCR), restriction enzyme digestion and sequencing, all using standard methods know in the art.


A set of constructs containing transgenes Cd47, Cd200, FasL and H2-M3 (Set 1) were transfected into mouse embryonic stem cells derived from the inventors' C57BL/6 mouse ES line (C2). The presence of the transgenes was verified by PCR and expression of the expressed proteins was documented by immunohistochemistry (FIGS. 1A-D). A second set of constructs containing transgenes Ccl21, Mfge8, TGF-β and Spi6 (Set 2) were transfected into ES cells derived from FVB/N (ES line C2).


Similar methods were used to generate cloaked B16F10 melanoma cells, except that the media used DMEM containing 10% fetal bovine serum (FBS).


Example 3: Screening Process for Inhibition of T-Cell Activation

A modified in vitro Mixed Lymphocyte Reaction (MLR) assay was used to screen for the transgene combination resulting in the most efficient inhibition of T-cell activation. Cell lines transfected with Set 1 and Set 2 cloaking transgenes from Example 1 were used. Donor OT-I splenocytes were labeled with carboxyfluorescein succinimidyl ester CFSE and 60,000 cells were added to each well of the 96-well plate. ES or melanoma cells were mixed 10:1 with ova expressing cells. 10,000 of these were added to each well of splenocytes. IL-2 was added as a general activator and T-cell proliferation was measured by flow cytometry 3 days later (FIGS. 2A-2E). Cells were initially gated to include CD8+ cells only and all conditions were set up in 4 replicates.


The negative control (splenocytes only) resulted in a baseline 6.12% proliferation rate (FIG. 2A). Wildtype B16 melanoma (+10% ova expressing) cells resulted in distinct acceleration of proliferation to 17.1% (FIG. 2B), while cloaked cells reduced this proliferation to 9.51% (FIG. 2C). Similar results were obtained for wildtype (FIG. 2D) versus cloaked ES cells (FIG. 2E).


Example 4: Studies with WT and Cloaked Cancer Cells in Iso- and Allografted B16F10 Melanoma Cells

Since some of the candidate cloaking transgenes are intended to inhibit or modulate the initiation phase of the immune recognition cascade, the effect of these transgenes could be evaluated by the MLR alone as these events act on the maturation and physical migration of host APCs to local lymph nodes where they subsequently activate naïve T and B cells.


This called for an alternative assay that can screen a large number of transgene combinations in an in vivo allogeneic setting. Intraperitoneal and intravenous injection ES cells harboring a variety of transgene combinations was tried as an option. However, teratoma formation is dependent on the aggregation of a minimum number of ES cells (1×105-5×106 depending on site of injection), rendering this option not compatible with such a screen. However, the murine melanoma cancer cell line B16F10 derived from C57BL/6 mice is not limited in such a way. Intravenous injection of less than 5×103 results in the efficient induction of a multitude of small cancer nodules in the lung. By limiting number of cells injected, one can anticipate that the cancer cells are trapped in the lung alveoli will form nodules derived from single or just a very small number of cells. By isolating and genotyping these nodules, the transgene can be identified.


Injection B16F10 melanoma cells into the blood-stream of C57BL/6 mice (isogenic graft control) resulted in the formation of cancer nodules in the lung (FIG. 3A, left panel). However, small melanoma nodules formed also in the lungs of the negative controls—wild type B16F10 melanoma grafted into allogeneic control FVB mice when observed at day 14 post injection. However, when the melanoma was allowed to grow for 24 days, the nodules regressed almost completely (FIG. 3A, right panel).


The above experiment was repeated, by injecting a mixture of cancer cells that expressed random combinations of the candidate cloaking genes, generated using the PiggyBack transposon system. Lung nodules developed in the allogeneic settings contained the successful combination(s) needed to protect the allograft from recognition and rejection (FIG. 3B, right panel). The same immune cloaked cells also gave rise to an accelerated development in the isogenic host (FIG. 3B, left panel).


Example 5: Non-Cloaked Embryonic Stem Cells do not Form Teratoma in Allogenic Settings

As shown in Table 4, it was verified that wild-type ESCs derived from C57BL/6 mice are not capable of forming teratomas in FVB/N mice. Likewise, we have also shown that wild-type ESCs derived from the FVB/N background are not capable of forming teratomas in C57BL/6 hosts. ES cell colonies were dissociated with Trypsin, washed once with DMEM without additives and resuspended in Matrigel HC at a concentration of about 50 million cells per milliliter. Recipient mice were anaesthetized and one hundred microliter injected subcutaneously in each flank area. Developing teratomas were followed for 12 weeks and verified by palpation and measurement of volume with caliper.









TABLE 4







Teratomas formed in FVB/N mice and C57BL/6 hosts injected with


wild-type ESCs derived from C57BL/6 mice or wild-type ESCs


derived from the FVB/N background










Donor ESCs
Recipient mouse
# injection sites
# teratomas





C57BL/6
C57BL/6
18
14 


C57BL/6
FVB
22
0


FVB
FVB
 8
8


FVB
C57BL/6
 8
0









Example 6: Cloaked ES Cells can Proliferate in Isogenic Hosts and Allogenic Hosts

To verify the cloaking ability of the candidate transgenes, ESCs were transfected with the same transgenes while also adding a Luciferase transgene that can be detected by imaging. Briefly, ES cells were prepared as described above. The presence of viable cells were repeatedly measured by imaging. The images in FIG. 4 were taken on day 17 post injection.


In FIG. 4, the top panel shows the proliferation of immune cloaked cells in isogenic hosts, while the lower panel shows the proliferation of immune cloaked cells in allogeneic hosts.


In another experiment, cloaked ES cells from C57BL/6 mice that had high expression of the 8 immunomodulatory transgenes (clone NT2) were injected subcutaneously into different allogenic mouse strains (C3H, FVB/N, and CD1) with mismatched MHC alleles. Red arrows indicate the teratoma that formed (FIGS. 5A-5C).


Example 7: Mice with Cloaked Tissues are not Immune Compromised

Non-immune cloaked (wild type) ESCs were transplanted into mice carrying an existing immune cloaked tissue and the mouse was evaluated to determine if it could effectively reject a non-immune cloaked graft (FIG. 6). The same mice were imaged several times over a period of 15 days. As shown in the left panel of FIG. 6, in isogenic mouse controls, the graft was not rejected over time. With allogenic FVB mice, the left mouse in the right panel of FIG. 6 had a pre-existing immune cloaked graft (arrows). The middle mouse in the right panel of FIG. 6 had previously been grafted with C57BL/6 allogeneic ESCs but rejected the graft (while not being bound to a theory, the rejection may have been due to pre-formed antibodies against C57BL/6 cells). The mouse on the right in the right panel of FIG. 6 had never been grafted before. All three mice successfully rejected the non-immune cloaked graft. The mouse on the right rejected the graft slower, which may have been because it did not have any preformed antibodies against C57BL/6 cells.


A similar experiment was conducted where wild type embryonic stem cells were detected up to 9 days post injection into FVB/N mice with cloaked teratomas (FIG. 7). However, at day 12, no evidence of cells remaining could be detected. Control animals were C57BL/6 mice also carrying the cloaked tumors. The signal in these mice increased over the time-course of the experiment.


Example 8: Cloaked and Fail-Safe Embryonic Stem Cell Line

When a Fail-Safe C57BL/6 ES cell line (as described, for example, in WO/2016/141480) was co-transfected with 5 candidate cloaking transgenes (PD-L1, FasL, Cd47, Cd200 and H2-M3), none of these transgene lines resulted in teratomas in allograft settings. When the set of co-transfected genes was expanded by three additional candidate cloaking genes: Spi6, Ccl21b and Mfge8, 38 clonal lines were generated. One of these lines, NT2, created teratomas in an allogeneic recipient (FVB). The expression levels of the cloaking genes in the 38 clonal lines, including the NT2 line (see arrows in FIGS. 8A-H), were measured using quantitative PCR (FIGS. 8A-H). Of the 38 clones, NT2 was the highest overexpression of Ccl21b (16,000×), FasL (25,000×), Cd200 (1700×), Cd47 (16×), Mfge8 (34×), Spi6 (600×) and H2-M3 (750×) compared to WT ES cells. PD-L1, although not the highest level expresser among the clones, the 350× expression over ES cells was also a significant increase. The expression of these genes was also checked in the Project Grandiose dataset (www.stemformatics.org/project_grandiose) and found that Ccl21b, FasL, Cd200, PD-L1 and Spi6 expression is under the detection threshold, therefore, their relative-to-ES cells expression is very high. Based on this data these eight, highly activated genes could have a primary role in inducing immune tolerance of an allograft.


NT2 cells were injected into both C57BL/6 to create teratomas in an FVB allogenic setting (FIGS. 11A-11B) and an FVB iso C57Bl/6 isogenic setting. Allogenic teratomas (n=6) were steadily growing from day 12 to day 38. At the size of 500 mm2, ganciclovir (GCV) treatment was started to remove the proliferative component of the tumors (FIGS. 12A-12B, upper panel (FIG. 12A) isogenic teratomas; bottom panel (FIG. 12B) allogenic teratomas)). Twenty days of treatment stopped the allograft growth. This experiment shows that: 1) Fail-safe and cloaked (NT2) cell-derived teratomas respond similarly to GCV treatment; they enter to dormancy after brief GCV exposure; 2) After GCV the teratomas remain stable. There is no sign of rejection of the dormant tissue; and 3). The dynamics of teratoma growth in FVB animals is different than in C57BL/6.


Cloaking transgenes expressed at a high level survive to form teratomas in an allogenic mouse. In our system, the cloaking transgenes are expressed under a very strong synthetic promoter, CAG (depicted in the schematic in FIG. 19). The CAG promoter is a combination of the cytomegalovirus early enhancer element, the splicer acceptor of the rabbit beta-globin gene, and also the promoter, first exon and first intron of the chicken beta-actin gene. We have performed extensive qPCR analysis on the level of transgene transcripts in many different ES cell clones, each of which has a different expression level of the transgenes. Only those ES clones that have the highest expression of cloaking transgenes survive in allogenic hosts.


As shown in FIG. 9, transcript expression level of the immunomodulatory genes relevant to the cloaking technology varied between ES cell clones. Concentric circles are depicted on a log 10 scale. The thick black line is 1×, the next outer ring is 10×, and then 100×. The innermost ring is 0.1×. All values are normalized to positive controls, which were activated leukocytes isolated from murine lymph organs that naturally express the immunomodulatory transgenes. The upper left panel shows wild-type ES cells with no transgenic modifications for reference—they express little or none of the relevant immunomodulatory transgenes. By contrast, clone NT2 and clone 15 (indicated by red squares), both with high expression of the genes, survived in allogenic hosts. All other clones shown in FIG. 9 did not survive in allogenic hosts.


The high expression of the cloaking transgenes is also depicted in FIG. 10. As shown in FIG. 10, all 8 cloaking transgenes in the NT2 cell line and NT2-derived teratoma had an expression level that was among the top 5% of all genes in the ES cell genome, with 5 of the cloaking transgenes having an expression level in the top 1% of all genes in the ES cell genome.


The expression of these genes is much lower in WT ES cells, as only one of the genes has an expression level among the top 5% of all genes in the genome.


Example 9: Cloaked ESCs Contribute to all Three Germ Layers in Allogenic Teratomas

It was next asked if immune cloaking would allow the full pluripotent developmental potential of ESCs to unfold in teratomas. Teratomas resulting from the injection of cloaked and uncloaked ESCs derived from C57BL/6 mice into isogenic and allogeneic hosts were analyzed by histopathology (hematoxylin and eosin staining). FIGS. 13A-13B (isogenic host neuronal, bone and columnar epithelium in upper panels (FIG. 13A); and allogenic host neuronal, bone, columnar epithelium and blood vessels in lower panels (FIG. 13B)) shows representative images obtained from both backgrounds, proving that the expression of the cloaking transgenes do not interfere with the normal developmental potential of these ES cells and the tumors are well vascularized. Both isogenic and allogenic tissues did not show any immune cell infiltration.


In another experiment, we tested if the cloaked ES cell were truly pluripotent by testing whether they could form cells from all three germ layers—endoderm, ectoderm, and mesoderm (FIGS. 14A-14D). This was assayed by injecting between 106 and 107 cloaked ES cells subcutaneously into a mouse and allowing them to proliferate and differentiate into a tissue mass named a teratoma. The teratoma was then removed 3-4 weeks after ES cell injection, and tissue sections cut and stained with H&E. These sections were analyzed under the microscope for cell morphology to determine if all three germ layers were present.


We asked whether the 8 cloaking transgenes inserted into ES cells and expressed at high levels would disrupt their ability to form all three germ layers. They did not. FIGS. 14A-14C show the three germ layers (ec=ectoderm, shown in FIG. 14A; en=endoderm, shown in FIG. 14C; me=mesoderm, shown in FIG. 14B). FIG. 14D shows a blood vessel, which verifies that these tissues are well-vascularized.


Example 10: ES Cells that Express Cloaking Transgenes Produce the Proteins Encoded by the Transgenes

We confirmed the presence of the proteins encoded by the cloaking transgenes in NT2 ES cells (one of the clones with the highest expression) directly using fluorescent antibody-based microscopy (FIGS. 16A-16H). These data confirm that the proteins encoded by the transgenes are expressed in ES cells at easily detectable levels, which is expected based on the high levels of mRNA expression.


Example 11: ES Cells that Express High Levels of Cloaking Transgenes have Typical Morphology and Express Common ES Cell Markers

We analyzed cloaked ES cells to determine whether they expressed markers of ES cells and retained a normal ES cell morphology. Cloaked ES cells have the typical morphology observed with healthy and pluripotent ES cells (FIG. 17A) and also stain positively for alkaline phosphatase (FIG. 17B), which is characteristic of healthy and pluripotent ES cells. Furthermore, our cloaked ES cells stained positively for the transcription factor Oct4 (FIG. 18A) as well as SSEA (FIG. 18B) using fluorescent antibodies, both common markers of normal pluripotent ES cells. These data show that ES cells that express high levels of the 8 immunomodulatory cloaking transgenes appear as normal ES cells with respect to their morphology and expression of common ES cell markers. The insets show that staining for Oct4 and SSEA1 (lower left inset) colocalizes with ES cells (visualized using DAPI in upper right insets).


Example 12: IFNγR1 d39 Prevents Upregulation of MHCs in ES Cells

Activated T-cells secrete IFNγ, which binds to the IFNγR1/R2 complex expressed on many cell types, including tissues and cells derived from ES cells. IFNγ binding to the IFNγ receptor induces upregulation of HLA (MHC in mice) and HLA-related molecules on the cell surface, which increases the allogenicity of the allograft and the likelihood of immune rejection. Differences in HLA proteins (also called major antigens) between the donor and recipient are the primary cause of rejection in all allogenic transplants.


To evaluate whether disrupting IFNγ signaling prevents or reduces HLA upregulation, we transfected C57BL/6 ES cells with piggyback-integratable vectors containing a wild-type IFNγR1 or dominant negative IFNγR1 (IFNγR1 d39, which lacks 39 amino acids in the cytoplasmic tail) transgene. These transgenes were expressed under the control of a constitutive CAG promoter upstream of the transgene contained on the same piggyback-integrated cassette.


Wild type and transfected ES cells were then grown in culture and exposed to 100 ng/mL of IFNγ ligand for 24 hours. In wild-type ES and IFNγR1-transfected cells (left and middle panels of FIG. 20, respectively), IFNγ exposure resulted in increased expression of the H-2kb and H-2Db major histocompatibility surface molecules (MHC class I), but not in IFNγR1 d39 cells (right panel of FIG. 20). Exposure to PBS alone had no effect. MHC class I levels were detected by fluorescent antibody staining, and the expression level quantified by measuring the mean fluorescent intensity (MFI) by flow cytometry. These data show that overexpression of IFNγR1 d39 completely inhibits IFNγ-mediated upregulation of MHCs in ES cells, indicating that expression of IFNγR1 d39 in ES cells can be used to prevent activation of the immune system and reduce the likelihood of immune rejection. Therefore, IFNγR1 d39 is a useful immunosuppressive transgene that can be expressed by the cloaked cells described herein to reduce immune activation and transplant rejection.


Example 13: Administration of Cloaked Cells Expressing a VEGF Inhibitor to a Subject with Wet AMD

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with wet AMD to reduce vascularization of the eye or prevent or reduce disease progression. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked RPE cells or cloaked stem cells that have been differentiated into RPE cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and a VEGF inhibitor (e.g., VEGF-Trap, e.g., aflibercept) under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells may be administered to the patient, for example, by local administration to the eye (e.g., injection into the subretinal space), to treat wet AMD. Twenty five thousand to one hundred thousand cloaked cells (e.g., 25,000, 50,000, 75,000, or 100,000 cloaked cells) can be administered to each affected eye.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the VEGF inhibitor, and the patient's improvement in response to the therapy, by a variety of methods. For example, a physician can monitor the patient's vision and the vascularization of the eye using standard approaches. A finding that the patient's vision improves or does not worsen, or that vascularization of the eye decreases or does not worsen compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 14: Administration of Cloaked Dopaminergic Neurons to a Subject with Parkinson's Disease (PD)

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with PD to reduce motor symptoms of PD (e.g., bradykinesia, tremors, or rigidity) or prevent or reduce disease progression. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., dopaminergic neurons that have been modified to express cloaking transgenes or cloaked stem cells that have been differentiated into dopaminergic neurons) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells may be administered to the patient, for example, by local administration to the central nervous system (e.g., stereotactic injection into the substantia nigra), to treat PD. Twenty five thousand to one hundred thousand cloaked cells (e.g., 25,000, 50,000, 75,000, or 100,000 cloaked cells) can be administered. The patient can optionally be administered an additional therapy for PD, such as a dopamine agonist.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient's movement using standard neurological tests. A finding that the patient's motor symptoms improve or do not worsen compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 15: Administration of Cloaked Cardiac Muscle Cells to a Subject that has Suffered a Myocardial Infarction

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, who has recently suffered a myocardial infarction to improve cardiac function (e.g., to replace or dead or damaged cardiac muscle cells). To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked cardiac muscle cells or cloaked stem cells that have been differentiated into cardiac muscle cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells may be administered to the patient, for example, by local administration to the heart (e.g., injection into the cardiac muscle), to promote recovery after the myocardial infarction. The cells can be injected into the cardiac muscle as a monotherapy, or the cells can be delivered during the performance of a bypass surgery or another open heart surgical procedure. One million to five billion cloaked cardiac muscle cells (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, or 5×109 cloaked cells) can be administered.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient's cardiac function using standard approaches (e.g., EKG, echocardiogram, angiogram, stress test, or nuclear imaging). A finding that the patient's cardiac function improves or stabilizes compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 16: Administration of Cloaked Cells Expressing a TNFα Inhibitor to a Subject with RA

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with rheumatoid arthritis to reduce join stiffness, swelling, or pain. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked articular fibroblasts or cloaked stem cells that have been differentiated into articular fibroblasts) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and a TNFα inhibitor (e.g., a TNFα inhibitory antibody, such as adalimumab) under the control of an inducible promoter (e.g., a tetracycline response element). The cloaked cells may be administered to the patient, for example, by local administration to a joint (e.g., injection into an arthritic joint, such as joint in the hand), to treat RA. One million to one hundred million cloaked articular fibroblasts expressing an anti-inflammatory biologic (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108 cloaked articular fibroblasts) can be administered to each affected joint. When the patient experiences a flare up of RA symptoms, the patient can be treated with tetracycline or doxycycline to drive expression of the TNFα inhibitor. Tetracycline or doxycycline can be withdrawn when the patient's flare up has resolved.


Following administration of the cloaked cells and tetracycline or doxycycline to a patient, a practitioner of skill in the art can monitor the expression of the TNFα inhibitor, and the patient's improvement in response to the therapy, by a variety of methods. For example, a physician can monitor the patient's joint pain, swelling, and stiffness using standard approaches. A finding that the patient's joint pain, swelling, or stiffness is reduced compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 17: Administration of Cloaked Cells Expressing Insulin to a Subject with Type 1 Diabetes

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with Type 1 diabetes to increase insulin levels. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked stem cells, cloaked pancreatic beta cells, or cloaked stem cells that have been differentiated into pancreatic beta cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and insulin under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells may be administered to the patient, for example, by subcutaneous injection (e.g., to create a cloaked subcutaneous tissue), to treat Type 1 diabetes. One million to three billion cloaked cells expressing insulin (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked cells) can be administered subcutaneously.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor insulin levels or symptoms of Type 1 diabetes (e.g., unintended weight loss, fatigue, or blurred vision) using standard approaches. A finding that the patient's insulin levels are increased or the symptoms of Type 1 diabetes are reduced compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 18: Administration of Cloaked Cells Expressing Factor VIII to a Subject with Hemophilia

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with hemophilia to increase the levels of a blood clotting factor or reduce excessive bleeding or bruising. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked stem cells, cloaked endothelial cells, or cloaked stem cells that have been differentiated into endothelial cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and Factor VIII under the control of a constitutive promoter (e.g., CMV or CAG).


The cloaked cells may be administered to the patient, for example, by subcutaneous injection (e.g., to create a cloaked subcutaneous tissue), to treat hemophilia. One million to three billion cloaked cells expressing Factor VIII (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked cells) can be administered subcutaneously.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor Factor VIII levels or symptoms of hemophilia (e.g., excessive bleeding or frequent bruising) using standard approaches. A finding that the patient's Factor VIII levels are increased or the symptoms of hemophilia are reduced compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 19: Administration of Cloaked Cells Expressing Glucocerebrosidase to a Subject with Gaucher's Disease

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with Gaucher's disease to reduce the accumulation of glucocerebroside or to reduce symptoms of Gaucher's disease (e.g., fatigue, anemia, low blood platelet count, enlarged liver or spleen). To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked stem cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and glucocerebrosidase under the control of a constitutive promoter (e.g., CMV or CAG).


The cloaked cells may be administered to the patient, for example, by subcutaneous injection (e.g., to create a cloaked subcutaneous tissue), to treat Gaucher's disease. One million to three billion cloaked cells expressing glucocerebrosidase (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked cells) can be administered subcutaneously.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor accumulation of glucocerebroside or symptoms of Gaucher's disease (e.g., fatigue, anemia, low blood platelet count, enlarged liver or spleen) using standard approaches. A finding of a reduction in the patient's accumulation of glucocerebroside or symptoms of Gaucher's disease compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 20: Administration of Cloaked Cells to a Subject Receiving a Liver Transplant

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, who is receiving a liver transplant to reduce the risk of transplant rejection. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked stem cells, cloaked liver cells, or cloaked stem cells that have been differentiated into liver cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells may be administered to the patient, for example, by injection into the liver or near the site of the transplanted liver, to reduce the risk of transplant rejection. One million to one hundred billion cloaked cells (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, 3×109, 4×109, 5×109, 6×109, 7×109, 8×109, 9×109, 1×1010, 2×1010, 3×1010, 4×1010, 5×1010, 6×1010, 7×1010, 8×1010, 9×1010, or 1×1011 cloaked cells) can be administered to or near the liver.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient for symptoms that predict transplant rejection using standard approaches. A finding of an equivalent outcome in transplant rejection as that observed in subjects administered immunosuppressive agent(s) indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


Example 21: Administration of Cloaked and Fail Safe Cells Expressing Insulin to a Subject with Type 1 Diabetes

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with Type 1 diabetes to increase insulin levels. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked stem cells, cloaked pancreatic beta cells, or cloaked stem cells that have been differentiated into pancreatic beta cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-L1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and insulin under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells can also be modified to allow for control of their proliferation by linking the expression of a CDL with that of a DNA sequence encoding a negative selectable marker. For example, the cloaked cells can be modified to contain homozygous ALINKS (e.g., HSV-TK systems) in two CDL loci (e.g., Cdk1 and Top2A).


The cloaked cells may be administered to the patient, for example, by subcutaneous injection (e.g., to create a cloaked subcutaneous tissue), to treat Type 1 diabetes. One million to three billion cloaked cells expressing insulin (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked cells) can be administered subcutaneously.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor insulin levels or symptoms of Type 1 diabetes (e.g., unintended weight loss, fatigue, or blurred vision) using standard approaches. A finding that the patient's insulin levels are increased or the symptoms of Type 1 diabetes are reduced compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.


A practitioner of skill in the art can also monitor the size of the cloaked subcutaneous tissue. If it appears that the cloaked subcutaneous tissue is becoming tumorigenic, the practitioner can administer ganciclovir to the subject to ablate the proliferating cloaked cells. Non-proliferating cloaked cells will not express the CDLs, and, therefore, will not be ablated by ganciclovir treatment.


Example 22: Administration of Cloaked and Fail Safe Cells Expressing Insulin to a Subject with Type 1 Diabetes

According to the methods disclosed herein, a physician of skill in the art can treat a patient, such as a human patient, with Type 1 diabetes to increase insulin levels. To this end, a physician of skill in the art can administer to the human patient cloaked cells (e.g., cloaked stem cells, cloaked pancreatic beta cells, or cloaked stem cells that have been differentiated into pancreatic beta cells) that express one or more (e.g., one, two, three, four, five, six, seven, or all eight) of PD-1, HLA-G (H2-M3), Cd47, Cd200, FASLG (FasL), Ccl21 (Ccl21b), Mfge8, and Serpin B9 (Spi6) under the control of a constitutive promoter (e.g., CMV or CAG) and insulin under the control of a constitutive promoter (e.g., CMV or CAG). The cloaked cells can also be modified to allow for control of their proliferation by linking the expression of a CDL with that of a DNA sequence encoding an inducible activator system. For example, a dox-bridge can be inserted into two CDLs (e.g., Cdk1 and Top2A) to generate homozygous modifications in both CDLs in a cloaked cell, such that in the presence of an inducer (e.g., doxycycline) the dox-bridge permits CDL expression, thereby allowing cell division and proliferation. The cloaked cells may be administered to the patient, for example, by subcutaneous injection (e.g., to create a cloaked subcutaneous tissue), to treat Type 1 diabetes. One million to three billion cloaked cells expressing insulin (e.g., 1×106, 2×106, 3×106, 4×106, 5×106, 6×106, 7×106, 8×106, 9×106, 1×107, 2×107, 3×107, 4×107, 5×107, 6×107, 7×107, 8×107, 9×107, or 1×108, 2×108, 3×108, 4×108, 5×108, 6×108, 7×108, 8×108, 9×108, 1×109, 2×109, or 3×109 cloaked cells) can be administered subcutaneously.


Following administration of the cloaked cells to a patient, a practitioner of skill in the art can monitor the expression of the patient's improvement in response to the therapy by a variety of methods. For example, a physician can monitor insulin levels or symptoms of Type 1 diabetes (e.g., unintended weight loss, fatigue, or blurred vision) using standard approaches. A finding that the patient's insulin levels are increased or the symptoms of Type 1 diabetes are reduced compared to measurements taken prior to administration of the cloaked cells indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed. If the practitioner determines that the subject needs a higher level of insulin, the practitioner can allow the cloaked cells to proliferate by treating the subject with doxycycline. Once the desired level of insulin is reached, treatment with doxycycline can be stopped and the cloaked cells will cease to proliferate.









TABLE 5







Predicted CDLs (ID refers to EntrezGene identification number; CS score refers


to the CRISPR score average provided in Wang et al., 2015; function refers to the known or


predicted function of the locus, predictions being based on GO terms, as set forth in the Gene


Ontology Consortium website http://geneontology.org/; functional category refers to 4 categories


of cell functions based on the GO term-predicted function; CDL (basis) refers to information that


the inventors used to predict that a gene is a CDL, predictions being based on CS score, available


gene knockout (KO) data, gene function, and experimental data provided in WO 2016 141480).















Name
ID
Name
ID
CS
Function
Functional
CDL



(mouse)
(mouse)
(human)
(human)
score
(GO term)
category
(basis)
Citation


















Actr8
56249
ACTR8
93973
−1.88
chromatin
Cell cycle
CS








remodeling

score,










function



Alg11
207958
ALG11
440138
−1.27
dolichol-
Cell cycle
CS








linked

score,








oligosaccharide

function








biosynthetic










process





Anapc11
66156
ANAPC11
51529
−2.68
protein
Cell cycle
CS








ubiquitination

score,








involved in

function








ubiquitin-










dependent










protein










catabolic










process





Anapc2
99152
ANAPC2
29882
−2.88
mitotic cell
Cell cycle
CS
Wirth KG,







cycle

score,
et al.









mouse
Genes









K.O.,
Dev. 2004









function
Jan.










1; 18(1):










88-98


Anapc4
52206
ANAPC4
29945
−1.79
regulation of
Cell cycle
CS








mitotic

score,








metaphase/a

function








naphase










transition





Anapc5
59008
ANAPC5
51433
−1.66
mitotic cell
Cell cycle
CS










score,








cycle

function



Aurka
20878
AURKA
6790
−2.26
meiotic
Cell cycle
CS
Sasai K,







spindle

score,
et al.







organization

mouse
Oncogene.









K.O.,
2008 Jul.









function
3; 27(29):4










122-7


Banf1
23825
BANF1
8815
−2.14
mitotic cell
Cell cycle
CS








cycle

score,










function



Birc5
11799
BIRC5
332
−2.24
regulation of
Cell cycle
CS
Uren AG,







signal

score,
et al. Curr







transduction

mouse
Biol. 2000









K.O.,
Nov.









function
2; 10(21):1










319-28


Bub3
12237
BUB3
9184
−3.15
mitotic sister
Cell cycle
CS
Kalitsis P,







chromatid

score,
et al.







segregation

mouse
Genes









K.O.,
Dev. 2000









function
Sep.










15; 14(18):










2277-82


Casc5
76464
CASC5
57082
−1.16
mitotic cell
Cell cycle
CS
Overbeek







cycle

score,
PA, et al.









mouse
MGI Direct









K.O.,
Data









function
Submission.










2011


Ccna2
12428
CCNA2
890
−1.59
regulation of
Cell cycle
CS
Kalaszczynska







cyclin-

score,
I, et







dependent

mouse
al. Cell.







protein

K.O.,
2009 Jul.







serine/threoni

function
23; 138(2):







ne kinase


352-65







activity





Ccnh
66671
CCNH
902
−2.01
regulation of
Cell cycle
CS








cyclin-

score,








dependent

function








protein










serine/threoni










ne kinase










activity





Cdc123
98828
CDC123
8872
−2.45
cell cycle
Cell cycle
CS










score,










function



Cdc16
69957
CDC16
8881
−3.58
cell division
Cell cycle
CS










score,










function



Cdc20
107995
CDC20
991
−2.97
mitotic cell
Cell cycle
CS
Li M, et al.







cycle

score,
Mol Cell









mouse
Biol. 2007









K.O.,
May; 27(9):









function
3481-8


Cdc23
52563
CDC23
8697
−2.28
mitotic cell
Cell cycle
CS








cycle

score,










function



Cdk1
12534
CDK1
983
−2.44
cell cycle
Cell cycle
CS
Diril MK,









score,
et al. Proc









mouse
Natl Acad









K.O.,
Sci U S A.









function
2012 Mar.










6; 109(10):










3826-31


Cenpa
12615
CENPA
1058
−1.87
cell cycle
Cell cycle
CS
Howman









score,
EV, et al.









mouse
Proc Natl









K.O.,
Acad Sci









function
USA.










2000 Feb.










1; 97(3):11










48-53


Cenpm
66570
CENPM
79019
−2.53
mitotic cell
Cell cycle
CS








cycle

score,










function



Chek1
12649
CHEK1
1111
−1.67
protein
Cell cycle
CS
Takai H,







phosphorylation

score,
et al.









mouse
Genes









K.O.,
Dev. 2000









function
Jun.










15; 14(12):










1439-47


Chmp2a
68953
CHMP2A
27243
−2.40
vacuolar
Cell cycle
CS








transport

score,










function



Ckap5
75786
CKAP5
9793
−2.94
G2/M
Cell cycle
CS
Barbarese







transition of

score,
E, et al.







mitotic cell

mouse
PLOS







cycle

K.O.,
One.









function
2013; 8(8):










e69989


Cltc
67300
CLTC
1213
−1.75
intracellular
Cell cycle
CS








protein

score,








transport

function



Cops5
26754
COPS5
10987
−1.75
protein
Cell cycle
CS
Tian L, et







deneddylation

score,
al.









mouse
Oncogene.









K.O.,
2010









function
Nov.










18; 29(46):










6125-37


Dctn2
69654
DCTN2
10540
−1.48
G2/M
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Dctn3
53598
DCTN3
11258
−1.77
G2/M
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Dhfr
13361
DHFR
1719
−2.84
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Dtl
76843
DTL
51514
−2.69
protein
Cell cycle
CS
Liu CL, et







poly-

score,
al. J Biol







ubiquitination

mouse
Chem.









K.O.,
2007 Jan.









function
12; 282(2):










1109-18


Dync1h1
13424
DYNC1H1
1778
−3.44
G2/M
Cell cycle
CS
Harada A,







transition of

score,
et al. J







mitotic cell

mouse
Cell Biol.







cycle

K.O.,
1998 Apr.









function
6; 141(1):5










1-9


Ecd
70601
ECD
11319
−3.18
regulation of
Cell cycle
CS








glycolytic

score,








process

function



Ect2
13605
ECT2
1894
−1.80
cell
Cell cycle
CS
Hansen J,







morphogenesis

score,
et al. Proc









mouse
Natl Acad









K.O.,
Sci U S A.









function
2003 Aug.










19; 100(17):










9918-22


Ep300
328572
EP300
2033
−2.04
G2/M
Cell cycle
CS
Yao TP, et







transition of

score,
al. Cell.







mitotic cell

mouse
1998 May







cycle

K.O.,
1; 93(3):36









function
1-72


Ercc3
13872
ERCC3
2071
−2.10
nucleotide-
Cell cycle
CS
Andressoo







excision

score,
JO, et al.







repair

mouse
Mol Cell









K.O.,
Biol. 2009









function
March; 29(5):










1276-90


Espl1
105988
ESPL1
9700
−3.24
proteolysis
Cell cycle
CS
Wirth KG,









score,
et al. J









mouse
Cell Biol.









K.O.,
2006 Mar.









function
13; 172(6):










847-60


Fntb
110606
FNTB
2342
−2.42
phototransdu
Cell cycle
CS
Mijimolle







ction, visible

score,
N, et al.







light

mouse
Cancer









K.O.,
Cell. 2005









function
April; 7(4):3










13-24


Gadd45gip1
102060
GADD45GIP1
90480
−1.81
organelle
Cell cycle
CS
Kwon MC,







organization

score,
et al.









mouse
EMBO J.









K.O.,
2008 Feb.









function
20; 27(4):6










42-53


Gins1
69270
GINS1
9837
−1.84
mitotic cell
Cell cycle
CS
Ueno M,







cycle

score,
et al. Mol









mouse
Cell Biol.









K.O.,
2005









function
December; 25










(23):10528-










32


Gnb2l1
14694
GNB2L1
10399
−2.84
osteoblast
Cell cycle
CS








differentiation

score,










function



Gspt1
14852
GSPT1
2935
−1.77
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Haus1
225745
HAUS1
115106
−1.92
spindle
Cell cycle
CS








assembly

score,










function



Haus3
231123
HAUS3
79441
−1.38
mitotic
Cell cycle
CS








nuclear

score,








division

function



Haus5
71909
HAUS5
23354
−2.55
spindle
Cell cycle
CS








assembly

score,










function



Haus8
76478
HAUS8
93323
−1.73
mitotic
Cell cycle
CS








nuclear

score,








division

function



Hdac3
15183
HDAC3
8841
−2.12
histone
Cell cycle
CS
Bhaskara







deacetylation

score,
S, et al.









mouse
Mol Cell.









K.O.,
2008 Apr.









function
11; 30(1):6










1-72


Kif11
16551
KIF11
3832
−3.23
microtubule-
Cell cycle
CS
Castillo A,







based

score,
et al.







movement

mouse
Biochem









K.O.,
Biophys









function
Res










Commun.










2007 Jun.










8; 357(3):6










94-9


Kif23
71819
KIF23
9493
−1.59
microtubule-
Cell cycle
CS








based

score,








movement

function



Kpnb1
16211
KPNB1
3837
−3.19
nucleocyto-
Cell cycle
CS
Miura K,







plasmic

score,
et al.







transport

mouse
Biochem









K.O.,
Biophys









function
Res










Commun.










2006 Mar.










3; 341(1):1










32-8


Mastl
67121
MASTL
84930
−2.36
protein
Cell cycle
CS
Alvarez-







phosphorylati

score,
Fernandez







on

mouse
M, et al.









K.O.,
Proc Natl









function
Acad Sci










USA.










2013 Oct.










22; 110(43):










17374-9


Mau2
74549
MAU2
23383
−2.71
mitotic cell
Cell cycle
CS
Smith TG,







cycle

score,
et al.









mouse
Genesis.









K.O.,
2014









function
July; 52(7):6










87-94


Mcm3
17215
MCM3
4172
−2.52
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Mcm4
17217
MCM4
4173
−1.87
G1/S
Cell cycle
CS
Shima N,







transition of

score,
et al. Nat







mitotic cell

mouse
Genet.







cycle

K.O.,
2007









function
January;










39(1):










93-8


Mcm7
17220
MCM7
4176
−2.39
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Mnat1
17420
MNAT1
4331
−1.22
regulation of
Cell cycle
CS
Rossi DJ,







cyclin-

score,
et al.







dependent

mouse
EMBO J.







protein

K.O.,
2001 Jun.







serine/threonine

function
1; 20(11):2







kinase


844-56







activity





Mybbp1a
18432
MYBBP1A
10514
−2.17
osteoblast
Cell cycle
CS
Mori S, et







differentiation

score,
al. PLOS









mouse
One.









K.O.,
2012; 7(10):









function
e39723


Ncapd2
68298
NCAPD2
9918
−2.03
mitotic
Cell cycle
CS








chromosome

score,








condensation

function



Ncaph
215387
NCAPH
23397
−2.33
mitotic
Cell cycle
CS
Nishide K,







chromosome

score,
et al.







condensation

mouse
PLOS









K.O.,
Genet.









function
2014










December;










10(12):e100484










7


Ndc80
67052
NDC80
10403
−2.98
attachment of
Cell cycle
CS








mitotic

score,








spindle

function








microtubules










to kinetochore





Nle1
217011
NLE1
54475
−1.88
somitogenesi
Cell cycle
CS
Hentges







S

score,
KE, et al.









mouse
Gene Expr









K.O.,
Patterns.









function
2006










August; 6(6):6










53-65


Nsl1
381318
NSL1
25936
−1.90
mitotic cell
Cell cycle
CS








cycle

score,










function



Nudc
18221
NUDC
10726
−1.93
mitotic cell
Cell cycle
CS








cycle

score,










function



Nuf2
66977
NUF2
83540
−1.78
mitotic
Cell cycle
CS








nuclear

score,








division

function



Nup133
234865
NUP133
55746
−2.26
mitotic cell
Cell cycle
CS
Garcia-







cycle

score,
Garcia









mouse
MJ, et al.









K.O.,
Proc Natl









function
Acad Sci










USA.










2005 Apr.










26;










102(17):5913-9


Nup160
59015
NUP160
23279
−2.64
mitotic cell
Cell cycle
CS








cycle

score,










function



Nup188
227699
NUP188
23511
−1.16
mitotic cell
Cell cycle
CS








cycle

score,










function



Nup214
227720
NUP214
8021
−2.70
mitotic cell
Cell cycle
CS
van







cycle

score,
Deursen









mouse
J, et al.









K.O.,
EMBO J.









function
1996 Oct.










15; 15(20):










5574-83


n/a
n/a
NUP62
23636
−2.35
mitotic cell
Cell cycle
CS








cycle

score,










function



Nup85
445007
NUP85
79902
−2.47
mitotic cell
Cell cycle
CS








cycle

score,










function



Orc3
50793
ORC3
23595
−1.67
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Pafah1b1
18472
PAFAH1B1
5048
−2.34
G2/M
Cell cycle
CS
Cahana A,







transition of

score,
et al. Proc







mitotic cell

mouse
Natl Acad







cycle

K.O.,
Sci U S A.









function
2001 May










22; 98(11):










6429-34


Pcid2
234069
PCID2
55795
−1.98
negative
Cell cycle
CS








regulation of

score,








apoptotic

function








process





Pfas
237823
PFAS
5198
−2.58
purine
Cell cycle
CS








nucleotide

score,








biosynthetic

function








process





Phb2
12034
PHB2
11331
−2.98
protein import
Cell cycle
CS
Park SE,







into nucleus,

score,
et al. Mol







translocation

mouse
Cell Biol.









K.O.,
2005









function
March; 25(5):










1989-99


Pkmyt1
268930
PKMYT1
9088
−1.93
regulation of
Cell cycle
CS








cyclin-

score,








dependent

function








protein










serine/threoni










ne kinase










activity





Plk1
18817
PLK1
5347
−2.83
protein
Cell cycle
CS
Lu LY, et







phosphorylation

score,
al. Mol









mouse
Cell Biol.









K.O.,
2008









function
November;










28(22):6870-6


Pmf1
67037
PMF1
11243
−2.15
mitotic cell
Cell cycle
CS








cycle

score,










function



Pole2
18974
POLE2
5427
−3.08
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Ppat
231327
PPAT
5471
−2.15
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psma6
26443
PSMA6
5687
−3.51
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psma7
26444
PSMA7
5688
−2.91
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psmb1
19170
PSMB1
5689
−1.63
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psmb4
19172
PSMB4
5692
−2.91
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psmd12
66997
PSMD12
5718
−1.69
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psmd13
23997
PSMD13
5719
−1.57
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psmd14
59029
PSMD14
10213
−3.01
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Psmd7
17463
PSMD7
5713
−2.18
G1/S
Cell cycle
CS
Soriano P,







transition of

score,
et al.







mitotic cell

mouse
Genes







cycle

K.O.,
Dev. 1987









function
June; 1(4):3










66-75


Racgap1
26934
RACGAP1
29127
−1.94
mitotic
Cell cycle
CS
Van de







spindle

score,
Putte T, et







assembly

mouse
al. Mech









K.O.,
Dev. 2001









function
April; 102(1-










2):33-44


Rad21
19357
RAD21
5885
−2.12
mitotic cell
Cell cycle
CS








cycle

score,










function



Rae1
66679
RAE1
8480
−2.15
mitotic cell
Cell cycle
CS
Babu JR,







cycle

score,
et al. J









mouse
Cell Biol.









K.O.,
2003 Feb.









function
3; 160(3):










341-53


Rcc1
100088
RCC1
1104
−2.91
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Rfc3
69263
RFC3
5983
−2.74
mitotic cell
Cell cycle
CS








cycle

score,










function



Rps27a
78294
RPS27A
6233
−2.74
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Rrm2
20135
RRM2
6241
−3.09
G1/S
Cell cycle
CS








transition of

score,








mitotic cell

function








cycle





Sae1
56459
SAE1
10055
−2.08
cellular
Cell cycle
CS








protein

score,








modification

function








process





Sec13
110379
SEC13
6396
−2.96
mitotic cell
Cell cycle
CS








cycle

score,










function



Smarcb1
20587
SMARCB1
6598
−1.98
chromatin
Cell cycle
CS
Guidi CJ,







remodeling

score,
et al. Mol









mouse
Cell Biol.









K.O.,
2001 May









function
15; 21(10):










3598-603


Smc2
14211
SMC2
10592
−2.13
mitotic
Cell cycle
CS
Nishide K,







chromosome

score,
et al.







condensation

mouse
PLoS









K.O.,
Genet.









function
2014










December; 10










(12):e100484










7


Smc4
70099
SMC4
10051
−1.47
chromosome
Cell cycle
CS








organization

score,










function



Son
20658
SON
6651
−1.99
microtubule
Cell cycle
CS








cytoskeleton

score,








organization

function



Spc24
67629
SPC24
147841
−2.83
mitotic cell
Cell cycle
CS








cycle

score,










function



Spc25
66442
SPC25
57405
−1.63
mitotic cell
Cell cycle
CS








cycle

score,










function



Terf2
21750
TERF2
7014
−2.17
telomere
Cell cycle
CS
Celli GB,







maintenance

score,
et al. Nat









mouse
Cell Biol.









K.O.,
2005









function
July; 7(7):71










2-8


Tpx2
72119
TPX2
22974
−2.08
apoptotic
Cell cycle
CS
Aguirre-







process

score,
Portoles









mouse
C, et al.









K.O.,
Cancer









function
Res. 2012










Mar.










15; 72(6):1










518-28


Tubg1
103733
TUBG1
7283
−2.08
microtubule
Cell cycle
CS
Yuba-







nucleation

score,
Kubo A, et









mouse
al. Dev









K.O.,
Biol. 2005









function
Jun.










15; 282(2):










361-73


Tubgcp2
74237
TUBGCP2
10844
−2.78
microtubule
Cell cycle
CS








cytoskeleton

score,








organization

function



Tubgcp5
233276
TUBGCP5
114791
−1.76
microtubule
Cell cycle
CS








cytoskeleton

score,








organization

function



Tubgcp6
328580
TUBGCP6
85378
−1.52
microtubule
Cell cycle
CS








cytoskeleton

score,








organization

function



Txnl4a
27366
TXNL4A
10907
−3.89
mitotic
Cell cycle
CS








nuclear

score,








division

function



Usp39
28035
USP39
10713
−2.85
spliceosomal
Cell cycle
CS








complex

score,








assembly

function



Wdr43
72515
WDR43
23160
−3.02
reproduction
Cell cycle
CS










score,










function



Zfp830
66983
ZNF830
91603
−1.52
blastocyst
Cell cycle
CS
Houlard







growth

score,
M, et al.









mouse
Cell Cycle.









K.O.,
2011 Jan.









function
1; 10(1):10










8-17


Aatf
56321
AATF
26574
−1.46
cellular
DNA
CS
Thomas T,







response to
replication,
score,
et al. Dev







DNA damage
DNA repair
mouse
Biol. 2000







stimulus

K.O.,
Nov.









function
15; 227(2):










324-42


Alyref
21681
ALYREF
10189
−1.92
regulation of
DNA
CS








DNA
replication,
score,








recombination
DNA repair
function



Brf2
66653
BRF2
55290
−2.30
DNA-
DNA
CS








templated
replication,
score,








transcription,
DNA repair
function








initiation





Cdc45
12544
CDC45
8318
−3.69
DNA
DNA
CS
Yoshida







replication
replication,
score,
K, et al.







checkpoint
DNA repair
mouse
Mol Cell









K.O.,
Biol. 2001









function











July; 21(14):










4598-603


Cdc6
23834
CDC6
990
−1.87
DNA
DNA
CS








replication
replication,
score,








initiation
DNA repair
function



Cdt1
67177
CDT1
81620
−2.74
DNA
DNA
CS








replication
replication,
score,








checkpoint
DNA repair
function



Cinp
67236
CINP
51550
−1.64
DNA
DNA
CS








replication
replication
score,









DNA repair
function



Cirh1a
21771
CIRH1A
84916
−2.62
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Ddb1
13194
DDB1
1642
−2.14
nucleotide-
DNA
CS
Cang Y, et







excision
replication,
score,
al. Cell.







repair, DNA
DNA repair
mouse
2006 Dec.







damage

K.O.,
1; 127(5):9







removal

function
29-40










de Boer J,










et al.


Ercc2
13871
ERCC2
2068
−2.80
DNA duplex
DNA
CS
Cancer







unwinding
replication,
score,
Res. 1998








DNA repair
mouse
Jan.









K.O.,
1; 58(1):89









function
-94


Gabpb1
14391
GABPB1
2553
−1.74
transcription,
DNA
CS
Xue HH,







DNA-
replication,
score,
et al. Mol







templated
DNA repair
mouse
Cell Biol.









K.O.,
2008









function
July; 28(13):










4300-9


Gtf2b
229906
GTF2B
2959
−2.76
regulation of
DNA
CS








transcription,
replication,
score,








DNA-
DNA repair
function








templated





Gtf2h4
14885
GTF2H4
2968
−1.93
nucleotide-
DNA
CS








excision
replication,
score,








repair, DNA
DNA repair
function








damage










removal





Gtf3a
66596
GTF3A
2971
−2.25
regulation of
DNA
CS








transcription,
replication,
score,








DNA-
DNA repair
function








templated





Gtf3c1
233863
GTF3C1
2975
−2.45
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Gtf3c2
71752
GTF3C2
2976
−2.09
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Hinfp
102423
HINFP
25988
−2.35
DNA damage
DNA
CS
Xie R, et







checkpoint
replication,
score,
al. Proc








DNA repair
mouse
Natl Acad









K.O.,
Sci U S A.









function
2009 Jul. 9


n/a
n/a
HIST2H2AA3
8337
−1.71
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Ints3
229543
INTS3
65123
−3.14
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Kin
16588
KIN
22944
−1.99
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Mcm2
17216
MCM2
4171
−2.86
DNA
DNA
CS








replication
replication,
score,








initiation
DNA repair
function



Mcm6
17219
MCM6
4175
−1.55
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Mcrs1
51812
MCRS1
10445
−1.23
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Med11
66172
MED11
400569
−2.39
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Mtpap
67440
MTPAP
55149
−1.86
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Myc
17869
MYC
4609
−2.49
regulation of
DNA
CS
Trumpp A,







transcription,
replication
score,
et al.







DNA-
DNA repair
mouse
Nature.







templated

K.O.,
2001 Dec.









function
13; 414(68










65):768-










73


Ndnl2
66647
NDNL2
56160
−2.03
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Nol11
68979
NOL11
25926
−1.59
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Nol8
70930
NOL8
55035
−1.35
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Pcna
18538
PCNA
5111
−3.60
DNA
DNA
CS
Roa S, et







replication
replication,
score,
al. Proc








DNA repair
mouse
Natl Acad









K.O.,
Sci U S A.









function
2008 Oct.










21; 105(42):










16248-










53


Pola1
18968
POLA1
5422
−2.28
DNA-
DNA
CS








dependent
replication,
score,








DNA
DNA repair
function








replication





Pold2
18972
POLD2
5425
−2.51
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Pole
18973
POLE
5426
−2.90
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Polr1a
20019
POLR1A
25885
−2.62
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



n/a
n/a
POLR2J2
246721
−3.08
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Polr3a
218832
POLR3A
11128
−2.43
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Polr3c
74414
POLR3C
10623
−2.02
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Polr3h
78929
POLR3H
171568
−2.66
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Prmt1
15469
PRMT1
3276
−2.40
regulation of
DNA
CS
Pawlak







transcription,
replication,
score,
MR, et al.







DNA-
DNA repair
mouse
Mol Cell







templated

K.O.,
Biol. 2000









function
July; 20(13):










4859-69


Prmt5
27374
PRMT5
10419
−2.69
regulation of
DNA
CS
Tee WW,







transcription,
replication,
score,
et al.







DNA-
DNA repair
mouse
Genes







templated

K.O.,
Dev. 2010









function
Dec.










15; 24(24):










2772-7


Puf60
67959
PUF60
22827
−2.69
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Rad51
19361
RAD51
5888
−2.29
DNA repair
DNA
CS
Tsuzuki T,








replication,
score,
et al. Proc








DNA repair
mouse
Natl Acad









K.O.,
Sci U S A.









function
1996 Jun.










25; 93(13):










6236-40


Rad51c
114714
RAD51C
5889
−1.62
DNA repair
DNA
CS
Smeenk








replication,
score,
G, et al.








DNA repair
mouse
Mutat









K.O.,
Res. 2010









function
Jul.










7; 689(1-










2):50-58


Rbx1
56438
RBX1
9978
−2.19
DNA repair
DNA
CS
Tan M, et








replication,
score,
al. Proc








DNA repair
mouse
Natl Acad









K.O.,
Sci U S A.









function
2009 Apr.










14; 106(15):










6203-8


Rfc2
19718
RFC2
5982
−2.88
DNA-
DNA
CS








dependent
replication,
score,








DNA
DNA repair
function








replication





Rfc4
106344
RFC4
5984
−1.92
DNA-
DNA
CS








dependent
replication,
score,








DNA
DNA repair
function








replication





Rfc5
72151
RFC5
5985
−2.78
DNA-
DNA
CS








dependent
replication,
score,








DNA
DNA repair
function








replication





Rpa1
68275
RPA1
6117
−2.61
DNA
DNA
CS
Wang Y,







replication
replication,
score,
et al. Nat








DNA repair
mouse
Genet.









K.O.,
2005









function
July; 37(7):










750-5


Rps3
27050
RPS3
6188
−2.75
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Rrm1
20133
RRM1
6240
−4.16
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Ruvbl1
56505
RUVBL1
8607
−3.26
DNA duplex
DNA
CS








unwinding
replication,
score,









DNA repair
function



Ruvbl2
20174
RUVBL2
10856
−3.91
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Sap30bp
57230
SAP30BP
29115
−2.18
regulation of
DNA
CS








transcription,
replication,
score,








DNA-
DNA repair
function








templated





Smc1a
24061
SMC1A
8243
−2.76
DNA repair
DNA
CS









replication,
score,









DNA repair
function



Smc3
13006
SMC3
9126
−3.22
DNA repair
DNA
CS
White JK,








replication,
score,
et al. Cell.








DNA repair
mouse
2013 Jul.









K.O.,
18; 154(2):









function
452-64


Snapc4
227644
SNAPC4
6621
−2.78
regulation of
DNA
CS








transcription,
replication,
score,








DNA-
DNA repair
function








templated





Snapc5
330959
SNAPC5
10302
−2.24
regulation of
DNA
CS








transcription,
replication,
score,








DNA-
DNA repair
function








templated





Snip1
76793
SNIP1
79753
−1.78
regulation of
DNA
CS








transcription,
replication,
score,








DNA-
DNA repair
function








templated





Srrt
83701
SRRT
51593
−2.18
transcription,
DNA
CS
Wilson







DNA-
replication,
score,
MD, et al.







templated
DNA repair
mouse
Mol Cell









K.O.,
Biol. 2008









function
March; 28(5):










1503-14


Ssrp1
20833
SSRP1
6749
−1.45
DNA
DNA
CS
Cao S, et







replication
replication,
score,
al. 5








DNA repair
mouse
mouse









K.O.,
embryos.









function
Mol Cell










Biol. 2003










August; 23










(15):5301-7


Taf10
24075
TAF10
6881
−1.38
DNA-
DNA
CS
Mohan







templated
replication
score,
WS Jr, et







transcription,
DNA repair
mouse
al. Mol







initiation

K.O.,
Cell Biol.









function
2003










June; 23(12):










4307-18


Taf1c
21341
TAF1C
9013
−1.80
chromatin
DNA
CS








silencing at
replication,
score,








rDNA
DNA repair
function



Taf6
21343
TAF6
6878
−1.84
DNA-
DNA
CS








templated
replication,
score,








transcription,
DNA repair
function








initiation





Taf6l
67706
TAF6L
10629
−1.53
DNA-
DNA
CS








templated
replication,
score,








transcription,
DNA repair
function








initiation





Ticrr
77011
TICRR
90381
−2.03
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Top1
21969
TOP1
7150
−2.02
DNA
DNA
CS
Morham







topological
replication,
score,
SG, et al.







change
DNA repair
mouse
Mol Cell









K.O.,
Biol. 1996









function
December;










16(12):6804-9


Top2a
21973
TOP2A
7153
−1.50
DNA
DNA
CS








replication
replication,
score,









DNA repair
function



Trrap
100683
TRRAP
8295
−2.36
DNA repair
DNA
CS
Herceg Z,








replication,
score,
et al. Nat








DNA repair
mouse
Genet.










2001









K.O.,
October; 29(2):









function
206-11


Zbtb11
271377
ZBTB11
27107
−2.34
transcription,
DNA
CS








DNA-
replication,
score,








templated
DNA repair
function



Actl6a
56456
ACTL6A
86
−2.33
neural retina
DNA
CS
Krasteva







development
replication,
score,
V, et al.








DNA repair
mouse
Blood.









K.O.,
2012 Dec.









function
6; 120(24):


Atr
245000
ATR
545
−2.01
double-strand
DNA
CS
4720-32







break repair
replication,
score,
de Klein







via
DNA repair
mouse
A, et al.







homologous

K.O.,
Curr Biol.







recombination

function
2000 Apr.










20; 10(8):










479-82


Chd4
107932
CHD4
1108
−1.71
chromatin
DNA
CS








organization
replication,
score,









DNA repair
function



Ciao1
26371
CIAO1
9391
−1.94
chromosome
DNA
CS








segregation
replication,
score,









DNA repair
function



Ddx21
56200
DDX21
9188
−2.84
osteoblast
DNA
CS








differentiation
replication,
score,









DNA repair
function



Dnaja3
83945
DNAJA3
9093
−2.19
mitochondrion
DNA
CS
Lo JF, et







organization
replication,
score,
al. Mol








DNA repair
mouse
Cell Biol.









K.O.,
2004









function
March; 24(6):










2226-36


Dnmt1
13433
DNMT1
1786
−1.97
methylation
DNA
CS
Lei H, et








replication,
score,
al.








DNA repair
mouse
Development.









K.O.,
1996









function
October;










122(10):3195-










205


Gins2
272551
GINS2
51659
−3.32
double-strand
DNA
CS








break repair
replication,
score,








via break-
DNA repair
function








induced










replication





Gtf2h3
209357
GTF2H3
2967
−1.84
nucleotide-
DNA
CS








excision
replication,
score,








repair
DNA repair
function



n/a
n/a
HIST2H2BF
440689
−1.70
chromatin
DNA
CS








organization
replication,
score,









DNA repair
function



Mms22l
212377
MMS22L
253714
−1.38
double-strand
DNA
CS








break repair
replication,
score,








via
DNA repair
function








homologous










recombination





Mtor
56717
MTOR
2475
−1.98
double-strand
DNA
CS
Murakami







break repair
replication,
score,
M, et al.







via
DNA repair
mouse
Mol Cell







homologous

K.O.,
Biol. 2004







recombination

function
August;









CS
24(15):6710-8


Narfl
67563
NARFL
64428
−2.13
response to
DNA
score,
Song D, et







hypoxia
replication,
mouse
al. J Biol








DNA repair
K.O.,
Chem.









function
2011 Mar.










2


Ndufa13
67184
NDUFA13
51079
−1.31
positive
DNA
CS
Huang G,







regulation of
replication,
score,
et al. Mol







peptidase
DNA repair
mouse
Cell Biol.







activity

K.O.,
2004









function
October;










24(19):8447-56


Nol12
97961
NOL12
79159
−1.61
poly(A) RNA
DNA
CS








binding
replication,
score,









DNA repair
function



Nup107
103468
NUP107
57122
−1.30
transport
DNA
CS









replication,
score,









DNA repair
function



Oraov1
72284
ORAOV1
220064
−2.26
biological_
DNA
CS








process
replication,
score,









DNA repair
function



Pam16
66449
PAM16
51025
−2.13
protein import
DNA
CS








into
replication,
score,








mitochondrial
DNA repair
function








matrix





Pola2
18969
POLA2
23649
−2.84
protein import
DNA
CS








into nucleus,
replication,
score,








translocation
DNA repair
function



Ppie
56031
PPIE
10450
−1.63
protein
DNA
CS








peptidyl-prolyl
replication,
score,








isomerization
DNA repair
function



Prpf19
28000
PRPF19
27339
−3.96
generation of
DNA
CS
Fortschegger







catalytic
replication,
score,
K, et







spliceosome
DNA repair
mouse
al. Mol







for first

K.O.,
Cell Biol.







trans-

function
2007







esterifica-


April; 27(8):







tion step


3123-30


Psmc5
19184
PSMC5
5705
−2.57
ER-
DNA
CS








associated
replication,
score,








ubiquitin-
DNA repair
function








dependent










protein










catabolic










process





Rbbp5
213464
RBBP5
5929
−1.70
chromatin
DNA
CS








organization
replication,
score,









DNA repair
function



Rbbp6
19647
RBBP6
5930
−1.78
in utero
DNA
CS
Li L, et al.







embryonic
replication,
score,
Proc Natl







development
DNA repair
mouse
Acad Sci









K.O.,
USA.









function
2007 May










8; 104(19):










7951-6


Rptor
74370
RPTOR
57521
−2.43
TOR
DNA
CS
Guertin







signaling
replication,
score,
DA, et al.








DNA repair
mouse
Dev Cell.









K.O.,
2006









function
December;










11(6):859-71


Rrn3
106298
RRN3
54700
−1.85
in utero
DNA
CS
Yuan X, et







embryonic
replication,
score,
al. Mol







development
DNA repair
mouse
Cell. 2005









K.O.,
Jul.









function
1; 19(1):77-










87


Smg1
233789
SMG1
23049
−1.94
double-strand
DNA
CS
Roberts







break repair
replication,
score,
TL, et al.







via
DNA repair
mouse
Proc Natl







homologous

K.O.,
Acad Sci







recombination

function
USA.










2013 Jan.










22; 110(4):










E285-94


Supt6
20926
SUPT6H
6830
−1.78
chromatin
DNA
CS
Dietrich







remodeling
replication,
score,
JE, et al.








DNA repair
mouse
EMBO









K.O.,
Rep. 2015









function
August; 16(8):










1005-21


Tada2b
231151
TADA2B
93624
−1.23
chromatin
DNA
CS








organization
replication,
score,









DNA repair
function



Tfip11
54723
TFIP11
24144
−2.19
spliceosomal
DNA
CS








complex
replication,
score,








disassembly
DNA repair
function



Tonsl
66914
TONSL
4796
−3.03
double-strand
DNA
CS








break repair
replication,
score,








via
DNA repair
function








homologous










recombination





Tpt1
22070
TPT1
7178
−2.05
calcium ion
DNA
CS
Susini L,







transport
replication,
score,
et al. Cell








DNA repair
mouse
Death









K.O.,
Differ.









function
2008










August; 15(8):










1211-20


Uba1
22201
UBA1
7317
−2.90
protein
DNA
CS








ubiquitination
replication,
score,









DNA repair
function



Vps25
28084
VPS25
84313
−2.31
protein
DNA
CS








targeting to
replication,
score,








vacuole
DNA repair
function








involved in










ubiquitin-










dependent










protein










catabolic










process via










the










multivesicular










body sorting










pathway





Wbscr22
66138
WBSCR22
114049
−2.70
methylation
DNA
CS









replication,
score,









DNA repair
function



Wdr5
140858
WDR5
11091
−1.99
skeletal
DNA
CS








system
replication,
score,








development
DNA repair
function



Xab2
67439
XAB2
56949
−2.86
generation of
DNA
CS
Yonemasu







catalytic
replication,
score,
R, et al.







spliceosome
DNA repair
mouse
DNA







for first

K.O.,
Repair







transesteri-

function
(Amst).







fication step


2005 Apr.










4; 4(4):479-










91


Zmat2
66492
ZMAT2
153527
−2.17
histidine-
DNA
CS








tRNA ligase
replication,
score,








activity
DNA repair
function



Zfp335
329559
ZNF335
63925
−1.58
in utero
DNA
CS
Yang YJ,







embryonic
replication,
score,
et al. Cell.







development
DNA repair
mouse
2012 Nov.









K.O.,
21; 151(5):









function
1097-112


Acly
104112
ACLY
47
−1.54
acetyl-CoA
Metabolism
CS
Beigneux







metabolic

score,
AP, et al.







process

mouse
J Biol









K.O.,
Chem.









function
2004 Mar.










5; 279(10):










9557-64


Adsl
11564
ADSL
158
−2.39
metabolic
Metabolism
CS








process

score,










function



Ahcy
269378
AHCY
191
−2.07
sulfur amino
Metabolism
CS








acid

score,








metabolic

function








process





Arl2
56327
ARL2
402
−2.29
energy
Metabolism
CS








reserve

score,








metabolic

function








process





Chka
12660
CHKA
1119
−1.64
lipid
Metabolism
CS
Wu G, et







metabolic

score,
al. J Biol







process

mouse
Chem.









K.O.,
2008 Jan.









function
18; 283(3):










1456-62


Coasy
71743
COASY
80347
−1.82
vitamin
Metabolism
CS








metabolic

score,








process

function



Cox4i1
12857
COX4I1
1327
−2.00
generation of
Metabolism
CS








precursor

score,








metabolites

function








and energy





n/a
n/a
COX7C
1350
−1.59
generation of
Metabolism
CS








precursor

score,








metabolites

function








and energy





n/a
n/a
CTPS1
1503
−2.52
nucleobase-
Metabolism
CS








containing

score,








compound

function








metabolic










process





Ddx10
77591
DDX10
1662
−2.02
metabolic
Metabolism
CS








process

score,










function



Ddx20
53975
DDX20
11218
−2.49
metabolic
Metabolism
CS
Mouillet







process

score,
JF, et al.









mouse
Endocrinology.









K.O.,
2008









function
May; 149(5):










2168-75


Dhdds
67422
DHDDS
79947
−2.86
metabolic
Metabolism
CS








process

score,










function



Dhx30
72831
DHX30
22907
−1.93
metabolic
Metabolism
CS








process

score,










function



Dhx8
217207
DHX8
1659
−2.61
metabolic
Metabolism
CS








process

score,










function



Dhx9
13211
DHX9
1660
−1.73
metabolic
Metabolism
CS
Lee CG,







process

score,
et al. Proc









mouse
Natl Acad









K.O.,
Sci U S A.









function
1998 Nov.










10; 95(23):










13709-13


Dlst
78920
DLST
1743
−1.93
metabolic
Metabolism
CS








process

score,










function



Dpagt1
13478
DPAGT1
1798
−2.80
UDP-N-
Metabolism
CS
Marek







acetylglucosa-

score,
KW, et al.







mine

mouse
Glycobiology.







metabolic

K.O.,
1999







process

function
November;










9(11):1263-71


Gfpt1
14583
GFPT1
2673
−1.81
fructose 6-
Metabolism
CS








phosphate

score,








metabolic

function








process





Gmps
229363
GMPS
8833
−1.80
purine
Metabolism
CS








nucleobase

score,








metabolic

function








process





Gpn1
74254
GPN1
11321
−1.79
metabolic
Metabolism
CS








process

score,










function



Gpn3
68080
GPN3
51184
−3.12
metabolic
Metabolism
CS








process

score,










function



Guk1
14923
GUK1
2987
−2.67
purine
Metabolism
CS








nucleotide

score,








metabolic

function








process





Hsd17b10
15108
HSD17B10
3028
−1.84
lipid
Metabolism
CS








metabolic

score,








process

function



Lrr1
69706
LRR1
122769
−3.44
metabolic
Metabolism
CS








process

score,










function



Mtg2
52856
MTG2
26164
−2.04
metabolic
Metabolism
CS








process

score,










function



Myh9
17886
MYH9
4627
−1.70
metabolic
Metabolism
CS
Matsushita







process

score,
T, et al.









mouse
Biochem









K.O.,
Biophys









function
Res










Commun.










2004 Dec.










24; 325(4):










1163-71


Nampt
59027
NAMPT
10135
−2.40
vitamin
Metabolism
CS
Revollo







metabolic

score,
JR, et al.







process

mouse
Cell









K.O.,
Metab.









function
2007










November;










6(5):363-75


Ncbp1
433702
NCBP1
4686
−1.62
RNA
Metabolism
CS








metabolic

score,








process

function



Nfs1
18041
NFS1
9054
−2.40
metabolic
Metabolism
CS








process

score,










function



Ppcdc
66812
PPCDC
60490
−1.98
metabolic
Metabolism
CS








process

score,










function



Qrsl1
76563
QRSL1
55278
−1.67
metabolic
Metabolism
CS








process

score,










function



Rpp14
67053
RPP14
11102
−1.72
fatty acid
Metabolism
CS








metabolic

score,








process

function



Smarca4
20586
SMARCA4
6597
−1.89
metabolic
Metabolism
CS
Bultman







process

score,
S, et al.









mouse
Mol Cell.









K.O.,
2000









function
December;










6(6):










1287-95


Snrnp200
320632
SNRNP200
230200
−2.50
metabolic
Metabolism
CS








process

score,










function



Srbd1
78586
SRBD1
55133
−2.35
nucleobase-
Metabolism
CS








containing

score,








compound

function








metabolic










process





Srcap
100043597
SRCAP
10847
−1.43
metabolic
Metabolism
CS








process

score,










function



Ube2i
22196
UBE2I
7329
−2.55
metabolic
Metabolism
CS
Nacerddine







process

score,
K, et al.









mouse
Dev Cell.









K.O.,
2005









function
December;










9(6):769-79


Ube2m
22192
UBE2M
9040
−2.39
metabolic
Metabolism
CS








process

score,










function



Vcp
269523
VCP
7415
−2.85
metabolic
Metabolism
CS
Muller JM,







process

score,
et al.









mouse
Biochem









K.O.,
Biophys









function
Res










Commun.










2007 Mar.










9; 354(2):459-465


Aamp
227290
AAMP
14
−2.37
angiogenesis
Metabolism
CS










score,










function



Acin1
56215
ACIN1
22985
−1.53
positive
Metabolism
CS








regulation of

score,








defense

function








response to










virus by host





Aco2
11429
ACO2
50
−2.08
tricarboxylic
Metabolism
CS








acid cycle

score,










function



Adss
11566
ADSS
159
−2.46
purine
Metabolism
CS








nucleotide

score,








biosynthetic

function








process





Alg2
56737
ALG2
85365
−2.29
biosynthetic
Metabolism
CS








process

score,










function



Ap2s1
232910
AP2S1
1175
−2.00
intracellular
Metabolism
CS








protein

score,








transport

function



Arcn1
213827
ARCN1
372
−1.91
intracellular
Metabolism
CS








protein

score,








transport

function



Armc7
276905
ARMC7
79637
−2.02
molecular_
Metabolism
CS








function

score,










function



Atp2a2
11938
ATP2A2
488
−3.01
calcium ion
Metabolism
CS
Andersson







transmembrane

score,
KB, et al.







transport

mouse
Cell









K.O.,
Calcium.









function
2009










September; 46(3):










219-25


Atp5a1
11946
ATP5A1
498
−1.99
negative
Metabolism
CS








regulation of

score,








endothelial

function








cell










proliferation





Atp5d
66043
ATP5D
513
−2.21
oxidative
Metabolism
CS








phosphorylation

score,










function



Atp50
28080
ATP50
539
−1.17
ATP
Metabolism
CS








biosynthetic

score,








process

function



Atp6v0b
114143
ATP6V0B
533
−3.01
cellular iron
Metabolism
CS








ion

score,








homeostasis

function



Atp6v0c
11984
ATP6V0C
527
−3.84
cellular iron
Metabolism
CS
Sun-Wada







ion

score,
GH, et al.







homeostasis

mouse
Dev Biol.









K.O.,
2000 Dec.









function
15; 228(2):










315-25


Atp6v1a
11964
ATP6V1A
523
−3.58
proton
Metabolism
CS








transport

score,










function



Atp6v1b2
11966
ATP6V1B2
526
−2.94
cellular iron
Metabolism
CS








ion

score,








homeostasis

function



Atp6v1d
73834
ATP6V1D
51382
−2.58
transmembra
Metabolism
CS








ne transport

score,










function



Aurkaip1
66077
AURKAIP1
54998
−1.56
organelle
Metabolism
CS








organization

score,










function



n/a
n/a
C1orf109
54955
−2.43
molecular_
Metabolism
CS








function

score,










function



n/a
n/a
C21orf59
56683
−2.77
cell projection
Metabolism
CS








morphogenesis

score,










function



Ccdc84
382073
CCDC84
338657
−1.86
molecular_
Metabolism
CS








function

score,










function



Cct2
12461
CCT2
10576
−3.23
protein folding
Metabolism
CS










score,










function



Cct3
12462
CCT3
7203
−3.31
protein folding
Metabolism
CS










score,










function



Cct4
12464
CCT4
10575
−2.62
protein folding
Metabolism
CS










score,










function



Cct5
12465
CCT5
22948
−2.84
protein folding
Metabolism
CS










score,










function



Cct7
12468
CCT7
10574
−2.47
protein folding
Metabolism
CS










score,










function



Cct8
12469
CCT8
10694
−2.03
protein folding
Metabolism
CS










score,










function



Cdipt
52858
CDIPT
10423
−2.53
phospholipid
Metabolism
CS








biosynthetic

score,








process

function



Cenpi
102920
CENPI
2491
−1.81
centromere
Metabolism
CS








complex

score,








assembly

function



Chordc1
66917
CHORDC1
26973
−1.52
regulation of
Metabolism
CS
Ferretti R,







centrosome

score,
et al. Dev







duplication

mouse
Cell. 2010









K.O.,
Mar.









function
16; 18(3):4










86-95


Coa5
76178
COA5
493753
−2.33
mitochondrion
Metabolism
CS










score,










function



Cog4
102339
COG4
25839
−1.39
Golgi vesicle
Metabolism
CS








transport

score,










function



Copa
12847
COPA
1314
−1.63
intracellular
Metabolism
CS








protein

score,








transport

function



Copb1
70349
COPB1
1315
−2.30
intracellular
Metabolism
CS








protein

score,








transport

function



Copb2
50797
COPB2
9276
−2.65
intracellular
Metabolism
CS








protein

score,








transport

function



Cope
59042
COPE
11316
−2.93
ER to Golgi
Metabolism
CS








vesicle-

score,








mediated

function








transport





Copz1
56447
COPZ1
22818
−1.87
transport
Metabolism
CS










score,










function



Coq4
227683
COQ4
51117
−1.29
ubiquinone
Metabolism
CS








biosynthetic

score,








process

function



Cox15
226139
COX15
1355
−2.14
mitochondrial
Metabolism
CS
Viscomi C,







electron

score,
et al. Cell







transport,

mouse
Metab.







cytochrome c

K.O.,
2011 Jul.







to oxygen

function
6; 14(1):80-90


Cox17
12856
COX17
10063
−1.97
copper ion
Metabolism
CS
Takahashi







transport

score,
Y, et al.









mouse
Mol Cell









K.O.,
Biol. 2002









function
November;










22(21):7614-21


Cse1l
110750
CSE1L
1434
−2.31
protein export
Metabolism
CS
Bera TK,







from nucleus

score,
et al. Mol









mouse
Cell Biol.









K.O.,
2001









function
October; 21(20):










7020-4


Csnk2b
13001
CSNK2B
1460
−1.94
regulation of
Metabolism
CS
Buchou T,







protein kinase

score,
et al. Mol







activity

mouse
Cell Biol.









K.O.,
2003









function
February; 23(3):










908-15


Cycs
13063
CYCS
54205
−2.36
response to
Metabolism
CS
Li K, et al.







reactive

score,
Cell. 2000







oxygen

mouse
May







species

K.O.,
12; 101(4):









function
389-99


Dad1
13135
DAD1
1603
−2.21
protein
Metabolism
CS
Brewster







glycosylation

score,
JL, et al.









mouse
Genesis.









K.O.,
2000









function
April; 26(4):










271-8


Dap3
65111
DAP3
7818
−1.70
apoptotic
Metabolism
CS
Kim HR,







process

score,
et al.









mouse
FASEB J.









K.O.,
2007









function
January; 21(1):










188-96


Dctn5
59288
DCTN5
84516
−2.39
antigen
Metabolism
CS








processing

score,








and

function








presentation










of exogenous










peptide










antigen via










MHC class II





Ddost
13200
DDOST
1650
−2.38
protein N-
Metabolism
CS








linked

score,








glycosylation

function








via










asparagine





Dgcr8
94223
DGCR8
54487
−2.10
gene
Metabolism
CS
Ouchi Y,







expression

score,
et al. J









mouse
Neurosci.









K.O.,
2013 May









function
29; 33(22):










9408-19


Dhodh
56749
DHODH
1723
−2.57
de novo′
Metabolism
CS








pyrimidine

score,








nucleobase

function








biosynthetic










process





Dnlz
52838
DNLZ
728489
−1.92
protein folding
Metabolism
CS










score,










function



Dnm1l
74006
DNM1L
10059
−3.25
mitochondrial
Metabolism
CS
Wakabaya







fission

score,
shi J, et al.









mouse
J Cell Biol.









K.O.,
2009 Sep.









function
21; 186(6):










805-16


Dnm2
13430
DNM2
1785
−3.98
endocytosis
Metabolism
CS
Ferguson









score,
SM, et al.









mouse
Dev Cell.









K.O.,
2009









function
December; 17(6):










811-22


Dohh
102115
DOHH
83475
−1.76
peptidyl-
Metabolism
CS








lysine

score,








modification

function








to peptidyl-










hypusine





Dolk
227697
DOLK
22845
−2.38
dolichol-
Metabolism
CS








linked

score,








oligosaccharide

function








biosynthetic










process





Donson
60364
DONSON
29980
−2.30
multicellular
Metabolism
CS








organismal

score,








development

function



Dph3
105638
DPH3
285381
−1.62
peptidyl-
Metabolism
CS
Liu S, et







diphthamide

score,
al. Mol







biosynthetic

mouse
Cell Biol.







process from

K.O.,
2006







peptidyl-

function
May; 26(10):







histidine


3835-41


Dtymk
21915
DTYMK
1841
−3.54
phosphorylation
Metabolism
CS










score,










function



Eif2b2
217715
EIF2B2
8892
−2.24
ovarian
Metabolism
CS








follicle

score,








development

function



Eif2s2
67204
EIF2S2
8894
−2.33
in utero
Metabolism
CS
Heaney







embryonic

score,
JD, et al.







development

mouse
Hum Mol









K.O.,
Genet.









function
2009 Apr.










15; 18(8):1










395-404


Emc1
230866
EMC1
23065
−1.34
protein folding
Metabolism
CS








in

score,








endoplasmic

function








reticulum





Emc7
73024
EMC7
56851
−2.27
biological_
Metabolism
CS








process

score,










function



Eno1
13806
ENO1
2023
−2.03
glycolytic
Metabolism
CS
Couldrey







process

score,
C, et al.









mouse
Dev Dyn.









K.O.,
1998









function
June; 212(2):










284-92


Fam50a
108160
FAM50A
9130
−3.16
spermatogenesis
Metabolism
CS










score,










function



Fam96b
68523
FAM96B
51647
−1.90
iron-sulfur
Metabolism
CS








cluster

score,








assembly

function



Fdps
110196
FDPS
2224
−2.41
isoprenoid
Metabolism
CS








biosynthetic

score,








process

function



Gapdh
14433
GAPDH
2597
−2.40
oxidation-
Metabolism
CS








reduction

score,








process

function



Gart
14450
GART
2618
−1.87
purine
Metabolism
CS








nucleobase

score,








biosynthetic

function








process





Gemin4
276919
GEMIN4
50628
−1.56
spliceosomal
Metabolism
CS








snRNP

score,








assembly

function



Gemin5
216766
GEMIN5
25929
−2.51
spliceosomal
Metabolism
CS








snRNP

score,








assembly

function



Ggps1
14593
GGPS1
9453
−1.62
cholesterol
Metabolism
CS








biosynthetic

score,








process

function



Gmppb
331026
GMPPB
29925
−3.22
biosynthetic
Metabolism
CS








process

score,










function



Gnb1l
13972
GNB1L
54584
−1.93
G-protein
Metabolism
CS








coupled

score,








receptor

function








signaling










pathway





n/a
n/a
GOLGA6L1
283767
−3.15

Metabolism
CS










score,










function



Gosr2
56494
GOSR2
9570
−1.13
protein
Metabolism
CS








targeting to

score,








vacuole

function



Gpkow
209416
GPKOW
27238
−1.36
biological_
Metabolism
CS








process

score,










function



Gpn2
100210
GPN2
54707
−3.71
biological_
Metabolism
CS








process

score,










function



Gps1
209318
GPS1
2873
−2.11
inactivation of
Metabolism
CS








MAPK activity

score,










function



Grpel1
17713
GRPEL1
80273
−2.61
protein folding
Metabolism
CS










score,










function



Grwd1
101612
GRWD1
83743
−1.90
poly(A) RNA
Metabolism
CS








binding

score,










function



Hmgcr
15357
HMGCR
3156
−2.94
cholesterol
Metabolism
CS
Ohashi K,







biosynthetic

score,
et al. J







process

mouse
Biol









K.O.,
Chem.









function
2003 Oct.










31; 278(44):










42936-










41


Hmgcs1
208715
HMGCS1
3157
−2.41
liver
Metabolism
CS








development

score,










function



Hspa5
14828
HSPA5
3309
−3.86
platelet
Metabolism
CS
Luo S, et







degranulation

score,
al. Mol









mouse
Cell Biol.









K.O.,
2006









function
August; 26(15):










5688-97


Hspa9
15526
HSPA9
3313
−3.55
protein folding
Metabolism
CS










score,










function



Hspd1
15510
HSPD1
3329
−1.95
response to
Metabolism
CS
Christensen







hypoxia

score,
JH, et al.









mouse
Cell









K.O.,
Stress









function
Chaperones.










2010










November; 15(6):










851-63


Hspe1
15528
HSPE1
3336
−3.75
osteoblast
Metabolism
CS








differentiation

score,










function



Hyou1
12282
HYOU1
10525
−2.06
response to
Metabolism
CS








ischemia

score,










function



Ipo13
230673
IPO13
9670
−2.84
intracellular
Metabolism
CS








protein

score,








transport

function



Iscu
66383
ISCU
23479
−2.40
cellular iron
Metabolism
CS








ion

score,








homeostasis

function



Itpk1
217837
ITPK1
3705
−1.55
phosphorylation
Metabolism
CS










score,










function



Kansl2
69612
KANSL2
54934
−1.19
chromatin
Metabolism
CS








organization

score,










function



Kansl3
226976
KANSL3
55683
−1.53
chromatin
Metabolism
CS








organization

score,










function



Kri1
215194
KRI1
65095
−2.49
poly(A) RNA
Metabolism
CS








binding

score,










function



Lamtor2
83409
LAMTOR2
28956
−1.62
activation of
Metabolism
CS
Teis D, et







MAPKK

score,
al. J Cell







activity

mouse
Biol. 2006









K.O.,
Dec.









function
18; 175(6):










861-8


Leng8
232798
LENG8
114823
−1.75
biological_
Metabolism
CS








process

score,










function



Ltv1
353258
LTV1
84946
−1.81
nucleoplasm
Metabolism
CS










score,










function



Mak16
67920
MAK16
84549
−2.30
poly(A) RNA
Metabolism
CS








binding

score,










function



Mat2a
232087
MAT2A
4144
−2.34
S-
Metabolism
CS








adenosylmeth-

score,








ionine

function








biosynthetic










process





Mcm3ap
54387
MCM3AP
8888
−1.58
immune
Metabolism
CS
Yoshida







system

score,
M, et al.







process

mouse
Genes









K.O.,
Cells.









function
2007










October; 12(10):










1205-13


Mdn1
100019
MDN1
23195
−1.68
protein
Metabolism
CS








complex

score,








assembly

function



n/a
n/a
MFAP1
4236
−1.94
biological_
Metabolism
CS








process

score,










function



Mmgt1
236792
MMGT1
93380
−1.55
magnesium
Metabolism
CS








ion transport

score,










function



Mrpl16
94063
MRPL16
54948
−1.80
organelle
Metabolism
CS








organization

score,










function



Mrpl17
27397
MRPL17
63875
−1.80
mitochondrial
Metabolism
CS








genome

score,








maintenance

function



Mrpl33
66845
MRPL33
9553
−1.62
organelle
Metabolism
CS








organization

score,










function



Mrpl38
60441
MRPL38
64978
−1.95
organelle
Metabolism
CS








organization

score,










function



Mrpl39
27393
MRPL39
54148
−1.71
organelle
Metabolism
CS








organization

score,










function



Mrpl45
67036
MRPL45
84311
−1.75
organelle
Metabolism
CS








organization

score,










function



Mrpl46
67308
MRPL46
26589
−1.83
organelle
Metabolism
CS








organization

score,










function



Mrpl53
68499
MRPL53
116540
−1.84
organelle
Metabolism
CS








organization

score,










function



Mrps22
64655
MRPS22
56945
−1.32
organelle
Metabolism
CS








organization

score,










function



Mrps25
64658
MRPS25
64432
−1.63
organelle
Metabolism
CS








organization

score,










function



Mrps35
232536
MRPS35
60488
−1.60
organelle
Metabolism
CS








organization

score,










function



Mrps5
77721
MRPS5
64969
−1.65
organelle
Metabolism
CS








organization

score,










function



Mvd
192156
MVD
4597
−3.24
isoprenoid
Metabolism
CS








biosynthetic

score,








process

function



Mvk
17855
MVK
4598
−1.73
isoprenoid
Metabolism
CS








biosynthetic

score,








process

function



Naa25
231713
NAA25
80018
−2.40
peptide
Metabolism
CS








alpha-N-

score,








acetyltransferase

function








activity





Napa
108124
NAPA
8775
−2.31
intracellular
Metabolism
CS








protein

score,








transport

function



Nat10
98956
NAT10
55226
−2.16
biological_
Metabolism
CS








process

score,










function



Ndor1
78797
NDOR1
27158
−2.10
cell death
Metabolism
CS










score,










function



Ndufab1
70316
NDUFAB1
4706
−1.83
fatty acid
Metabolism
CS








biosynthetic

score,








process

function



Nol10
217431
NOL10
79954
−1.79
poly(A) RNA
Metabolism
CS








binding

score,










function



Nop9
67842
NOP9
161424
−1.44
biological_
Metabolism
CS








process

score,










function



Nrde2
217827
NRDE2
55051
−2.69
biological_
Metabolism
CS








process

score,










function



Nsf
18195
NSF
4905
−2.76
intra-Golgi
Metabolism
CS








vesicle-

score,








mediated

function








transport





Nubp1
26425
NUBP1
4682
−2.05
cellular iron
Metabolism
CS








ion

score,








homeostasis

function



Nudcd3
209586
NUDCD3
23386
−1.71
molecular_
Metabolism
CS








function

score,










function



Nup155
170762
NUP155
9631
−1.59
nucleocytoplas-
Metabolism
CS
Zhang X,







mic transport

score,
et al. Cell.









mouse
2008 Dec.









K.O.,
12; 135(6):









function
1017-27


Nup93
71805
NUP93
9688
−2.11
protein import
Metabolism
CS








into nucleus

score,










function



Nus1
52014
NUS1
116150
−1.94
angiogenesis
Metabolism
CS
Park EJ,









score,
et al. Cell









mouse
Metab.









K.O.,
2014 Sep.









function
2; 20(3):44










8-57


Nvl
67459
NVL
4931
−2.61
positive
Metabolism
CS








regulation of

score,








telomerase

function








activity





Ogdh
18293
OGDH
4967
−2.98
tricarboxylic
Metabolism
CS








acid cycle

score,










function



Osbp
76303
OSBP
5007
−2.06
lipid transport
Metabolism
CS










score,










function



Pak1ip1
68083
PAK1IP1
55003
−2.28
cell
Metabolism
CS








proliferation

score,










function



Pfdn2
18637
PFDN2
5202
−1.32
protein folding
Metabolism
CS










score,










function



Pgam1
18648
PGAM1
5223
−2.37
glycolytic
Metabolism
CS








process

score,










function



Pkm
18746
PKM
5315
−1.68
glycolytic
Metabolism
CS
Lewis SE,







process

score,
et al.









mouse
1983:267-









K.O.,
78.









function
Plenum










Publ.










Corp.


Pmpcb
73078
PMPCB
9512
−1.77
proteolysis
Metabolism
CS










score,










function



Ppil2
66053
PPIL2
23759
−3.01
protein
Metabolism
CS








polyubiquitina-

score,








tion

function



Ppp4c
56420
PPP4C
5531
−2.89
protein
Metabolism
CS
Toyo-oka







dephosphoryla-

score,
K, et al. J







tion

mouse
Cell Biol.









K.O.,
2008 Mar.









function
24; 180(6):










1133-47


Prelid1
66494
PRELID1
27166
−2.27
apoptotic
Metabolism
CS








process

score,










function



Prpf31
68988
PRPF31
26121
−3.20
spliceosomal
Metabolism
CS
Bujakowska







tri-snRNP

score,
K, et al.







complex

mouse
Invest







assembly

K.O.,
Ophthalmol









function
Vis Sci.










2009










December; 50(12):










5927-33


Prpf6
68879
PRPF6
24148
−2.96
spliceosomal
Metabolism
CS








tri-snRNP

score,








complex

function








assembly





Psma1
26440
PSMA1
5682
−2.39
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psma2
19166
PSMA2
5683
−2.23
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psma3
19167
PSMA3
5684
−2.30
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psmb2
26445
PSMB2
5690
−2.12
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psmb3
26446
PSMB3
5691
−2.78
proteolysis
Metabolism
CS








involved in

score,








cellular

function








protein










catabolic










process





Psmb5
19173
PSMB5
5693
−1.67
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psmb6
19175
PSMB6
5694
−2.42
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psmb7
19177
PSMB7
5695
−2.69
proteasomal
Metabolism
CS








ubiquitin-

score,








independent

function








protein










catabolic










process





Psmc2
19181
PSMC2
5701
−2.35
protein
Metabolism
CS








catabolic

score,








process

function



Psmc3
19182
PSMC3
5702
−2.76
ER-
Metabolism
CS
Sakao Y,







associated

score,
et al.







ubiquitin-

mouse
Genomics.







dependent

K.O.,
2000 Jul.







protein

function
1; 67(1):1-







catabolic


7







process





Psmc4
23996
PSMC4
5704
−2.36
blastocyst
Metabolism
CS
Sakao Y,







development

score,
et al.









mouse
Genomics.









K.O.,
2000 Jul.









function
1; 67(1):1-










7


Psmd1
70247
PSMD1
5707
−1.88
regulation of
Metabolism
CS








protein

score,








catabolic

function








process





Psmd2
21762
PSMD2
5708
−2.16
regulation of
Metabolism
CS








protein

score,








catabolic

function








process





Psmd3
22123
PSMD3
5709
−2.10
regulation of
Metabolism
CS








protein

score,








catabolic

function








process





Psmd4
19185
PSMD4
5710
−1.77
ubiquitin-
Metabolism
CS
Soriano P,







dependent

score,
et al.







protein

mouse
Genes







catabolic

K.O.,
Dev. 1987







process

function
June; 1(4):3










66-75


Psmd6
66413
PSMD6
9861
−2.27
proteasome-
Metabolism
CS








mediated

score,








ubiquitin-

function








dependent










protein










catabolic










process





Psmg3
66506
PSMG3
84262
−2.57
molecular_
Metabolism
CS








function

score,










function



Ptpmt1
66461
PTPMT1
114971
−2.89
protein
Metabolism
CS
Shen J, et







dephosphoryl

score,
al. Mol







ation

mouse
Cell Biol.









K.O.,
2011









function
December; 31(24):










4902-16


Ptpn23
104831
PTPN23
25930
−1.59
negative
Metabolism
CS
Gingras







regulation of

score,
MC, et al.







epithelial cell

mouse
Int J Dev







migration

K.O.,
Biol.









function
2009; 53(7):










1069-74


Rabggta
56187
RABGGTA
5875
−3.18
protein
Metabolism
CS








prenylation

score,










function



Rabggtb
19352
RABGGTB
5876
−2.44
protein
Metabolism
CS








geranyl-

score,








geranylation

function



Rbm19
74111
RBM19
9904
−2.03
multicellular
Metabolism
CS
Zhang J,







organismal

score,
et al. BMC







development

mouse
Dev Biol.









K.O.,
2008; 8:11









function
5


Rfk
54391
RFK
55312
−1.56
riboflavin
Metabolism
CS
Yazdanpanah







biosynthetic

score,
B, et







process

mouse
al. Nature.









K.O.,
2009 Aug.









function
27; 460(72










59):1159-










63


Rheb
19744
RHEB
6009
−1.38
signal
Metabolism
CS
Zou J, et







transduction

score,
al. Dev









mouse
Cell. 2011









K.O.,
Jan.









function
18; 20(1):9










7-108


Riok1
71340
RIOK1
83732
−1.27
protein
Metabolism
CS








phosphorylation

score,










function



Rpn1
103963
RPN1
6184
−2.13
protein
Metabolism
CS








glycosylation

score,










function



Rtfdc1
66404
RTFDC1
51507
−2.09
biological_
Metabolism
CS








process

score,










function



Sacm1l
83493
SACM1L
22908
−1.80
protein
Metabolism
CS








dephosphoryla-

score,








tion

function



Samm50
68653
SAMM50
25813
−1.62
protein
Metabolism
CS








targeting to

score,








mitochondrion

function



Sco2
100126824
SCO2
9997
−1.60
eye
Metabolism
CS
Yang H, et







development

score,
al. Hum









mouse
Mol









K.O.,
Genet.









function
2010 Jan.










1; 19(1):17










0-80


Sdha
66945
SDHA
6389
−2.20
tricarboxylic
Metabolism
CS








acid cycle

score,










function



Sdhb
67680
SDHB
6390
−2.33
tricarboxylic
Metabolism
CS








acid cycle

score,










function



Sec61a1
53421
SEC61A1
29927
−2.42
protein
Metabolism
CS








transport

score,










function



Slc20a1
20515
SLC20A1
6574
−2.38
sodium ion
Metabolism
CS
Festing







transport

score,
MH, et al.









mouse
Genesis.









K.O.,
2009









function
December;










47(12):858-63


Slc7a6os
66432
SLC7A6OS
84138
−2.30
hematopoietic
Metabolism
CS








progenitor cell

score,








differentiation

function



Smn1
20595
SMN1
6606
−1.58
spliceosomal
Metabolism
CS
Hsieh-Li







complex

score,
HM, et al.







assembly

mouse
Nat









K.O.,
Genet.









function
2000










January; 24(1):










66-70


Smu1
74255
SMU1
55234
−3.65
molecular_
Metabolism
CS








function

score,










function



Snrpd1
20641
SNRPD1
6632
−2.79
spliceosomal
Metabolism
CS








complex

score,








assembly

function



Snrpd3
67332
SNRPD3
6634
−3.62
spliceosomal
Metabolism
CS








complex

score,








assembly

function



Snrpe
20643
SNRPE
6635
−2.74
spliceosomal
Metabolism
CS








complex

score,








assembly

function



Spata5
57815
SPATA5
166378
−1.50
multicellular
Metabolism
CS








organismal

score,








development

function



Spata5l1
214616
SPATA5L1
79029
−2.70
molecular_
Metabolism
CS








function

score,










function



Tango6
272538
TANGO6
79613
−2.29
integral
Metabolism
CS








component of

score,








membrane

function



n/a
n/a
TBC1D3B
414059
−1.67
positive
Metabolism
CS








regulation of

score,








GTPase

function








activity





n/a
n/a
TBC1D3C
414060
−2.01
positive
Metabolism
CS








regulation of

score,








GTPase

function








activity





Tbcb
66411
TBCB
1155
−1.97
nervous
Metabolism
CS








system

score,








development

function



Tbcc
72726
TBCC
6903
−3.02
cell
Metabolism
CS








morphogenesis

score,










function



Tbcd
108903
TBCD
6904
−1.82
microtubule
Metabolism
CS








cytoskeleton

score,








organization

function



Tcp1
21454
TCP1
6950
−2.34
protein folding
Metabolism
CS










score,










function



Telo2
71718
TELO2
9894
−2.34
regulation of
Metabolism
CS
Takai H,







TOR

score,
et al. Cell.







signaling

mouse
2007 Dec.









K.O.,
28; 131(7):









function
1248-59


Tex10
269536
TEX10
54881
−1.26
integral
Metabolism
CS








component of

score,








membrane

function



Tfrc
22042
TFRC
7037
−3.40
cellular iron
Metabolism
CS
Levy JE,







ion

score,
et al. Nat







homeostasis

mouse
Genet.









K.O.,
1999









function
April; 21(4):










396-9


Timm10
30059
TIMM10
26519
−1.99
protein
Metabolism
CS








targeting to

score,








mitochondrion

function



Timm13
30055
TIMM13
26517
−1.62
protein
Metabolism
CS








targeting to

score,








mitochondrion

function



Timm23
53600
TIMM23
100287932
−2.00
protein
Metabolism
CS
Ahting U,







targeting to

score,
et al.







mitochondrion

mouse
Biochim









K.O.,
Biophys









function
Acta. 2009










May;










1787(5):371-6


Timm44
21856
TIMM44
10469
−1.73
protein import
Metabolism
CS








into

score,








mitochondrial

function








matrix





Tmx2
66958
TMX2
51075
−2.29
biological_
Metabolism
CS








process

score,










function



Tnpo3
320938
TNPO3
23534
−1.82
splicing factor
Metabolism
CS








protein import

score,








into nucleus

function



Trmt112
67674
TRMT112
51504
−3.70
peptidyl-
Metabolism
CS








glutamine

score,








methylation

function



Trnau1ap
71787
TRNAU1AP
54952
−1.40
selenocysteine
Metabolism
CS








incorporation

score,










function



Ttc1
66827
TTC1
7265
−1.74
protein folding
Metabolism
CS










score,










function



Ttc27
74196
TTC27
55622
−2.54
biological_
Metabolism
CS








process

score,










function



Tti1
75425
TTI1
9675
−2.91
regulation of
Metabolism
CS








TOR

score,








signaling

function



Tti2
234138
TTI2
80185
−1.94
molecular_
Metabolism
CS








function

score,










function



n/a
n/a
TUBB
203068
−3.40
microtubule-
Metabolism
CS








based

score,








process

function



Txn2
56551
TXN2
25828
−1.41
sulfate
Metabolism
CS
Nonn L, et







assimilation

score,
al. Mol









mouse
Cell Biol.









K.O.,
2003









function
February; 23(3):










916-22


Uqcrc1
22273
UQCRC1
7384
−1.29
oxidative
Metabolism
CS








phosphorylation

score,










function



Uqcrh
66576
UQCRH
7388
−1.28
oxidative
Metabolism
CS








phosphorylation

score,










function



Urb2
382038
URB2
9816
−2.25
molecular_
Metabolism
CS








function

score,










function



Vmp1
75909
VMP1
81671
−1.75
exocytosis
Metabolism
CS










score,










function



n/a
n/a
VPS28
51160
−3.06
protein
Metabolism
CS








targeting to

score,








vacuole

function








involved in










ubiquitin-










dependent










protein










catabolic










process via










the










multivesicular










body sorting










pathway





Vps29
56433
VPS29
51699
−2.05
intracellular
Metabolism
CS








protein

score,








transport

function



Vps52
224705
VPS52
6293
−1.85
ectodermal
Metabolism
CS
Sugimoto







cell

score,
M, et al.







differentiation

mouse
Cell Rep.









K.O.,
2012 Nov.









function
29; 2(5):13










63-74


Wars2
70560
WARS2
10352
−1.16
vasculogenesis
Metabolism
CS










score,










function



Wdr7
104082
WDR7
23335
−1.47
hematopoietic
Metabolism
CS








progenitor cell

score,








differentiation

function



Wdr70
545085
WDR70
55100
−1.69
enzyme
Metabolism
CS








binding

score,










function



Wdr74
107071
WDR74
54663
−2.84
blastocyst
Metabolism
CS








formation

score,










function



Wdr77
70465
WDR77
79084
−2.19
spliceosomal
Metabolism
CS
Zhou L, et







snRNP

score,
al. J Mol







assembly

mouse
Endocrinol.









K.O.,
2006









function
October; 37(2):










283-300


Yae1d1
67008
YAE1D1
57002
−1.71
molecular_
Metabolism
CS








function

score,










function



Yrdc
230734
YRDC
79693
−2.33
negative
Metabolism
CS








regulation of

score,








transport

function



Znhit2
29805
ZNHIT2
741
−2.70
metal ion
Metabolism
CS








binding

score,










function



Aars
234734
AARS
16
−2.48
alanyl-tRNA
RNA
CS








aminoacylation
transcription,
score,









protein
function









translation




Bms1
213895
BMS1
9790
−1.36
ribosome
RNA
CS








assembly
transcription,
score,









protein
function









translation




Bud31
231889
BUD31
8896
−2.46
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Bysl
53414
BYSL
705
−2.24
maturation of
RNA
CS
Aoki R, et







SSU-rRNA
transcription,
score,
al. FEBS







from
protein
mouse
Lett. 2006







tricistronic
translation
K.O.,
Nov.







rRNA

function
13; 580(26):







transcript


6062-8







(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Cars
27267
CARS
833
−2.45
tRNA
RNA









aminoacylation
transcription,
CS








for protein
protein
score,








translation
translation
function



Cdc5l
71702
CDC5L
988
−2.09
mRNA
RNA









splicing, via
transcription,
CS








spliceosome
protein
score,









translation
function



Cdc73
214498
CDC73
79577
−2.58
negative
RNA
CS
Wang P,







regulation of
transcription,
score,
et al. Mol







transcription
protein
mouse
Cell Biol.







from RNA
translation
K.O.,
2008







polymerase II

function
May; 28(9):







promoter


2930-40


Cebpz
12607
CEBPZ
10153
−2.11
transcription
RNA
CS








from RNA
transcription,
score,








polymerase II
protein
function








promoter
translation




Clasrp
53609
CLASRP
11129
−1.30
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Clp1
98985
CLP1
10978
−3.47
mRNA
RNA
CS
Hanada T,







splicing, via
transcription,
score,
et al.







spliceosome
protein
mouse
Nature.








translation
K.O.,
2013 Mar.









function
28; 495(74










42):474-










80


Cox5b
12859
COX5B
1329
−1.50
transcription
RNA
CS








initiation from
transcription,
score,








RNA
protein
function








polymerase II
translation









promoter





Cpsf1
94230
CPSF1
29894
−2.58
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Cpsf2
51786
CPSF2
53981
−2.55
mRNA
RNA









polyadenylation
transcription,
CS









protein
score,









translation
function



Cpsf3l
71957
CPSF3L
54973
−2.09
snRNA
RNA









processing
transcription,
CS









protein
score,









translation
function



Dars
226414
DARS
1615
−2.90
translation
RNA
CS









transcription,
score,









protein
function









translation




Dbr1
83703
DBR1
51163
−3.75
RNA splicing,
RNA
CS








via
transcription,
score,








transesterifica
protein
function








tion reactions
translation




Ddx18
66942
DDX18
8886
−2.33
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx23
74351
DDX23
9416
−3.01
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx24
27225
DDX24
57062
−1.40
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx41
72935
DDX41
51428
−1.74
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx46
212880
DDX46
9879
−2.79
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Ddx47
67755
DDX47
51202
−2.20
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx49
234374
DDX49
54555
−3.20
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx54
71990
DDX54
79039
−2.94
RNA
RNA
CS








secondary
transcription,
score,








structure
protein
function








unwinding
translation




Ddx56
52513
DDX56
54606
−2.85
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Dgcr14
27886
DGCR14
8220
−1.76
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Dhx15
13204
DHX15
1665
−2.58
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Dhx16
69192
DHX16
8449
−1.35
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Dhx38
64340
DHX38
9785
−1.76
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Diexf
215193
DIEXF
27042
−2.03
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Dimt1
66254
DIMT1
27292
−1.87
rRNA
RNA
CS








methylation
transcription,
score,









protein
function









translation




Dis3
72662
DIS3
22894
−1.77
mRNA
RNA









catabolic
transcription,
CS








process
protein
score,









translation
function



Dkc1
245474
DKC1
1736
−2.37
box H/ACA
RNA
CS
He J, et al.







snoRNA 3′-
transcription,
score,
Oncogene.







end
protein
mouse
2002 Oct.







processing
translation
K.O.,
31; 21(50):









function
7740-4


Dnajc17
69408
DNAJC17
55192
−2.25
negative
RNA

Amendola







regulation of
transcription,
CS
E, et al.







transcription
protein
score,
Endocrinology.







from RNA
translation
mouse
2010







polymerase II

K.O.,
April; 151(4):







promoter

function
1948-58


Ears2
67417
EARS2
124454
−1.91
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Ebna1bp2
69072
EBNA1BP2
10969
−1.52
ribosome
RNA
CS








biogenesis
transcription,
score,









protein
function









translation




Eef1a1
13627
EEF1A1
1915
−3.11
translational
RNA
CS








elongation
transcription,
score,









protein
function









translation




Eef1g
67160
EEF1G
1937
−1.42
translation
RNA
CS









transcription,
score,









protein
function









translation




Eef2
13629
EEF2
1938
−3.53
translation
RNA
CS









transcription,
score,









protein
function









translation




Eftud2
20624
EFTUD2
9343
−3.79
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Eif1ad
69860
EIF1AD
84285
−2.26
translational
RNA
CS








initiation
transcription,
score,









protein
function









translation




Eif2b1
209354
EIF2B1
1967
−2.23
regulation of
RNA
CS








translational
transcription,
score,








initiation
protein
function









translation




Eif2b3
108067
EIF2B3
8891
−3.00
translational
RNA
CS








initiation
transcription,
score,









protein
function









translation




Eif2s1
13665
EIF2S1
1965
−3.93
translation
RNA
CS









transcription,
score,









protein
function









translation




Eif3c
56347
EIF3C
8663
−2.59
formation of
RNA
CS








translation
transcription,
score,








preinitiation
protein
function








complex
translation




n/a
n/a
EIF3CL
728689
−2.71
formation of
RNA
CS








translation
transcription,
score,








preinitiation
protein
function








complex
translation




Eif3d
55944
EIF3D
8664
−3.23
formation of
RNA
CS








translation
transcription,
score,








preinitiation
protein
function








complex
translation




Eif3f
66085
EIF3F
8665
−1.44
formation of
RNA
CS








translation
transcription,
score,








preinitiation
protein
function








complex
translation




Eif3g
53356
EIF3G
8666
−3.10
translational
RNA
CS








initiation
transcription,
score,









protein
function









translation




Eif3i
54709
EIF3I
8668
−2.24
formation of
RNA
CS








translation
transcription,
score,








preinitiation
protein
function








complex
translation




Eif3l
223691
EIF3L
51386
−1.28
translational
RNA
CS








initiation
transcription,
score,









protein
function









translation




Eif4a1
13681
EIF4A1
1973
−1.97
translational
RNA
CS








initiation
transcription,
score,









protein
function









translation




Eif4a3
192170
EIF4A3
9775
−4.32
RNA splicing
RNA
CS









transcription,
score,









protein
function









translation




Eif4g1
208643
EIF4G1
1981
−1.79
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Eif5b
226982
EIF5B
9669
−2.93
translational
RNA
CS








initiation
transcription,
score,









protein
function









translation




Eif6
16418
EIF6
3692
−2.75
mature
RNA
CS
Gandin V,







ribosome
transcription,
score,
et al.







assembly
protein
mouse
Nature.








translation
K.O.,
2008 Oct.









function
2; 455(7213):










684-8


Elac2
68626
ELAC2
60528
−2.06
tRNA 3′-trailer
RNA
CS








cleavage,
transcription,
score,








endonucleolytic
protein
function









translation




Ell
13716
ELL
8178
−2.23
transcription
RNA
CS
Mitani K,







elongation
transcription,
score,
et al.







from RNA
protein
mouse
Biochem







polymerase II
translation
K.O.,
Biophys







promoter

function
Res










Commun.










2000 Dec.










20; 279(2):










563-7


Etf1
225363
ETF1
2107
−2.44
translational
RNA
CS








termination
transcription,
score,









protein
function









translation




Exosc2
227715
EXOSC2
23404
−1.66
exonucleolytic
RNA
CS








trimming to
transcription,
score,








generate
protein
function








mature 3′-end
translation









of 5.8S rRNA










from










tricistronic










rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Exosc4
109075
EXOSC4
54512
−3.21
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Exosc5
27998
EXOSC5
56915
−2.09
rRNA
RNA
CS








catabolic
transcription,
score,








process
protein
function









translation




n/a
n/a
EXOSC6
118460
−3.20
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Exosc7
66446
EXOSC7
23016
−2.17
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Exosc8
69639
EXOSC8
11340
−2.08
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Fars2
69955
FARS2
10667
−1.90
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Farsa
66590
FARSA
2193
−3.30
phenylalanyl-
RNA
CS








tRNA
transcription,
score,








aminoacylation
protein
function









translation




Farsb
23874
FARSB
10056
−2.49
phenylalanyl-
RNA
CS








tRNA
transcription,
score,








aminoacylation
protein
function









translation




Fau
14109
FAU
2197
−2.64
translation
RNA
CS









transcription,
score,









protein
function









translation




Fip1l1
66899
FIP1L1
81608
−1.93
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Ftsj3
56095
FTSJ3
117246
−1.50
rRNA
RNA
CS








methylation
transcription,
score,









protein
function









translation




Gle1
74412
GLE1
2733
−1.89
mRNA export
RNA
CS








from nucleus
transcription,
score,









protein
function









translation




Gnl3l
237107
GNL3L
54552
−1.35
ribosome
RNA
CS








biogenesis
transcription,
score,









protein
function









translation




Gtf2e1
74197
GTF2E1
2960
−1.22
transcriptional
RNA
CS








open complex
transcription,
score,








formation at
protein
function








RNA
translation









polymerase II










promoter





Gtpbp4
69237
GTPBP4
23560
−2.25
ribosome
RNA
CS








biogenesis
transcription,
score,









protein
function









translation




Hars
15115
HARS
3035
−3.49
histidyl-tRNA
RNA
CS








aminoacylation
transcription,
score,









protein
function









translation




Hars2
70791
HARS2
23438
−1.92
histidyl-tRNA
RNA
CS








aminoacylation
transcription,
score,









protein
function









translation




Heatr1
217995
HEATR1
55127
−2.58
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Hnrnpc
15381
HNRNPC
3183
−1.95
mRNA
RNA
CS
Williamson







splicing, via
transcription,
score,
DJ, et al.







spliceosome
protein
mouse
Mol Cell








translation
K.O.,
Biol. 2000









function
June; 20(11):










4094-105


Hnrnpk
15387
HNRNPK
3190
−2.39
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Hnrnpl
15388
HNRNPL
3191
−1.88
mRNA
RNA
CS
Gaudreau







processing
transcription,
score,
MC, et al.








protein
mouse
J








translation
K.O.,
Immunol.









function
2012 Jun.










1; 188(11):










5377-88


Hnrnpu
51810
HNRNPU
3192
−2.44
mRNA
RNA
CS
Roshon







splicing, via
transcription,
score,
MJ, et al.







spliceosome
protein
mouse
Transgenic








translation
K.O.,
Res.









function
2005










April; 14(2):










179-92


lars
105148
IARS
3376
−3.87
isoleucyl-
RNA
CS








tRNA
transcription,
score,








aminoacylation
protein
function









translation




lars2
381314
IARS2
55699
−2.83
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Imp3
102462
IMP3
55272
−3.46
rRNA
RNA









processing
transcription,
CS









protein
score,









translation
function



Imp4
27993
IMP4
92856
−2.01
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Ints1
68510
INTS1
26173
−1.93
snRNA
RNA
CS
Nakayama







processing
transcription,
score,
M, et al.








protein
mouse
FASEB J.








translation
K.O.,
2006









function
August; 20(10):










1718-20


Ints4
101861
INTS4
92105
−1.75
snRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Ints5
109077
INTS5
80789
−2.10
snRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Ints8
72656
INTS8
55656
−1.35
snRNA
RNA









processing
transcription,
CS









protein
score,









translation
function



Ints9
210925
INTS9
55756
−2.26
snRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Isg20l2
229504
ISG20L2
81875
−2.27
ribosome
RNA
CS








biogenesis
transcription,
score,









protein
function









translation




Kars
85305
KARS
3735
−2.76
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




n/a
n/a
KIAA0391
9692
−1.56
tRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Lars
107045
LARS
51520
−1.83
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Lars2
102436
LARS2
23395
−1.60
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Las1l
76130
LAS1L
81887
−2.12
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Lrpprc
72416
LRPPRC
10128
−1.39
negative
RNA
CS
Ruzzenente







regulation of
transcription,
score,
B, et al.







mitochondrial
protein
mouse
EMBO J.







RNA
translation
K.O.,
2012 Jan.







catabolic

function
18; 31(2):4







process


43-56


Lsm2
27756
LSM2
57819
−2.96
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Lsm3
67678
LSM3
27258
−1.66
nuclear-
RNA
CS








transcribed
transcription,
score








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Lsm7
66094
LSM7
51690
−1.96
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Magoh
17149
MAGOH
4116
−1.78
nuclear-
RNA
CS
Silver DL,







transcribed
transcription,
score,
et al. Nat







mRNA
protein
mouse
Neurosci.







catabolic
translation
K.O.,
2010







process,

function
May; 13(5):







nonsense-


551-8







mediated










decay





Mars
216443
MARS
4141
−3.24
methionyl-
RNA
CS








tRNA
transcription,
score,








aminoacylation
protein
function









translation




Mars2
212679
MARS2
92935
−2.31
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Med17
234959
MED17
9440
−1.78
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Med20
56771
MED20
9477
−2.00
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Med22
20933
MED22
6837
−1.86
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Med27
68975
MED27
9442
−1.48
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Med30
69790
MED30
90390
−2.21
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase Il
translation









promoter





Med8
80509
MED8
112950
−1.64
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Mepce
231803
MEPCE
56257
−2.08
negative
RNA
CS








regulation of
transcription,
score,








transcription
protein
function








from RNA
translation









polymerase II










promoter





Mettl16
67493
METTL16
79066
−2.10
rRNA base
RNA
CS








methylation
transcription,
score,









protein
function









translation




Mphosph
67973
MPHOSP
10199
−1.85
RNA splicing,
RNA
CS



10

H10


via
transcription,
score,








transesterifica-
protein
function








tion reactions
translation




Mrpl10
107732
MRPL10
124995
−1.38
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl12
56282
MRPL12
6182
−1.56
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl21
353242
MRPL21
219927
−1.91
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl28
68611
MRPL28
10573
−1.50
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl3
94062
MRPL3
11222
−1.58
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl34
94065
MRPL34
64981
−1.66
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl4
66163
MRPL4
51073
−2.41
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl41
107733
MRPL41
64975
−2.15
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrpl51
66493
MRPL51
51258
−1.40
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps14
64659
MRPS14
63931
−1.82
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps15
66407
MRPS15
64960
−1.28
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps16
66242
MRPS16
51021
−2.29
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps18a
68565
MRPS18A
55168
−1.55
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps2
118451
MRPS2
51116
−1.59
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps21
66292
MRPS21
54460
−1.51
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps24
64660
MRPS24
64951
−1.71
translation
RNA
CS









transcription,
score,









protein
function









translation




Mrps6
121022
MRPS6
64968
−1.65
translation
RNA
CS









transcription,
score,









protein
function









translation




Nars
70223
NARS
4677
−3.31
tRNA
RNA









aminoacylation
transcription,
CS








for protein
protein
score,








translation
translation
function



Nars2
244141
NARS2
79731
−1.32
tRNA
RNA









aminoacylation
transcription,
CS








for protein
protein
score,








translation
translation
function



Ncbp2
68092
NCBP2
22916
−3.00
mRNA cis
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Nedd8
18002
NEDD8
4738
−2.45
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Ngdn
68966
NGDN
25983
−2.35
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Nhp2
52530
NHP2
55651
−1.74
rRNA
RNA
CS








pseudouridine
transcription,
score,








synthesis
protein
function









translation




Nip7
66164
NIP7
51388
−2.03
ribosome
RNA
CS








assembly
transcription,
score,









protein
function









translation




Noc2l
57741
NOC2L
26155
−2.34
negative
RNA
CS








regulation of
transcription,
score,








transcription
protein
function








from RNA
translation









polymerase I










promoter





Noc4l
100608
NOC4L
79050
−2.11
ribosome
RNA
CS








biogenesis
transcription,
score,









protein
function









translation




Nol6
230082
NOL6
65083
−2.28
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Nol9
74035
NOL9
79707
−2.20
cleavage in
RNA
CS








ITS2 between
transcription,
score,








5.8S rRNA
protein
function








and LSU-
translation









rRNA of










tricistronic










rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Nop16
28126
NOP16
51491
−2.10
ribosomal
RNA
CS








large subunit
transcription,
score,








biogenesis
protein
function









translation




Nop2
110109
NOP2
4839
−2.14
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Nop58
55989
NOP58
51602
−2.54
rRNA
RNA
CS








modification
transcription,
score,









protein
function









translation




Nsa2
59050
NSA2
10412
−1.78
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Nudt21
68219
NUDT21
11051
−2.36
mRNA
RNA
CS








polyadenylation
transcription,
score,









protein
function









translation




Osgep
66246
OSGEP
55644
−1.98
tRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Pabpn1
54196
PABPN1
8106
−1.92
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Pdcd11
18572
PDCD11
22984
−1.47
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Pes1
64934
PES1
23481
−2.92
maturation of
RNA
CS
Lerch-







LSU-rRNA
transcription,
score,
Gaggl A,







from
protein
mouse
et al. J







tricistronic
translation
K.O.,
Biol







rRNA

function
Chem.







transcript


2002 Nov.







(SSU-rRNA,


22; 277(47):







5.8S rRNA,


45347-







LSU-rRNA)


55


Phb
18673
PHB
5245
−2.26
regulation of
RNA
CS
He B, et







transcription
transcription,
score,
al.







from RNA
protein
mouse
Endocrinology.







polymerase II
translation
K.O.,
2011







promoter

function
March; 152(3):










1047-56


Phf5a
68479
PHF5A
84844
−3.52
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Pnn
18949
PNN
5411
−1.34
mRNA
RNA
CS
Joo JH, et







splicing, via
transcription,
score,
al. Dev







spliceosome
protein
mouse
Dyn. 2007








translation
K.O.,
August; 236(8):









function
2147-58


Polr1b
20017
POLR1B
84172
−3.23
transcription
RNA
CS
Chen H, et







from RNA
transcription,
score,
al.







polymerase I
protein
mouse
Biochem







promoter
translation
K.O.,
Biophys









function
Res










Commun.










2008 Jan.










25; 365(4):










636-42


Polr1c
20016
POLR1C
9533
−2.79
transcription
RNA
CS








from RNA
transcription,
score,








polymerase I
protein
function








promoter
translation




Polr2a
20020
POLR2A
5430
−3.15
transcription
RNA
CS








from RNA
transcription,
score,








polymerase II
protein
function








promoter
translation




Polr2b
231329
POLR2B
5431
−3.09
transcription
RNA
CS








from RNA
transcription,
score,








polymerase II
protein
function








promoter
translation




Polr2c
20021
POLR2C
5432
−3.15
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Polr2d
69241
POLR2D
5433
−2.23
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










deadenylation-










dependent










decay





Polr2f
69833
POLR2F
5435
−2.31
transcription
RNA
CS








from RNA
transcription,
score,








polymerase I
protein
function








promoter
translation




Polr2g
67710
POLR2G
5436
−2.78
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










exonucleolytic





Polr2h
245841
POLR2H
5437
−1.83
transcription
RNA
CS








from RNA
transcription,
score,










function








polymerase I
protein









promoter
translation




Polr2i
69920
POLR2I
5438
−2.92
maintenance
RNA
CS








of
transcription,
score,








transcriptional
protein
function








fidelity during
translation









DNA-










templated










transcription










elongation










from RNA










polymerase II










promoter





Polr2j
20022
POLR2J
5439
−3.31
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Polr2l
66491
POLR2L
5441
−3.55
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Polr3e
26939
POLR3E
55718
−2.33
transcription
RNA
CS








from RNA
transcription,
score,








polymerase III
protein
function








promoter
translation




Pop1
67724
POP1
10940
−1.79
tRNA 5′-
RNA
CS








leader
transcription,
score,








removal
protein
function









translation




Pop4
66161
POP4
10775
−1.87
RNA
RNA
CS








phosphodiest
transcription,
score,








er bond
protein
function








hydrolysis
translation




Ppa1
67895
PPA1
5464
−1.63
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Ppan
235036
PPAN
56342
−1.62
ribosomal
RNA
CS








large subunit
transcription,
score,








assembly
protein
function









translation




Ppp2ca
19052
PPP2CA
5515
−3.01
nuclear-
RNA
CS
Gu P, et







transcribed
transcription,
score,
al.







mRNA
protein
mouse
Genesis.







catabolic
translation
K.O.,
2012







process,

function
May; 50(5):







nonsense-


429-36







mediated










decay





Prim1
19075
PRIM1
5557
−2.07
DNA
RNA









replication,
transcription,
CS








synthesis of
protein
score,








RNA primer
translation
function



Prpf38b
66921
PRPF38B
55119
−2.68
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Prpf4
70052
PRPF4
9128
−2.24
RNA splicing
RNA
CS









transcription,
score,









protein
function









translation




Prpf8
192159
PRPF8
10594
−3.43
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Ptcd1
71799
PTCD1
26024
−1.77
tRNA 3′-end
RNA
CS








processing
transcription,
score,









protein
function









translation




Pwp2
110816
PWP2
5822
−2.52
ribosomal
RNA
CS








small subunit
transcription,
score,








assembly
protein
function









translation




Qars
97541
QARS
5859
−3.35
tRNA
RNA
CS








aminoacylation
transcription,
score,










function








for protein
protein









translation
translation




Ran
19384
RAN
5901
−3.09
ribosomal
RNA
CS








large subunit
transcription,
score,








export from
protein
function








nucleus
translation




Rars
104458
RARS
5917
−2.30
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Rars2
109093
RARS2
57038
−1.93
arginyl-tRNA
RNA
CS








aminoacylation
transcription,
score,









protein
function









translation




Rbm25
67039
RBM25
58517
−2.15
regulation of
RNA
CS








alternative
transcription,
score,








mRNA
protein
function








splicing, via
translation









spliceosome





Rbm8a
60365
RBM8A
9939
−2.97
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rbmx
19655
RBMX
27316
−1.95
regulation of
RNA
CS








alternative
transcription,
score,








mRNA
protein
function








splicing, via
translation









spliceosome





Rcl1
59028
RCL1
10171
−2.08
endonucleolytic
RNA
CS








cleavage of
transcription,
score,








tricistronic
protein
function








rRNA
translation









transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Rngtt
24018
RNGTT
8732
−2.90
transcription
RNA
CS








from RNA
transcription,
score,








polymerase Il
protein
function








promoter
translation




Rnmt
67897
RNMT
8731
−1.45
7-
RNA
CS








methylguanosine
transcription,
score,








mRNA
protein
function








capping
translation




Rnpc3
67225
RNPC3
55599
−1.95
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Rpap1
68925
RPAP1
26015
−2.58
transcription
RNA
CS








from RNA
transcription,
score,








polymerase II
protein
function








promoter
translation




Rpl10
110954
RPL10
6134
−3.76
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl10a
19896
RPL10A
4736
−2.15
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl11
67025
RPL11
6135
−2.99
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl12
269261
RPL12
6136
−2.64
ribosomal
RNA
CS








large subunit
transcription,
score,








assembly
protein
function









translation




Rpl13
270106
RPL13
6137
−3.28
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl14
67115
RPL14
9045
−2.92
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl15
66480
RPL15
6138
−3.50
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl18
19899
RPL18
6141
−3.72
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl18a
76808
RPL18A
6142
−3.37
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl23
65019
RPL23
9349
−3.02
translation
RNA
CS









transcription,
score,









protein
function









translation




n/a
n/a
RPL23A
6147
−4.25
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl24
68193
RPL24
6152
−2.55
ribosomal
RNA
CS
Oliver ER,







large subunit
transcription,
score,
et al.







assembly
protein
mouse
Developm








translation
K.O.,
ent. 2004









function
August;










131(16):3907-










20


Rpl26
19941
RPL26
6154
−2.88
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl27
19942
RPL27
6155
−2.25
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl27a
26451
RPL27A
6157
−2.87
translation
RNA
CS
Terzian T,








transcription,
score,
et al. J








protein
mouse
Pathol.








translation
K.O.,
2011









function
August;










224(4):540-52


Rpl3
27367
RPL3
6122
−3.27
ribosomal
RNA
CS








large subunit
transcription,
score,








assembly
protein
function









translation




Rpl30
19946
RPL30
6156
−2.53
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl31
114641
RPL31
6160
−1.92
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl32
19951
RPL32
6161
−3.70
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





n/a
n/a
RPL34
6164
−2.37
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl35
66489
RPL35
11224
−2.25
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl35a
57808
RPL35A
6165
−3.20
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl36
54217
RPL36
25873
−3.44
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl37
67281
RPL37
6167
−3.02
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl37a
19981
RPL37A
6168
−2.62
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl38
67671
RPL38
6169
−2.57
translation
RNA
CS
MORGAN








transcription,
score,
WC, et al.








protein
mouse
J Hered.








translation
K.O.,
1950









function
August; 41(8):










208-15


Rpl4
67891
RPL4
6124
−2.67
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl5
100503670
RPL5
6125
−3.20
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl6
19988
RPL6
6128
−3.07
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl7
19989
RPL7
6129
−2.15
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpl7a
27176
RPL7A
6130
−3.45
ribosome
RNA
CS









biogenesisn,
score,









protein
function









translation




Rpl7l1
66229
RPL7L1
285855
−1.86
maturation of
RNA
CS








LSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Rpl8
26961
RPL8
6132
−4.00
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpl9
20005
RPL9
6133
−3.57
translation
RNA
CS









transcription,
score,









protein
function









translation




Rplp0
11837
RPLP0
6175
−2.61
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rpp21
67676
RPP21
79897
−2.96
tRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Rpp30
54364
RPP30
10556
−1.79
tRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Rps10
67097
RPS10
6204
−2.88
ribosomal
RNA
CS








small subunit
transcription,
score,








assembly
protein
function









translation




Rps11
27207
RPS11
6205
−2.93
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps12
20042
RPS12
6206
−3.33
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rps13
68052
RPS13
6207
−3.13
translation
RNA
CS









transcription,
score,









protein
function









translation




n/a
n/a
RPS14
6208
−3.18
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps15
20054
RPS15
6209
−3.20
ribosomal
RNA
CS








small subunit
transcription,
score,








assembly
protein
function









translation




Rps15a
267019
RPS15A
6210
−3.18
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps16
20055
RPS16
6217
−2.35
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps17
20068
RPS17
6218
−2.69
ribosomal
RNA
CS








small subunit
transcription,
score,








assembly
protein
function









translation




Rps19
20085
RPS19
6223
−3.49
translation
RNA
CS
Matsson








transcription,
score,
H, et al.








protein
mouse
Mol Cell








translation
K.O.,
Biol. 2004









function
May; 24(9):










4032-7


Rps2
16898
RPS2
6187
−2.50
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps21
66481
RPS21
6227
−1.84
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rps23
66475
RPS23
6228
−2.86
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps25
75617
RPS25
6230
−2.38
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





n/a
n/a
RPS3A
6189
−3.72
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps4x
20102
RPS4X
6191
−3.04
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps5
20103
RPS5
6193
−2.61
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps6
20104
RPS6
6194
−3.31
translation
RNA
CS









transcription,
score,









protein
function









translation




Rps7
20115
RPS7
6201
−2.97
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rps8
20116
RPS8
6202
−3.44
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Rps9
76846
RPS9
6203
−3.16
translation
RNA
CS









transcription,
score,









protein
function









translation




Rpsa
16785
RPSA
3921
−3.06
ribosomal
RNA
CS
Han J, et







small subunit
transcription,
score,
al. MGI







assembly
protein
mouse
Direct








translation
K.O.,
Data









function
Submission.










2008


Rsl24d1
225215
RSL24D1
51187
−2.76
translation
RNA
CS









transcription,
score,









protein
function









translation




Sars
20226
SARS
6301
−2.67
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Sars2
71984
SARS2
54938
−2.25
seryl-tRNA
RNA
CS








aminoacylation
transcription,
score,










function









protein










translation




Sart1
20227
SART1
9092
−2.13
maturation of
RNA
CS








5S rRNA
transcription,
score,









protein
function









translation




Sart3
53890
SART3
9733
−1.88
RNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Sdad1
231452
SDAD1
55153
−1.96
ribosomal
RNA
CS








large subunit
transcription,
score,








export from
protein
function









translation









nucleus





Sf1
22668
SF1
7536
−3.04
mRNA
RNA
CS
Shitashige







splicing, via
transcription,
score,
M, et al.







spliceosome
protein
mouse
Cancer








translation
K.O.,
Sci. 2007









function
December;










98(12):1862-7


Sf3a1
67465
SF3A1
10291
−3.18
mRNA 3′-
RNA
CS








splice site
transcription,
score,








recognition
protein
function









translation




Sf3a2
20222
SF3A2
8175
−2.66
mRNA 3′-
RNA
CS








splice site
transcription,
score,








recognition
protein
function









translation




Sf3a3
75062
SF3A3
10946
−2.26
RNA splicing,
RNA
CS








via
transcription,
score,








transesterifica-
protein
function








tion reactions
translation




Sf3b2
319322
SF3B2
10992
−2.51
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Sf3b3
101943
SF3B3
23450
−4.13
RNA splicing,
RNA
CS








via
transcription,
score,










function








transesterifica-
protein









tion reactions
translation




Sf3b4
107701
SF3B4
10262
−2.60
RNA splicing,
RNA
CS








via
transcription,
score,








transesterifica-
protein
function








tion reactions
translation




Sfpq
71514
SFPQ
6421
−2.27
negative
RNA
CS








regulation of
transcription,
score,








transcription
protein
function








from RNA
translation









polymerase II










promoter





Sin3a
20466
SIN3A
25942
−1.74
negative
RNA
CS
Dannenbe







regulation of
transcription,
score,
rg JH, et







transcription
protein
mouse
al. Genes







from RNA
translation
K.O.,
Dev. 2005







polymerase II

function
Jul.







promoter


1; 19(13):1










581-95


Smg5
229512
SMG5
23381
−2.35
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Smg6
103677
SMG6
23293
−1.18
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










nonsense-










mediated










decay





Snrnp25
78372
SNRNP25
79622
−2.43
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Snrnp27
66618
SNRNP27
11017
−1.36
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Snrpd2
107686
SNRPD2
6633
−2.47
RNA splicing
RNA
CS









transcription,
score,









protein
function









translation




Snrpf
69878
SNRPF
6636
−3.58
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Srrm1
51796
SRRM1
10250
−1.81
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Srsf1
110809
SRSF1
6426
−2.75
mRNA 5′-
RNA
CS
Xu X, et







splice site
transcription,
score,
al. Cell.







recognition
protein
mouse
2005 Jan.








translation
K.O.,
14; 120(1):









function
59-72


Srsf2
20382
SRSF2
6427
−3.66
regulation of
RNA
CS
Ding JH,







alternative
transcription,
score,
et al.







mRNA
protein
mouse
EMBO J.







splicing, via
translation
K.O.,
2004 Feb.







spliceosome

function
25; 23(4):8










85-96


Srsf3
20383
SRSF3
6428
−2.28
mRNA
RNA
CS
Jumaa H,







splicing, via
transcription,
score,
et al. Curr







spliceosome
protein
mouse
Biol. 1999








translation
K.O.,
Aug.









function
26; 9(16):8










99-902


Srsf7
225027
SRSF7
6432
−2.06
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Ssu72
68991
SSU72
29101
−2.57
mRNA
RNA
CS








polyadenylation
transcription,
score,









protein
function









translation




Sugp1
70616
SUGP1
57794
−1.36
RNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Tars
110960
TARS
6897
−2.53
tRNA
RNA









aminoacylation
transcription,
CS








for protein
protein
score,








translation
translation
function



Tars2
71807
TARS2
80222
−1.91
threonyl-tRNA
RNA









aminoacylation
transcription,
CS









protein
score,









translation
function



Tbl3
213773
TBL3
10607
−2.4
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Thoc2
331401
THOC2
57187
−2.52
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Thoc5
107829
THOC5
8563
−1.57
mRNA
RNA
CS
Mancini A,







processing
transcription,
score,
et al. BMC








protein
mouse
Biol.








translation
K.O.,
2010; 8:1









function



Thoc7
66231
THOC7
80145
−2.23
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Timeless
21853
TIMELESS
8914
−2.27
negative
RNA
CS
Gotter AL,







regulation of
transcription,
score,
et al. Nat







transcription
protein
mouse
Neurosci.







from RNA
translation
K.O.,
2000







polymerase II

function
August; 3(8):7







promoter


55-6


Tsen2
381802
TSEN2
80746
−1.41
tRNA-type
RNA
CS








intron splice
transcription,
score,








site
protein
function








recognition
translation









and cleavage





Tsr1
104662
TSR1
55720
−1.76
ribosome
RNA
CS








biogenesis
transcription,
score,









protein
function









translation




Tsr2
69499
TSR2
90121
−2.82
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Tufm
233870
TUFM
7284
−1.92
translational
RNA
CS








elongation
transcription,
score,









protein
function









translation




Tut1
70044
TUT1
64852
−2.65
mRNA
RNA
CS








polyadenylation
transcription,
score,









protein
function









translation




Twistnb
28071
TWISTNB
221830
−2.17
transcription
RNA
CS








from RNA
transcription,
score,








polymerase I
protein
function








promoter
translation




U2af1
108121
U2AF1
7307
−2.41
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




U2af2
22185
U2AF2
11338
−2.80
mRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Uba52
22186
UBA52
7311
−2.54
translation
RNA
CS









transcription,
score,









protein
function









translation




Ubl5
66177
UBL5
59286
−2.56
mRNA
RNA
CS








splicing, via
transcription,
score,








spliceosome
protein
function









translation




Upf1
19704
UPF1
5976
−2.63
nuclear-
RNA
CS
Medghalc







transcribed
transcription,
score,
hi SM, et







mRNA
protein
mouse
al. Hum







catabolic
translation
K.O.,
Mol







process,

function
Genet.







nonsense-


2001 Jan.







mediated


15; 10(2):9







decay


9-105


Upf2
326622
UPF2
26019
−2.16
nuclear-
RNA
CS
Weischenf







transcribed
transcription,
score,
eldt J, et







nRNA
protein
mouse
al. Genes







catabolic
translation
K.O.,
Dev. 2008







process,

function
May







nonsense-


15; 22(10):







mediated


1381-96







decay





Utp15
105372
UTP15
84135
−1.65
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Utp20
70683
UTP20
27340
−2.28
endonucleolytic
RNA
CS








cleavage in
transcription,
score,








ITS1 to
protein
function








separate
translation









SSU-rRNA










from 5.8S










rRNA and










LSU-rRNA










from










tricistronic










rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Utp23
78581
UTP23
84294
−2.54
rRNA
RNA
CS








processing
transcription,
score,









protein
function









translation




Utp3
65961
UTP3
57050
−1.58
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Utp6
216987
UTP6
55813
−1.99
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Vars
22321
VARS
7407
−3.35
tRNA
RNA
CS








aminoacylation
transcription,
score,








for protein
protein
function








translation
translation




Wars
22375
WARS
7453
−2.22
tryptophanyl-
RNA
CS








tRNA
transcription,
score,








aminoacylation
protein
function









translation




Wdr12
57750
WDR12
55759
−2.16
maturation of
RNA
CS








LSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Wdr3
269470
WDR3
10885
−2.65
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Wdr33
74320
WDR33
55339
−2.63
mRNA
RNA
CS








polyadenylation
transcription,
score,









protein
function









translation




Wdr36
225348
WDR36
134430
−2.04
rRNA
RNA
CS
Gallenber







processing
transcription,
score,
ger M, et








protein
mouse
al. Hum








translation
K.O.,
Mol









function
Genet.










2011 Feb.










1; 20(3):42










2-35


Wdr46
57315
WDR46
9277
−2.41
maturation of
RNA
CS








SSU-rRNA
transcription,
score,








from
protein
function








tricistronic
translation









rRNA










transcript










(SSU-rRNA,










5.8S rRNA,










LSU-rRNA)





Wdr61
66317
WDR61
80349
−2.63
nuclear-
RNA
CS








transcribed
transcription,
score,








mRNA
protein
function








catabolic
translation









process,










exonucleolytic,










3′-5′





Wdr75
73674
WDR75
84128
−2.12
regulation of
RNA
CS








transcription
transcription,
score,








from RNA
protein
function








polymerase II
translation









promoter





Xpo1
103573
XPO1
7514
−3.50
ribosomal
RNA
CS








large subunit
transcription,
score,








export from
protein
function








nucleus
translation




Yars
107271
YARS
8565
−2.78
tRNA
RNA









aminoacylation
transcription,
CS








for protein
protein
score,








translation
translation
function



Yars2
70120
YARS2
51067
−2.40
translation
RNA
CS









transcription,
score,









protein
function









translation




Ythdc1
231386
YTHDC1
91746
−2.35
mRNA splice
RNA
CS








site selection
transcription,
score,









protein
function









translation




Zbtb8os
67106
ZBTB8OS
339487
−2.54
tRNA splicing,
RNA
CS








via
transcription,
score,








endonucleolytic
protein
function








cleavage
translation









and ligation





Zc3h3
223642
ZC3H3
23144
−1.22
mRNA
RNA









polyadenylation
transcription,
CS









protein
score,









translation
function









Although the disclosure has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art. Any examples provided herein are included solely for the purpose of illustrating the disclosure and are not intended to limit the disclosure in any way. Any drawings provided herein are solely for the purpose of illustrating various aspects of the disclosure and are not intended to be drawn to scale or to limit the disclosure in any way. The scope of the claims appended hereto should not be limited by the preferred embodiments set forth in the above description, but should be given the broadest interpretation consistent with the present specification as a whole. The disclosures of all prior art recited herein are incorporated herein by reference in their entirety.

Claims
  • 1.-192. (canceled)
  • 193. A cell genetically modified to comprise transgenes comprising: human FASLG, CD200, CCL21, SERPINB9, MFGE8, PD-L1, HLA-G, and CD47; ormurine FasL, Cd200, Ccl21b, Spi6, Mfge8, Pd-l1, H2-M3, and Cd47.
  • 194. The cell of claim 193, wherein the cell is an allogeneic cell in reference to a subject.
  • 195. The cell of claim 193, wherein the cell is a human cell or a murine cell.
  • 196. The cell of claim 193, wherein the cell is a stem cell.
  • 197. The cell of claim 193, where the cell further comprises a heterologous sequence encoding a therapeutic agent.
  • 198. The cell of claim 197, wherein the therapeutic agent comprises a wild-type version of a gene that is mutated within a subject.
  • 199. The cell of claim 197, wherein the therapeutic agent comprises an enzyme, an antibody, a growth factor, or a cytokine.
  • 200. The cell of claim 193, wherein the human FASLG transgene encodes a protein having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 10,the human CD200 transgene encodes a protein having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 6,the human CCL21 transgene encodes a protein having at least 95% sequence identity to the sequence as set forth in SEQ ID NO: 2,the human SERPINB9 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 8,the human MFGE8 transgene encodes a protein having at least 95% identity to sequence as set forth in SEQ ID NO: 14,the human PD-L1 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 12,the human HLA-G transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 16, andthe human CD47 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 4; orthe murine Fasl transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 9,the murine Cd200 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 5,the murine Ccl21b transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 1,the murine Spi6 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 7,the murine Mfge8 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 13,the murine Pd-l1 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 11,the murine H2-M3 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 15, andthe murine Cd47 transgene encodes a protein having at least 95% sequence identity to sequence as set forth in SEQ ID NO: 3.
  • 201. The cell of claim 193, wherein expression of the transgenes is under the control of one or more constitutive promoters.
  • 202. The cell of claim 201, wherein the one or more constitutive promoters comprise a CAG promoter, a cytomegalovirus (CMV) promoter, a human elongation factor-1 alpha (EF1α) promoter, a 3-phosphoglycerate kinase (PGK) promoter, an adenovirus late promoter, a vaccinia virus 7.5K promoter, a Simian Virus 40 (SV40) promoter, a thymidine kinase (tk) promoter of herpes simplex virus (HSV), mouse mammary tumor virus (MMTV) promoter, a long terminal repeat (LTR) promoter of human immunodeficiency virus (HIV), a promoter of Moloney virus, an Epstein barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter.
  • 203. The cell of claim 193, wherein the cell further comprises one or more of the following transgenes: TGF-β, Cd73, Cd39, Lag3, Il1r2, Ackr2, Tnfrsf22, Tnfrs23, Tnfrsf10, Dad1, or IFNγR1 d39.
  • 204. The cell of claim 193, wherein the cell further comprises a genetic modification of one or more cell division locus/loci (CDL).
  • 205. The cell of claim 204, wherein the genetic modification of the one or more cell division locus/loci (CDL) comprises insertion of an ablation link (ALINK) system or an exogenous activator of regulation of cell division locus/loci (EARC) system.
  • 206. The cell of claim 204, wherein the CDL comprises CDK1, TOP2A, CENPA, BIRC5, or EEF2.
  • 207. A method for reducing an immune response of a subject to an allogeneic cell, the method comprising: providing the allogeneic cell to the subject wherein the allogeneic cell expresses transgenes comprising: human FASLG, CD200, CCL21, SERPINB9, MFGE8, PD-L1, HLA-G, and CD47; ormurine FasL, Cd200, Ccl21b, Spi6, Mfge8, Pd-l1, H2-M3, and Cd47.
  • 208. The method of claim 207, wherein the allogeneic cell is a human cell or a murine cell.
  • 209. The method of claim 207, wherein the subject is a human or a mouse.
  • 210. The method of claim 207, wherein the allogeneic cell is a stem cell.
  • 211. The method of claim 207, where the allogeneic cell further comprises a heterologous sequence encoding a therapeutic agent.
  • 212. A composition comprising the cell of claim 193 and a pharmaceutically acceptable excipient.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/621,490, filed Dec. 11, 2019, which is a U.S. national phase application based on International Patent Application No. PCT/CA2018/050706 filed Jun. 12, 2018, which claims priority to U.S. Provisional Patent Application No. 62/666,626, filed May 3, 2018, and U.S. Provisional Patent Application No. 62/518,151, filed Jun. 12, 2017, the contents of each of which are incorporated by reference herein in their entirety as if fully set forth herein.

Provisional Applications (2)
Number Date Country
62666626 May 2018 US
62518151 Jun 2017 US
Continuations (1)
Number Date Country
Parent 16621490 Dec 2019 US
Child 18175409 US